Amsurg (AMSG) 10-K 27 Feb 15 2014 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Feb. 26, 2015	Jun. 30, 2014
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Entity Registrant Name	AMSURG CORP
Entity Central Index Key	895930
Current Fiscal Year End Date	-19
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		48,367,128
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	Yes
Entity Public Float			$1,438,900,000

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Assets
Cash and cash equivalents	$208,079	$50,840
Restricted cash and marketable securities	10,219	0
Accounts receivable, net of allowance of $113,357 and $27,862, respectively	233,053	105,072
Supplies inventory	19,974	18,414
Prepaid and other current assets	115,362	36,699
Total current assets	586,687	211,025
Property and equipment, net	180,448	163,690
Investments in unconsolidated affiliates	75,475	15,526
Goodwill	3,381,149	1,758,970
Intangible assets, net	1,273,879	27,867
Other assets	25,886	866
Total assets	5,523,524	2,177,944
Liabilities and Equity
Current portion of long-term debt	18,826	20,844
Accounts payable	29,585	27,501
Accrued salaries and benefits	140,044	32,294
Accrued interest	29,644	1,885
Other accrued liabilities	67,986	7,346
Total current liabilities	286,085	89,870
Long-term debt	2,232,186	583,298
Deferred income taxes	633,480	176,020
Other long-term liabilities	89,443	25,503
Commitments and contingencies
Noncontrolling interests – redeemable	184,099	177,697
Equity:
Mandatory convertible preferred stock, no par value, 5,000 shares authorized, 1,725 and 0 shares issued and outstanding, respectively	166,632	0
Common stock, no par value, 70,000 shares authorized, 48,113 and 32,353 shares outstanding, respectively	885,393	185,873
Retained earnings	627,522	578,324
Total AmSurg Corp. equity	1,679,547	764,197
Noncontrolling interests – non-redeemable	418,684	361,359
Total equity	2,098,231	1,125,556
Total liabilities and equity	$5,523,524	$2,177,944

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Statement of Financial Position [Abstract]
Allowances for accounts receivable	$113,357	$27,862
Preferred stock, shares authorized	5,000	5,000
Preferred stock, shares issued	1,725	0
Preferred stock, shares outstanding	1,725	0
Common stock, shares authorized	70,000	70,000
Common stock, shares outstanding	48,113	32,353

Consolidated_Statements_Of_Ear

Consolidated Statements Of Earnings (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Revenues	$1,738,950	$1,057,196	$899,245
Provision for uncollectibles	-139,274	-21,947	-20,005
Net revenues	1,621,949	1,057,196	899,245
Operating expenses:
Salaries and benefits	694,576	327,585	284,528
Supply cost	164,296	153,126	126,919
Other operating expenses	284,928	216,501	185,866
Transaction costs	33,890	300	700
Depreciation and amortization	60,344	32,400	29,255
Total operating expenses	1,238,034	729,912	627,268
Gain on deconsolidation	3,411	2,237	0
Equity in earnings of unconsolidated affiliates	7,038	3,151	1,564
Operating income	394,364	332,672	273,541
Interest expense, net	83,285	29,525	16,950
Debt extinguishment costs	16,887	0	0
Earnings from continuing operations before income taxes	294,192	303,147	256,591
Income tax expense	48,103	48,654	40,893
Net earnings from continuing operations	246,089	254,493	215,698
Net earnings (loss) from discontinued operations	-1,296	7,051	7,945
Net earnings	244,793	261,544	223,643
Less net earnings attributable to noncontrolling interests	191,092	188,841	161,080
Net earnings attributable to AmSurg Corp. shareholders	53,701	72,703	62,563
Preferred stock dividends	-4,503	0	0
Net earnings attributable to AmSurg Corp. common shareholders	49,198	72,703	62,563
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax	50,777	71,009	60,037
Earnings (loss) from discontinued operations, net of income tax	-1,579	1,694	2,526
Net earnings attributable to AmSurg Corp. common shareholders	49,198	72,703	62,563
Basic earnings per share attributable to AmSurg Corp. common shareholders:
Net earnings from continuing operations (usd per share)	$1.29	$2.27	$1.95
Net earnings from discontinued operations (usd per share)	($0.04)	$0.05	$0.08
Net earnings (usd per share)	$1.25	$2.32	$2.03
Diluted earnings per share attributable to AmSurg Corp. common shareholders:
Net earnings from continuing operations (usd per share)	$1.28	$2.22	$1.90
Net earnings from discontinued operations (usd per share)	($0.04)	$0.05	$0.08
Net earnings (usd per share)	$1.24	$2.28	$1.98
Weighted average number of shares and share equivalents outstanding:
Basic (in shares)	39,311	31,338	30,773
Diluted (in shares)	39,625	31,954	31,608
Physician Services [Member]
Provision for uncollectibles	-117,001	0	0
Net revenues	$512,014	$0	$0

Consolidated_Statements_Of_Cha

Consolidated Statements Of Changes In Equity (USD $)	Total	Common Stock [Member]	Mandatory Convertible Preferred Stock [Member]	Retained Earnings [Member]	Non-Controlling Interests - Non-Redeemable [Member]	Total Equity (Permanent) [Member]	Non-controlling Interests - Redeemable (Temporary Equity) [Member]
In Thousands, except Share data, unless otherwise specified
Balance at Dec. 31, 2011		$173,187	$0	$443,058	$132,222	$748,467	$170,636
Balance (in shares) at Dec. 31, 2011		31,284,000	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	223,643			62,563	26,303	88,866	134,777
Issuance of restricted stock (in shares)		281,000
Cancellation of restricted stock (in shares)		-2,000
Stock options exercised		18,214				18,214
Stock options exercised (in shares)	841,599	842,000
Stock repurchased		-13,101				-13,101
Stock repurchased (in shares)		-464,000
Share-based compensation		6,692				6,692
Tax benefit related to exercise of stock options		1,834				1,834
Distributions to noncontrolling interests, net of capital contributions					-26,514	-26,514	-136,356
Acquisitions and other transactions impacting noncontrolling interests		252			174,615	174,867	6,957
Disposals and other transactions impacting noncontrolling interests		-3,211			4,352	1,141	-632
Balance at Dec. 31, 2012		183,867	0	505,621	310,978	1,000,466	175,382
Balance (in shares) at Dec. 31, 2012		31,941,000	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	261,544			72,703	49,789	122,492	139,052
Issuance of restricted stock (in shares)		292,000
Cancellation of restricted stock (in shares)		-16,000
Stock options exercised		33,349				33,349
Stock options exercised (in shares)	1,392,366	1,393,000
Stock repurchased		-45,964				-45,964
Stock repurchased (in shares)		-1,257,000
Share-based compensation		8,321				8,321
Tax benefit related to exercise of stock options		7,247				7,247
Distributions to noncontrolling interests, net of capital contributions					-49,533	-49,533	-134,298
Acquisitions and other transactions impacting noncontrolling interests		679			48,115	48,794	-319
Disposals and other transactions impacting noncontrolling interests		-1,626			2,010	384	-2,120
Balance at Dec. 31, 2013	1,125,556	185,873	0	578,324	361,359	1,125,556	177,697
Balance (in shares) at Dec. 31, 2013		32,353,000	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	244,793			53,701	56,048	109,749	135,044
Issuance of stock		693,289	166,632			859,921
Issuance of stock (in shares)		15,490,000	1,725,000
Issuance of restricted stock (in shares)		272,000
Cancellation of restricted stock (in shares)		-12,000
Stock options exercised		2,630				2,630
Stock options exercised (in shares)	111,743	111,000
Stock repurchased		-4,615				-4,615
Stock repurchased (in shares)		-101,000
Share-based compensation		10,104				10,104
Tax benefit related to exercise of stock options		3,177				3,177
Dividends paid on preferred stock				-4,503		-4,503
Distributions to noncontrolling interests, net of capital contributions					-56,439	-56,439	-133,594
Acquisitions and other transactions impacting noncontrolling interests		744			54,725	55,469	6,482
Disposals and other transactions impacting noncontrolling interests		-5,809			2,991	-2,818	-1,530
Balance at Dec. 31, 2014	$2,098,231	$885,393	$166,632	$627,522	$418,684	$2,098,231	$184,099
Balance (in shares) at Dec. 31, 2014		48,113,000	1,725,000

Consolidated_Statements_Of_Cas

Consolidated Statements Of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities:
Net earnings	$244,793	$261,544	$223,643
Adjustments to reconcile net earnings to net cash flows provided by operating activities:
Depreciation and amortization	60,344	32,400	29,255
Amortization of deferred loan costs	17,715	1,977	1,215
Provision for uncollectibles	139,274	21,947	20,005
Net (gain) loss on sale of long-lived assets	2,843	-1,468	-1,065
Gain on deconsolidation	-3,411	-2,237	0
Share-based compensation	10,104	8,321	6,692
Excess tax benefit from share-based compensation	-3,177	-7,247	-1,784
Deferred income taxes	30,780	38,363	24,558
Equity in earnings of unconsolidated affiliates	-7,038	-3,151	-1,564
Debt extinguishment costs	4,536	0	0
Increases (decreases) in cash and cash equivalents, net of acquisitions and dispositions:
Accounts receivable	-137,663	-23,244	-11,944
Supplies inventory	-206	132	110
Prepaid, supplies and other current assets	-9,091	-5,308	-4,651
Accounts payable	-8,440	441	579
Accrued expenses and other liabilities	66,175	6,693	7,550
Other, net	4,833	3,661	3,053
Net cash flows provided by operating activities	412,371	332,824	295,652
Cash flows from investing activities:
Acquisitions and related expenses	-2,184,058	-73,594	-277,388
Acquisition of property and equipment	-40,217	-28,856	-28,864
Proceeds from sale of interests in surgery centers	7,069	3,553	7,309
Purchases of marketable securities	-6,474	0	0
Maturities of marketable securities	3,486	0	0
Other	-4,941	159	0
Net cash flows used in investing activities	-2,225,135	-98,738	-298,943
Cash flows from financing activities:
Proceeds from long-term borrowings	2,048,958	162,204	565,566
Repayment on long-term borrowings	-408,475	-202,083	-394,164
Distributions to noncontrolling interests	-190,097	-184,149	-162,941
Proceeds from preferred stock offering	172,500	0	0
Cash dividends for preferred shares	-4,503	0	0
Proceeds from common stock offering	439,875	0	0
Proceeds from issuance of common stock upon exercise of stock options	2,630	33,349	18,214
Repurchase of common stock	-4,615	-45,964	-13,101
Excess tax benefit from share-based compensation	3,177	7,247	1,784
Payments of equity issuance costs	-24,494	0	0
Financing costs incurred	-65,811	-1,322	-7,982
Other	858	1,074	1,595
Net cash flows provided by (used in) financing activities	1,970,003	-229,644	8,971
Net increase in cash and cash equivalents	157,239	4,442	5,680
Cash and cash equivalents, beginning of year	50,840	46,398	40,718
Cash and cash equivalents, end of year	208,079	50,840	46,398
Supplemental cash flow information:
Interest payments	38,129	28,378	14,786
Income tax payments, net of refunds	$19,224	$7,756	$19,615

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Accounting Policies
	Below are a summary of the Company's policies that are not otherwise found within other notes.
	a.     Principles of Consolidation
	Ambulatory Services
	AmSurg Corp. (the “Company”), through its wholly-owned subsidiaries, owns interests, primarily 51%, in LPs and LLCs which own and operate ASCs primarily in the following specialties: gastroenterology; multi-specialty; ophthalmology; and orthopaedics.  The Company does not have an ownership interest in a LP or LLC greater than 51% which it does not consolidate.  The Company has ownership interests of less than 51% in ten LPs and LLCs, one of which it consolidates as the Company has substantive participation rights and nine of which it does not consolidate as the Company’s rights are limited to protective rights only.  The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries and the consolidated LPs and LLCs.  Consolidation of such LPs and LLCs is necessary as the Company’s wholly-owned subsidiaries have primarily 51% or more of the financial interest of the LPs and LLCs, are the general partner or majority member with all the duties, rights and responsibilities thereof, are responsible for the day-to-day management of the LPs and LLCs, and have control of the entities.  The responsibilities of the Company’s noncontrolling partners (LPs and noncontrolling members) are to supervise the delivery of medical services, with their rights being restricted to those that protect their financial interests, such as approval of the acquisition of significant assets or the incurrence of debt which they are generally required to guarantee on a pro rata basis based upon their respective ownership interests.  Intercompany profits, transactions and balances have been eliminated.  All LPs and LLCs and noncontrolling partners are referred to herein as “partnerships” and “partners”, respectively.
	Ownership interests in consolidated subsidiaries held by parties other than the Company are identified and generally presented in the consolidated financial statements within the equity section but separate from the Company’s equity.  However, for instances in which certain redemption features that are not solely within the control of the Company are present, classification of noncontrolling interests outside of permanent equity is required.  Consolidated net income attributable to the Company and to the noncontrolling interests are identified and presented on the consolidated statements of operations; changes in ownership interests are accounted for as equity transactions; and when a subsidiary is deconsolidated, any retained noncontrolling equity investment in the former subsidiary and the gain or loss on the deconsolidation of the subsidiary are measured at fair value.  Certain transactions with noncontrolling interests are also classified within financing activities in the statements of cash flows.
	As further described in note 19, upon the occurrence of various fundamental regulatory changes, the Company would be obligated, under the terms of certain partnership and operating agreements, to purchase the noncontrolling interests related to a substantial majority of the Company’s partnerships. While the Company believes that the likelihood of a change in current law that would trigger such purchases was remote as of December 31, 2014, the occurrence of such regulatory changes is outside the control of the Company. As a result, these noncontrolling interests that are subject to this redemption feature are not included as part of the Company’s equity and are classified as noncontrolling interests – redeemable on the Company’s consolidated balance sheets.
	Center profits and losses of consolidated entities are allocated to the Company’s partners in proportion to their ownership percentages and reflected in the aggregate as net earnings attributable to noncontrolling interests.  The partners of the Company’s center partnerships typically are organized as general partnerships, LPs or LLCs that are not subject to federal income tax.  Each partner shares in the pre-tax earnings of the center in which it is a partner.  Accordingly, the earnings attributable to noncontrolling interests in each of the Company’s consolidated partnerships are generally determined on a pre-tax basis, and total net earnings attributable to noncontrolling interests are presented after net earnings.  However, the Company considers the impact of the net earnings attributable to noncontrolling interests on earnings before income taxes in order to determine the amount of pre-tax earnings on which the Company must determine its tax expense.  In addition, distributions from the partnerships are made to both the Company’s wholly-owned subsidiaries and the partners on a pre-tax basis.
	Physician Services
	On July 16, 2014, the Company completed its acquisition of Sheridan. Sheridan is a national provider of multi-specialty physician and administrative services to hospitals, ambulatory surgery centers and other healthcare facilities. Sheridan focuses on delivering comprehensive physician services, primarily in the areas of anesthesiology, children's services, radiology and emergency medicine to healthcare facilities. Through its contracts with healthcare facilities, Sheridan is authorized to bill and collect charges for fee for service medical services rendered by its healthcare professionals and employees in exchange for the provision of services to the patients of these facilities. Contract revenue is earned directly from hospital customers through a variety of payment arrangements that are established when payments from third-party payors are inadequate to support the costs of providing the services required under the contract. Sheridan also provides physician services and manages office-based practices in the areas of gynecology, obstetrics and perinatology. The consolidated financial statements include the accounts of Sheridan and its wholly-owned subsidiaries along with the accounts of affiliated PCs with which Sheridan currently has management arrangements. Sheridan's agreements with these PCs provide that the term of the arrangements is permanent, subject only to termination by the Company, except in the case of gross negligence, fraud or bankruptcy of the Company. These arrangements are captive in nature as a majority of the outstanding voting equity instruments of the PCs are owned by nominee shareholders appointed at the sole discretion of the Company. The Company has a contractual right to transfer the ownership of the PCs at any time to any person it designates as the nominee shareholder. The Company has the right to receive income, both as ongoing fees and as proceeds from the sale of its interest in the PCs, in an amount that fluctuates based on the performance of the PCs and the change in the fair value of the Company’s interest in the PCs. The Company has exclusive responsibility for the provision of all non-medical services required for the day-to-day operation and management of the PCs and establishes the guidelines for the employment and compensation of the physicians and other employees of the PCs. In addition, the agreements provide that the Company has the right, but not the obligation, to purchase, or to designate a person(s) to purchase, the stock of the PCs for a nominal amount. Separately, in its sole discretion, the Company has the right to assign its interest in the management and purchase agreements. Based upon the provisions of these agreements, the Company has determined that the PCs are variable interest entities and that the Company is the primary beneficiary as defined in the accounting guidance for consolidation.
	b.    Cash and Cash Equivalents
	Cash and cash equivalents are comprised principally of demand deposits at banks and other highly liquid short-term investments with maturities of less than three months when purchased. Cash and cash equivalents are reflected in the financial statements at cost, which approximates fair value.
	c.    Restricted Cash and Marketable Securities
	As of December 31, 2014 the Company had $30.3 million of restricted cash and marketable securities in the accompanying consolidated balance sheets, which is restricted for the purpose of satisfying the obligations of the Company's wholly-owned captive insurance company. The Company has reflected $20.1 million of its restricted cash and marketable securities as a component of other assets in the accompanying consolidated balance sheet. The remaining $10.2 million is reflected as a component of total current assets in the accompanying consolidated balance sheet as such amount is available to satisfy the claims payments estimated to occur in the next twelve months. As of December 31, 2014, the Company had $3.0 million included in restricted cash and marketable securities which are certificates of deposit with maturities less than 180 days, which approximates fair value.
	d.    Supplies Inventory
	Supplies inventory consists of medical and drug supplies and is recorded at cost on a first-in, first-out basis.
	e.    Fair Value Measurements
	The fair value of a financial instrument is the amount at which the instrument could be exchanged in an orderly transaction between market participants to sell the asset or transfer the liability.  The inputs used by the Company to measure fair value are classified into the following hierarchy:
	Level 1: Quoted prices in active markets for identical assets or liabilities.
	Level 2: Inputs other than quoted prices included in Level 1 that are observable for the asset or liability through corroboration with market data at the measurement date.
	Level 3: Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date.
	In determining the fair value of assets and liabilities that are measured on a recurring basis at December 31, 2014 and 2013, with the exception of the contingent purchase price payable (further discussed in note 4), the Company utilized Level 1 and 2 inputs to perform such measurements methods, which were commensurate with the market approach. There were no transfers to or from Levels 1 and 2 during the year ended December 31, 2014. The Company's non-patient receivables and accounts payable are reflected in the financial statements at cost, which approximates fair value.
	f.    Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.
	g.    Reclassifications
	Certain amounts in the consolidated financial statements and these notes have been reclassified to conform to the current period presentation. Such reclassifications primarily result from the acquisition of Sheridan and the impact of additional discontinued operations as further discussed in note 6.
	h.    Recent Accounting Pronouncements
	In April 2014, the Financial Accounting Standards Board issued ASU 2014-08 “Presentation of Financial Statements and Property, Plant and Equipment,” which raised the threshold for a disposal to qualify as a discontinued operation and requires certain new disclosures for individually material disposals that do not meet the new definition of a discontinued operation.  The ASU’s intent is to reduce the number of disposals reported as discontinued operations by focusing on strategic shifts that have or will have a major effect on the Company’s operations and financial results rather than routine disposals that are not a change in the Company’s strategy.  The guidance is effective for interim and annual periods beginning after December 15, 2014, with earlier adoption permitted.  From time to time, the Company will dispose of certain of its entities due to management’s assessment of the Company’s strategy in the market and due to limited growth opportunities at those entities.  Historically, these dispositions were classified as discontinued operations and recorded separately from continuing operations.  Upon adoption in the first quarter of 2015, this ASU will require the Company to record the results of operations and the associated gain or loss from similar dispositions as a component of continuing operations.  The Company does not believe this ASU will have a material impact on the Company’s consolidated financial position or cash flows.
	In May 2014, Financial Accounting Standards Board issued ASU 2014-09 “Revenue from Contracts with Customers,” which will eliminate the transaction and industry-specific revenue recognition guidance under current GAAP and replace it with a principle-based approach using the following steps: identify the contract(s) with a customer, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract and recognize revenue when (or as) the entity satisfies a performance obligation. The guidance in ASU 2014-09 is effective for public entities for annual reporting periods beginning after December 15, 2016, including interim periods therein. Early adoption is not permitted. The Company has yet to assess the impact, if any, this ASU will have on the Company's consolidated financial position, results of operations or cash flows.
	In February 2015, the FASB issued ASU No. 2015-02, "Consolidations (Topic 810) - Amendments to the Consolidation Analysis". The new guidance makes amendments to the current consolidation guidance, including introducing a separate consolidation analysis specific to limited partnerships and other similar entities. Under this analysis, limited partnerships and other similar entities will be considered a variable-interest entity unless the limited partners hold substantive kick-out rights or participating rights. The standard is effective for annual periods beginning after December 15, 2015. The Company has yet to assess the impact, if any, this ASU will have on the Company's consolidated financial position, results of operations or cash flows.

Revenue_Recognition

Revenue Recognition	12 Months Ended
	Dec. 31, 2014
Revenue Recognition [Abstract]
Revenue Recognition	Revenue Recognition
	Ambulatory Services
	Ambulatory services revenues consist of billing for the use of the centers’ facilities directly to the patient or third-party payor and, at certain of the Company’s centers (primarily centers that perform gastrointestinal endoscopy procedures), billing for anesthesia services provided by medical professionals employed or contracted by the Company’s centers.  Such revenues are recognized when the related surgical procedures are performed.  Revenues exclude any amounts billed for physicians’ surgical services, which are billed separately by the physicians to the patient or third-party payor.
	Revenues from ambulatory services are recognized on the date of service, net of estimated contractual adjustments from third-party medical service payors including Medicare and Medicaid.  During the years ended December 31, 2014, 2013 and 2012, the Company derived approximately 25%, 25% and 27%, respectively, of its ambulatory services revenues from governmental healthcare programs, primarily Medicare and managed Medicare programs.  Concentration of credit risk with respect to other payors is limited due to the large number of such payors.
	Physician Services
	Physician services revenue primarily consists of fee for service revenue and contract revenue and is derived principally from the provision of physician services to patients of the healthcare facilities the Company serves. Contract revenue represents income earned from the Company's hospital customers to subsidize contract costs when payments from third-party payors are inadequate to support such costs.
	The Company records revenue at the time services are provided, net of a contractual allowance and a provision for uncollectibles. Revenue less the contractual allowance represents the net revenue expected to be collected from third-party payors (including managed care, commercial and governmental payors such as Medicare and Medicaid) and patients insured by these payors.
	The Company also recognizes revenue for services provided during the period but are not yet billed. Expected collections are estimated based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patients’ healthcare plan, mandated payment rates under the Medicare and Medicaid programs, and historical cash collections.
	The Company's provision for uncollectibles includes its estimate of uncollectible balances due from uninsured patients, uncollectible co-pay and deductible balances due from insured patients and special charges, if any, for uncollectible balances due from managed care, commercial and governmental payors. The Company records net revenue from uninsured patients at its estimated realizable value, which includes a provision for uncollectible balances, based on historical cash collections (net of recoveries).
	Net revenue for the physician services segment consists of the following major payors (in thousands):
		July 16, 2014 - December 31, 2014 (1)
	Medicare	$	61,378		12	%
	Medicaid	28,224			5.5
	Commercial and managed care	382,343			74.7
	Self-pay	102,727			20.1
	Net fee for service revenue	574,672			112.3
	Contract and other revenue	54,343			10.6
	Provision for uncollectibles	(117,001		)	(22.9	)
	Net revenue for physician services	$	512,014		100	%
	-1	Net revenue by payor is for the period July 16, 2014, the date of the acquisition of Sheridan, through December 31, 2014. As such, historical amounts are not included.

Accounts_Receivable

Accounts Receivable	12 Months Ended
	Dec. 31, 2014
Receivables [Abstract]
Accounts Receivable	Accounts Receivable
	The Company manages accounts receivable by regularly reviewing its accounts and contracts and by providing appropriate allowances for contractual adjustments and uncollectible amounts. Some of the factors considered by management in determining the amount of such allowances are the historical trends of cash collections, contractual and bad debt write-offs, accounts receivable agings, established fee schedules, contracts with payors, changes in payor mix and procedure statistics. Actual collections of accounts receivable in subsequent periods may require changes in the estimated contractual allowance and provision for uncollectibles. The Company tests its analysis by comparing cash collections to net patient revenues and monitoring self-pay utilization. In addition, when actual collection percentages differ from expected results, on a contract by contract basis, supplemental detailed reviews of the outstanding accounts receivable balances may be performed by the Company’s billing operations to determine whether there are facts and circumstances existing that may cause a different conclusion as to the estimate of the collectability of that contract’s accounts receivable from the estimate resulting from using the historical collection experience. The Company also supplements its allowance for doubtful accounts policy for its physician services quarterly using a hindsight calculation that utilizes write-off data for all payor classes during the previous 12-month period to estimate the allowance for doubtful accounts at a point in time. Changes in these estimates are charged or credited to the consolidated statements of operations in the period of change. Material changes in estimates may result from unforeseen write-offs of patient or third party accounts receivable, unsuccessful disputes with managed care payors, adverse macro-economic conditions which limit patients’ ability to meet their financial obligations for the care provided by physicians, or broad changes to government regulations that adversely impact reimbursement rates for services provided by the Company. Significant changes in payor mix, business office operations, general economic conditions and health care coverage provided by federal or state governments or private insurers may have a significant impact on the Company’s estimates and significantly affect its results of operations and cash flows.
	Due to the nature of the Company's operations, it is required to separate the presentation of its bad debt expense on the consolidated statement of earnings. The Company records the portion of its bad debts associated with its physician services segment as a component of net revenue in the accompanying consolidated statement of earnings, and the remaining portion, which is associated with its ambulatory services segment, is recorded as a component of other operating expenses in the accompanying consolidated statement of earnings. The bifurcation is a result of the Company's ability to assess the ultimate collection of the patient service revenue associated with its ambulatory services segment before services are provided. The Company's ambulatory services segment is generally able to verify a patient's insurance coverage and ability to pay before services are provided as those services are pre-scheduled and non-emergent. Bad debt expense for the ambulatory services segment is included in other operating expenses and was approximately $21.9 million, $21.7 million and $19.6 million for the years ended December 31, 2014, 2013 and 2012, respectively. Bad debt expense related to physician services was $117.0 million during the period from July 16, 2014 through December 31, 2014 and is included as a reduction to revenues in the accompanying consolidated statements of earnings.
	At December 31, 2014 and 2013 allowances for doubtful accounts were $113.4 million and $27.9 million, respectively. The significant increase in the Company's allowance for doubtful accounts as of December 31, 2014 was primarily due to the Sheridan acquisition. At December 31, 2014, approximately 73% of the Company’s allowance for doubtful accounts was related to receivables for fee for service patient visits. The principal exposure for uncollectible fee for service visits is from self-pay patients and, to a lesser extent, for co-payments and deductibles from patients with insurance. Concentration of credit risk is limited by the diversity and number of hospitals, patients, payors and by the geographic dispersion of the Company’s operations.

Acquisitions

Acquisitions	12 Months Ended
	Dec. 31, 2014
Business Combinations [Abstract]
Acquisitions	Acquisitions
	The Company accounts for its business combinations under the fundamental requirements of the acquisition method of accounting and under the premise that an acquirer be identified for each business combination.  The acquirer is the entity that obtains control of one or more businesses in the business combination and the acquisition date is the date the acquirer achieves control.  The assets acquired, liabilities assumed and any noncontrolling interests in the acquired business at the acquisition date are recognized at their fair values as of that date, and the direct costs incurred in connection with the business combination are recorded and expensed separately from the business combination.  Acquisitions in which the Company is able to exert significant influence but does not have control are accounted for using the equity method.
	Sheridan Acquisition
	On July 16, 2014 (the “acquisition date”), the Company completed the acquisition of Sheridan in a cash and stock transaction. At closing, the Company paid approximately $2.1 billion in cash and issued 5,713,909 shares of its common stock to the former owners of Sheridan in exchange for all of the outstanding equity interests of Sheridan. The shares issued to Sheridan were valued at approximately $272.0 million based on the closing price of the Company's common stock on July 16, 2014. The acquisition of Sheridan enhances the growth profile and diversity of the Company focusing on complementary specialties across the healthcare continuum.
	To fund the transaction, the Company completed offerings of common stock and mandatory convertible preferred stock resulting in the issuance of 9,775,000 shares of common stock and 1,725,000 shares of mandatory convertible preferred stock. Proceeds from the common stock offering and mandatory preferred stock offering, net of transaction fees, were approximately $421.3 million and $166.6 million, respectively. In addition, on July 16, 2014, the Company entered into a new senior secured credit facility, which includes an $870.0 million term loan and a $300.0 million revolving credit facility, and completed a private offering of $1.1 billion aggregate principal amount of 5.625% senior unsecured notes due 2022.
	Fees and expenses associated with the Sheridan transaction, which includes fees incurred related to the Company's equity issuances and debt financings, was approximately $139.1 million during the year ended December 31, 2014. Approximately $53.0 million was capitalized as deferred financing costs, $24.5 million was related to the equity offerings and recorded as a reduction to equity, $31.9 million was expensed as transaction costs, $12.8 million was amortized through interest expense and $16.9 million was recorded as debt extinguishment costs during the year ended December 31, 2014.
	The accounting for the acquisition of Sheridan is currently preliminary. The Company continues to obtain information relative to the fair values of assets acquired, liabilities assumed and any noncontrolling interests in the transaction. Acquired assets and assumed liabilities include, but are not limited to, fixed assets, licenses, intangible assets and professional liabilities. The valuations are based on appraisal reports, discounted cash flow analyses, actuarial analyses or other appropriate valuation techniques to determine the fair value of the assets acquired or liabilities assumed. A majority of the deferred income taxes recognized as a component of the Company's purchase price allocation is a result of the difference between the book and tax basis of the amortizable intangible assets recognized. The amount allocated to the deferred income tax liability is subject to change as a result of the final allocation of purchase price to amortizable intangibles. The Company expects to finalize the purchase price allocation for Sheridan as soon as practical.
	Ambulatory Services Acquisitions
	As a significant part of its growth strategy, the Company seeks to acquire interests in surgery centers. During 2014 and 2013, the Company, through a wholly-owned subsidiary, acquired a controlling interest in eight and five surgery centers, respectively. Of the centers acquired during 2014, three were acquired as part of the Sheridan transaction and five were individually acquired in separate transactions. The aggregate amount paid for the individually acquired centers and for settlement of purchase price payable obligations during December 31, 2014 and 2013 was approximately $50.9 million and $73.6 million, respectively, and was paid in cash and funded by a combination of operating cash flow and borrowings under the Company’s revolving credit facility.  The total fair value of an acquisition includes an amount allocated to goodwill, which results from the centers’ favorable reputations in their markets, their market positions and their ability to deliver quality care with high patient satisfaction consistent with the Company’s business model.
	During the year ended December 31, 2013, the Company paid $2.7 million as final settlement of a contingent earn out fee resulting from the purchase of 17 centers from National Surgical Care, Inc. during 2011.
	Physician Services Acquisitions
	The Company completed the acquisition of two physician group practices in 2014 following the acquisition of Sheridan. The total consideration consisted of cash of $19.0 million, which was funded at closing through operating cash flow, plus contingent consideration payable in the future based on meeting certain performance targets which include new contract, volume and other performance metrics.
	As a result of recent acquisitions, the Company has agreed to pay as additional consideration, certain amounts which are dependent on the acquired entity achieving future performance metrics. As of December 31, 2014, the Company has accrued $20.7 million as a component of accrued liabilities and other long-term liabilities in the accompanying consolidated balance sheet which represents management's estimate of the fair values of the contingent consideration. As of December 31, 2014, the Company estimates it may have to pay between $18 to $23 million in future contingent payments for acquisitions made prior to December 31, 2014 based upon the current projected financial performance or anticipated achievement of other targets of the acquired operations. The current estimate of future contingent payments could increase or decrease depending upon the actual performance of the acquisition over each respective measurement period. At December 31, 2013, the Company had no liability recorded related to contingent consideration.
	The Company utilizes Level 3 inputs, which includes unobservable data, to measure the fair value of the contingent consideration related to the physician practices acquired during the year ended December 31, 2014. The fair value was determined utilizing future forecasts of both earnings and other performance metrics which are expected to be achieved during the performance period, in accordance with each respective purchase agreement. In estimating the fair value, management developed various scenarios and weighted the probable outcome of each scenario using a range of expected probability specific to each agreement. Management utilized a market rate to discount the results of such analysis in order to record the present value of the expected future payout. During the year ended December 31, 2014, there was no change in the fair value of the Company's contingent liabilities primarily due to the fact that the acquisitions occurred in the latter half of the year. The timing of the payments of the additional consideration varies by agreement but are expected to occur within one to three years from the date of acquisition.
	Purchase Price Allocations
	The acquisition date fair value of the total consideration transferred and acquisition date fair value of each major class of consideration for the acquisitions completed during 2014 and 2013, including post acquisition date adjustments recorded to purchase price allocations, are as follows (in thousands):
		2014						2013
					Individual			Individual
		Sheridan (1)			Acquisitions (1)			Acquisitions
	Accounts receivable	$	130,260		$	1,816		$	4,011
	Other current assets	105,757			1,075			2,014
	Property and equipment	20,185			3,294			6,894
	Goodwill	1,534,656			101,865			116,243
	Intangible assets	1,200,028			14,207			—
	Other long-term assets	50,304			—			—
	Accounts payable	(5,862		)	(2,519		)	(2,214		)
	Other accrued liabilities	(118,548		)	(626		)	(532		)
	Deferred income taxes	(432,792		)	—			—
	Other long-term liabilities	(69,456		)	(8,588		)	(254		)
	Long-term debt	(4,594		)	(717		)	(3,028		)
	Total fair value	2,409,938			109,807			123,134
	Less:  Fair value attributable to noncontrolling interests	24,365			39,371			49,792
	Acquisition date fair value of total consideration transferred	$	2,385,573		$	70,436		$	73,342
	-1	Represents the preliminary allocation of fair value of acquired assets and liabilities associated with these acquisitions at December 31, 2014.
	Fair value attributable to noncontrolling interests is based on significant inputs that are not observable in the market.  Key inputs used to determine the fair value include financial multiples used in the purchase of noncontrolling interests primarily from acquisitions of centers.  Such multiples, based on earnings, are used as a benchmark for the discount to be applied for the lack of control or marketability.  The fair value of noncontrolling interests for acquisitions where the purchase price allocation is not finalized may be subject to adjustment as the Company completes its initial accounting for acquired intangible assets.
	During 2014, the Company expensed transaction costs of approximately $33.9 million primarily associated with the acquisition of Sheridan. Such costs excluded those amounts that were either capitalized or expensed as part of the financing transactions associated with the acquisition. During 2013, the Company expensed transaction costs of approximately $0.3 million associated with its acquisition of surgery centers.
	Revenues and net earnings included in the years ended December 31, 2014 and 2013 associated with completed acquisitions are as follows (in thousands):
		2014						2013
					Individual			Individual
		Sheridan			Acquisitions			Acquisitions
	Net revenues	$	517,213		$	20,844		$	15,616
	Net earnings	26,776			5,155			4,596
	Less:  Net earnings attributable to noncontrolling interests	459			2,859			2,603
	Net earnings attributable to AmSurg Corp. common shareholders	$	26,317		$	2,296		$	1,993
	The unaudited consolidated pro forma results for the years ended December 31, 2014 and 2013, assuming all 2014 acquisitions had been consummated on January 1, 2013, all 2013 acquisitions had been consummated on January 1, 2012 are as follows (in thousands):
		2014			2013
	Revenues	$	2,217,682		$	2,171,999
	Net earnings	295,156			243,675
	Amounts attributable to AmSurg Corp. common shareholders:
	Net earnings	97,538			39,980
	Net earnings per common share:
	Basic	$	1.88		$	0.66
	Diluted	$	1.86		$	0.65

Investments_in_Unconsolidated_

Investments in Unconsolidated Affiliates	12 Months Ended
	Dec. 31, 2014
Equity Method Investments and Joint Ventures [Abstract]
Investments in Unconsolidated Affiliates	Investments in Unconsolidated Affiliates
	Investments in unconsolidated affiliates in which the Company exerts significant influence but does not control or otherwise consolidate are accounted for using the equity method.  Equity method investments are initially recorded at cost, unless such investments are a result of the Company entering into a transaction whereby the Company loses control of a previously controlled entity but retains a noncontrolling interest.  Such transactions, which result in the deconsolidation of a previously consolidated entity, are measured at fair value. These investments are included as investments in unconsolidated affiliates in the accompanying consolidated balance sheets. The Company’s share of the profits and losses from these investments are reported in equity in earnings of unconsolidated affiliates in the accompanying consolidated statement of earnings.  The Company monitors its investments for other-than-temporary impairment by considering factors such as current economic and market conditions and the operating performance of the companies and records reductions in carrying values when necessary. The Company has recorded in the accompanying consolidated balance sheets, in investments in unconsolidated affiliates, approximately $75.5 million and $15.5 million as of December 31, 2014 and 2013, respectively, which represents the carrying value of the Company's equity method investments. During 2014 and 2013, the Company also recorded its share of the profits and losses from these investments of $7.0 million and $3.2 million, respectively, as a component of equity in earnings of unconsolidated affiliates in the accompanying consolidated statement of earnings, respectively.
	Partnerships with Health Systems - Ambulatory Services
	During 2014, the Company entered into certain transactions whereby it contributed its controlling interests in four centers in exchange for approximately $1.7 million and noncontrolling interests in three separate entities each jointly owned by a hospital that, after the completion of the transactions, controls the contributed centers. Additionally, during 2014, the Company paid $0.5 million in exchange for a noncontrolling interest in an entity jointly owned by a hospital that controls a center. As part of the Sheridan acquisition, the Company acquired a noncontrolling interest in an entity jointly owned by physician partners that control a center. During 2013, the Company entered into a transaction whereby it contributed $0.3 million plus a controlling interest in one center in exchange for a noncontrolling interest in an entity jointly owned by a hospital that, after the completion of the transaction, controlled the contributed center and one additional center. Management of the Company believes these structures provide both economies of scale and potential future growth opportunities in the markets in which the centers are located.
	As a result of these transactions, the Company recorded in the accompanying consolidated balance sheets, as a component of investments in unconsolidated affiliates, the fair value of the noncontrolling interest in the entities which control the contributed centers of approximately $7.0 million and $5.2 million for the years ended December 31, 2014 and 2013, respectively. Additionally, the Company also recorded its share of the profits and losses from these investments of $0.7 million and $0.2 million, as a component of equity in earnings of unconsolidated affiliates in the accompanying consolidated statement of earnings, for the years ended December 31, 2014 and 2013, respectively.
	In each of these transactions, the gain or loss on deconsolidation was determined based on the difference between the fair value of the Company’s noncontrolling interest in the new entity and the carrying value of both the tangible and intangible assets of the contributed centers immediately prior to each transaction. During 2014, the fair value of the Company’s noncontrolling interest was based on estimates of the expected future earnings, and in certain cases, the Company evaluated likely scenarios which were weighted by a range of expected probabilities of 5% to 35%. Accordingly, the Company recognized a net gain on deconsolidation in the accompanying consolidated statements of operations of approximately $3.4 million and $2.2 million for the years ended December 31, 2014 and 2013, respectively.
	Partnerships with Health Systems - Physician Services
	As part of the Sheridan acquisition, the Company acquired an interest in a joint venture with HCA Holdings, Inc. (HCA) that provides hospital-based physician services to certain HCA affiliates. In conjunction with the acquisition of Sheridan, the Company recorded its estimate of the fair value of its investment of $49.4 million on the acquisition date. The Company's investment in this entity is reflected in the accompanying consolidated balance sheets as a component of investments in unconsolidated affiliates. The Company owns 51% of the entity and, under the terms of the limited liability company and related agreements, earns billing and management fees and receives its share of earnings distributions. The Company has no other material obligations or guarantees related to the entity. The Company determined that the entity is a variable interest entity due to the Company’s equity interest, billing and management fees, and earnings distributions received; however, it is not the primary beneficiary of the entity as it does not have the power to direct the activities that most significantly impact the entity's economic performance as a result of its shared control with HCA. Therefore, the Company has accounted for its investment in the entity under the equity method of accounting.
	The Company has recorded its share of the entity's earnings of $3.4 million as a component of equity in earnings of unconsolidated affiliates in the accompanying consolidated statement of earnings during 2014. In addition, the Company recognized management and billing fees totaling $4.7 million during 2014, which are included in net revenue in the accompanying consolidated statement of earnings. Additionally, the Company has recorded a receivable from the entity in the amount of $3.5 million as of December 31, 2014 for certain operating expenses incurred on behalf of the entity. This receivable is included in other current assets in the accompanying consolidated balance sheets.

Dispositions

Dispositions	12 Months Ended
	Dec. 31, 2014
Discontinued Operations and Disposal Groups [Abstract]
Dispositions	Dispositions
	The Company initiated the disposition of certain of its centers due to management’s assessment of the Company’s strategy in the market and due to the limited growth opportunities at these centers. The results of operations of discontinued centers have been classified as discontinued operations in all periods presented.
	Results of operations and associated gain (loss) on disposal of the centers discontinued for the years ended December 31, 2014, 2013 and 2012 are as follows (in thousands):
		2014			2013		2012
	Revenues	$	9,545		$	25,373	$	34,911
	Earnings before income taxes	893			5,607		9,919
	Results of discontinued operations, net of tax:
	Earnings from operations of discontinued interests in surgery centers	710			4,449		7,920
	Gain (loss) on disposal of discontinued interests in surgery centers	(2,006		)	2,602		25
	Net earnings (loss) from discontinued operations	(1,296		)	7,051		7,945
	Less: Net earnings from discontinued operations attributable to noncontrolling interests	283			5,357		5,419
	Net earnings (loss) from discontinued operations attributable to AmSurg Corp. common shareholders	$	(1,579	)	$	1,694	$	2,526
	Cash proceeds from disposal for the years ended December 31, 2014, 2013 and 2012 were $7.1 million, $3.6 million and $7.3 million, respectively.
	As further described in note 1, beginning in 2015, dispositions of centers similar to those disposed of in prior years will no longer qualify for classification in discontinued operations.

Prepaid_and_Other_Current_Asse

Prepaid and Other Current Assets	12 Months Ended
	Dec. 31, 2014
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid and Other Current Assets	Prepaid and Other Current Assets
	The following table presents a summary of items comprising prepaid and other current assets in the accompanying consolidated balance sheets as of December 31, 2014 and 2013 (in thousands):
		2014		2013
	Income taxes receivable	$	28,694	$	1,865
	Prepaid expenses	18,682		12,730
	Deferred compensation plan assets	17,320		13,313
	Deferred income taxes	22,462		3,097
	Other	28,204		5,694
	Total prepaid and other current assets	$	115,362	$	36,699

Property_and_Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment
	Property and equipment are stated at cost.  Equipment held under capital leases is stated at the present value of minimum lease payments at the inception of the related leases.  Depreciation for buildings and improvements is recognized under the straight-line method over 20 to 40 years or, for leasehold improvements, over the remaining term of the lease plus renewal options for which failure to renew the lease imposes a penalty on the Company in such an amount that a renewal appears, at the inception of the lease, to be reasonably assured.  The primary penalty to which the Company is subject is the economic detriment associated with existing leasehold improvements which might be impaired if a decision is made not to continue the use of the leased property.  Depreciation for movable equipment is recognized over useful lives of three to ten years.
	Property and equipment at December 31, 2014 and 2013 were as follows (in thousands):
		2014			2013
	Building and improvements	$	170,420		$	161,805
	Movable equipment	215,444			207,176
	Construction in progress	11,940			2,321
		397,804			371,302
	Less accumulated depreciation	(217,356		)	(207,612		)
	Property and equipment, net	$	180,448		$	163,690
	At December 31, 2014, the Company and its partnerships had unfunded construction and equipment purchases of approximately $7.7 million in order to complete construction in progress.  Depreciation expense for continuing and discontinued operations for the years ended December 31, 2014, 2013 and 2012 was $33.2 million, $29.8 million and $26.7 million, respectively. The Company's capitalized interest for the years ended December 31, 2014, 2013 and 2012 was not significant.

Goodwill_And_Intangible_Assets

Goodwill And Intangible Assets	12 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill And Intangible Assets	Goodwill and Intangible Assets
	The Company’s intangible assets include goodwill and other intangibles, which include the fair value of both the customer relationships with hospitals and trade names acquired in our physician services segment. The Company's indefinite lived intangibles include goodwill and trade names. Goodwill represents the excess of purchase price over the fair value of net assets acquired. The Company evaluates indefinite-lived intangible assets, including goodwill, for impairment at least on an annual basis and more frequently if certain indicators are encountered. Indefinite lived intangibles are to be tested at the reporting unit level, defined as an operating segment or one level below an operating segment (referred to as a component), with the fair value of the reporting unit being compared to its carrying amount. If the fair value of a reporting unit exceeds its carrying amount, the indefinite lived intangibles associated with the reporting unit is not considered to be impaired. The Company completed its annual impairment test as of October 1, 2014, and determined that its indefinite lived intangibles were not impaired. The Company's finite lived intangibles includes its customer relationship with hospitals. The Company tests its finite lived intangibles for impairment whenever events or circumstances indicate that the carrying amount may not be recoverable. The Company's policy is to recognize an impairment charge when the carrying amount is not recoverable and such amount exceeds fair value. During the year ended December 31, 2014, there were no events or circumstances that indicated a potential impairment in the Company's finite lived intangibles.
	In the fourth quarter of 2014, the Company prospectively changed its annual goodwill impairment testing date from the last day of its fiscal year to the first day of October. The voluntary change was to better align its goodwill impairment testing procedures with the completion of its annual financial and strategic planning process and to provide the Company with adequate time to evaluate goodwill for impairment. As a result, during 2014, the Company tested the goodwill of all of its reporting units for impairment as of October 1, 2014 and concluded that there was no impairment of the carrying value of goodwill.  The change in accounting principle related to changing the annual goodwill impairment testing date did not accelerate, delay, avoid, or cause an impairment charge. This change was not applied retrospectively, as it is impracticable to objectively determine the assumptions that would have been used as of each October 1 for periods prior to October 1, 2014 without the use of hindsight. Accordingly, the change will be applied prospectively.
	The changes in the carrying amount of goodwill for the years ended December 31, 2014 and 2013 are as follows (in thousands):
		2014			2013
	Balance, beginning of year	$	1,758,970		$	1,652,002
	Goodwill acquired, including post acquisition adjustments	1,636,521			112,951
	Goodwill disposed, including impact of deconsolidation transactions	(14,342		)	(5,983		)
	Balance, end of year	$	3,381,149		$	1,758,970
	Although the determination of goodwill generated as a result of the Sheridan transaction is still preliminary as of December 31, 2014, the ambulatory services segment and the physician services segment had approximately $1.9 billion and $1.5 billion, respectively, of goodwill. During the year ended December 31, 2014, goodwill increased $131.2 million for the ambulatory services segment due to acquisitions of centers, including those purchased as part of Sheridan, net of dispositions and deconsolidations. During the year ended December 31, 2014, the majority of goodwill included in the physician services segment was generated as a result of the Sheridan acquisition with the remainder attributable to two acquisitions completed during the fourth quarter of 2014. For the years ended December 31, 2014 and 2013 approximately $51.7 million and $70.2 million, respectively, of goodwill recorded was deductible for tax purposes that relates to the ambulatory services segment. As of December 31, 2014, approximately $12.8 million of goodwill recorded was deductible for tax purposes related to the physician services segment. The acquisition of Sheridan did not result in additional tax deductible goodwill.
	Intangible assets consist primarily of customer relationships with hospitals, deferred financing costs, capitalized software and certain amortizable and non-amortizable non-compete and customer agreements.  Customer relationships with hospitals are initially recorded at their estimated fair value and typically amortized on a straight-line basis over 20 years. Deferred financing costs and amortizable non-compete agreements and customer agreements are amortized over the term of the related debt as interest expense and the contractual term or estimated life (five to ten years) of the agreements as amortization expense. Capitalized software is amortized over estimated useful lives of three to eight years.
	Intangible assets at December 31, 2014 and 2013 consisted of the following (in thousands):
		2014								2013
		Gross								Gross
		Carrying			Accumulated					Carrying		Accumulated
		Amount			Amortization			Net		Amount		Amortization			Net
	Amortizable intangible assets:
	Customer relationships with hospitals	$	971,645		$	(22,145	)	$	949,500	$	—	$	—		$	—
	Deferred financing costs	59,574			(5,151		)	54,423		15,814		(4,953		)	10,861
	Capitalized software	50,387			(19,197		)	31,190		21,036		(14,831		)	6,205
	Agreements, contracts and other	3,523			(2,752		)	771		3,448		(2,472		)	976
	Total amortizable intangible assets	1,085,129			(49,245		)	1,035,884		40,298		(22,256		)	18,042
	Non-amortizable intangible assets:
	Trade name	228,000			—			228,000		—		—			—
	Restrictive covenant arrangements	9,995			—			9,995		9,825		—			9,825
	Total non-amortizable intangible assets	237,995			—			237,995		9,825		—			9,825
	Total intangible assets	$	1,323,124		$	(49,245	)	$	1,273,879	$	50,123	$	(22,256	)	$	27,867
	As a result of the financing for the Sheridan acquisition, the Company recorded an additional $53.0 million and a write-off of $4.5 million of deferred financing costs during the year ended December 31, 2014. The Company amortizes the deferred loan costs to interest expense over the life of the respective debt instrument. Approximately $1.2 billion of intangible assets, primarily customer relationships and trade names, were recorded during the year ended December 31, 2014, of which approximately $1.0 billion are estimated to be amortized over a weighted average period of 20 years with no expected residual values. These acquired intangibles represent the Company’s preliminary estimate of the fair value of the intangible assets related to the customer relationships with hospitals, capitalized software and Sheridan's trade name obtained in the Sheridan acquisition. As previously discussed, this estimated amount is subject to change pending the completion of the valuation and appraisal analysis currently in process.
	Amortization of intangible assets for the years ended December 31, 2014, 2013 and 2012 was $32.5 million, $2.2 million and $1.4 million, respectively, and reflects amounts expensed to depreciation and amortization as well as the portion of amortized deferred financing cost charged to interest expense. Included in the 2014 amount above is also $12.8 million that was charged to interest expenses related to a write-off of a commitment fee for bridge financing, which the Company had secured in order to complete the acquisition of Sheridan but did not require upon obtaining permanent financing.
	Estimated amortization of intangible assets for the five years and thereafter subsequent to December 31, 2014 is $64.7 million, $63.8 million, $62.5 million, $61.6 million, $59.1 million and $724.2 million, respectively.  The Company expects to recognize amortization of all intangible assets over a weighted average period of 18.3 years with no expected residual values.

Other_Accrued_Liabilities

Other Accrued Liabilities	12 Months Ended
	Dec. 31, 2014
Accrued Liabilities, Current [Abstract]
Other Current Liabilities	Other Accrued Liabilities
	The following table presents a summary of items comprising other accrued liabilities in the accompanying consolidated balance sheets as of December 31, 2014 and 2013 (in thousands):
		2014		2013
	Refunds payable	$	17,752	$	—
	Accrued professional liabilities	11,983		1,171
	Contingent purchase price payable	12,213		—
	Other	26,038		6,175
	Total other accrued liabilities	$	67,986	$	7,346

Accrued_Professional_Liabiliti

Accrued Professional Liabilities	12 Months Ended
	Dec. 31, 2014
Payables and Accruals [Abstract]
Accounts Professional Liabilities	Accrued Professional Liabilities
	The Company maintains professional liability insurance policies with third-party insurers generally on a claims-made basis, subject to self-insured retention, exclusions and other restrictions. The Company’s self-insured retention under its professional liability insurance program is also maintained through a wholly-owned captive insurance subsidiary. The Company records an estimate of liabilities for self-insured amounts and claims incurred but not reported based on an actuarial valuation using historical loss patterns and are not discounted.
	At December 31, 2014, the Company had total accrued professional liabilities of $53.8 million, which are included in other accrued liabilities and other long-term liabilities in the accompanying consolidated balance sheets and consisted of the following (in thousands):
		2014
	Estimated losses under self-insured programs	$	25,337
	Incurred but not reported losses	28,448
	Total accrued professional liabilities	53,785
	Less estimated losses payable within one year	11,983
	Total	$	41,802
	The changes to the Company's estimated losses under self-insured programs as of December 31, 2014 were as follows (in thousands):
	Balance at December 31, 2013	$	1,171
	Assumed liabilities through acquisitions	53,512
	Provision related to current period reserves	5,423
	Payments for current period reserves	(1,595		)
	Benefit related to changes in prior period reserves	(661		)
	Payments for prior period reserves	(6,055		)
	Other, net	1,990
	Balance at December 31, 2014	$	53,785

LongTerm_Debt

Long-Term Debt	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Long-Term Debt	Long-term Debt
	Long-term debt at December 31, 2014 and 2013 consisted of the following (in thousands):
		2014			2013
	Revolving credit agreement	$	—		$	252,500
	Term loan	865,650			—
	5.625% Senior Unsecured Notes due 2020	250,000			250,000
	5.625% Senior Unsecured Notes due 2022	1,100,000			—
	8.04% Senior Secured Notes due 2020	—			69,643
	Other debt at an average rate of 3.4%, due through 2025	20,156			21,149
	Capitalized lease arrangements at an average rate of 5.4%, due through 2031	15,206			10,850
		2,251,012			604,142
	Less current portion	18,826			20,844
	Long-term debt	$	2,232,186		$	583,298
	Principal payments required on the Company’s long-term debt and capital leases in the five years and thereafter subsequent to December 31, 2014 are $18.8 million, $15.9 million, $13.7 million, $11.4 million, $10.2 million, and $2,181.0 million. The fair value of fixed rate long-term debt, with a carrying value of $1,383.4 million, was $1,418.6 million at December 31, 2014. The fair value of variable rate long-term debt approximates its carrying value of $867.6 million at December 31, 2014.  With the exception of the Company’s 2020 and 2022 Senior Unsecured Notes, the fair value of fixed rate debt (Level 2) is determined based on an estimation of discounted future cash flows of the debt at rates currently quoted or offered to the Company for similar debt instruments of comparable maturities by its lenders.  The fair value of the Company’s 2020 and 2022 Senior Unsecured Notes (Level 1) is determined based on quoted prices in an active market.
	a.     Term Loan and Credit Facility
	On July 16, 2014, the Company terminated its existing revolving credit facility and entered into a new credit facility that was comprised of an $870.0 million term loan and a $300.0 million revolving credit facility.
	The term loan matures on July 16, 2021 and bears interest at a rate equal to, at the Company’s option, ABR plus 1.75% to 2.00% or LIBOR plus 2.75% to 3.00%, with a LIBOR floor of 0.75%, or a combination thereof (3.75% on December 31, 2014). The term loan requires quarterly principal payments of 0.25% of the face amount totaling $8.7 million annually.
	The new revolving credit facility matures on July 16, 2019 and permits the Company to borrow up to $300.0 million at an interest rate equal to, at the Company’s option, the ABR plus 1.75% to 2.00% or LIBOR plus 2.75% to 3.00%, or a combination thereof; and provides for a fee of 0.375% of unused commitments. In accordance with the terms of the senior secured credit facility, principal payments are required quarterly in installments of an amount equal to 0.25% of the aggregate initial principal amount of the term loan. The Company has the option to increase borrowings under the new senior secured credit facility by an aggregate amount not to exceed the greater of $300.0 million and an unlimited amount as long as certain financial covenants are met and lender approval is obtained. The new senior credit facility contains certain covenants relating to the ratio of debt to operating performance measurements and interest coverage ratios and is secured by a pledge of the stock of the Company’s wholly-owned subsidiaries and certain of the Company’s partnership and membership interests in the limited partnerships and limited liability companies. As of December 31, 2014, the Company was in compliance with the covenants contained in the term loan and credit facility. As of December 31, 2014, the Company had not drawn upon the revolving credit facility.
	Prior to entering into the Company's new credit facility, the Company maintained a revolving credit facility which had a maturity of June 2018 and permitted the Company to borrow up to $475.0 million at an interest rate equal to either the base rate plus 0.25% to 1.00% or LIBOR plus 1.25% to 2.00%, or a combination thereof. On July 3, 2014, the Company utilized proceeds received from its common and preferred stock offerings to repay its outstanding obligation under the existing revolving credit facility. As a result of the early termination, the Company recognized approximately $4.5 million as debt extinguishment costs in the accompanying statements of operations during the year ended December 31, 2014 related to the write-off of net deferred loan costs.
	b.     Senior Unsecured Notes
	2020 Senior Unsecured Notes
	On November 20, 2012, the Company completed a private offering of $250.0 million aggregate principal amount of 5.625% senior unsecured notes due 2020 (the “2020 Senior Unsecured Notes”).  On May 31, 2013, the Company completed an offer to exchange the outstanding 2020 Senior Unsecured Notes for an equal amount of such notes that are registered under the Securities Act of 1933, as amended (the “Securities Act”). The net proceeds from the issuance of the 2020 Senior Unsecured Notes were used to reduce the outstanding indebtedness under the Company’s revolving credit agreement. The 2020 Senior Unsecured Notes are general unsecured obligations of the Company and are guaranteed by its existing and subsequently acquired or organized wholly-owned domestic subsidiaries. The 2020 Senior Unsecured Notes are pari passu in right of payment with all the existing and future senior debt of the Company and senior to all existing and future subordinated debt of the Company. Interest on the 2020 Senior Unsecured Notes accrues at the rate of 5.625% per annum and is payable semi-annually in arrears on May 30 and November 30, through the maturity date of November 30, 2020.
	Prior to November 30, 2015, the Company may redeem up to 35% of the aggregate principal amount of the 2020 Senior Unsecured Notes at a redemption price of 105.625% of the principal amount thereof, plus accrued and unpaid interest and liquidated damages, if any, using proceeds of one or more equity offerings.  On or after November 30, 2015, the Company may redeem the 2020 Senior Unsecured Notes in whole or in part. The redemption price for such a redemption (expressed as percentages of principal amount) is set forth below, plus accrued and unpaid interest and liquidated damages, if any, if redeemed during the twelve-month period beginning on November 30 of the years indicated below:
	Period		Redemption Price
	2015		104.219	%
	2016		102.813	%
	2017		101.406	%
	2018 and thereafter		100	%
	The 2020 Senior Unsecured Notes contain certain covenants which, among other things, limit, but may not restrict the Company’s ability to enter into or guarantee additional borrowings, sell preferred stock, pay dividends and repurchase stock.  The Company was in compliance with the covenants contained in the indenture relating to the 2020 Senior Unsecured Notes at December 31, 2014.
	2022 Senior Unsecured Notes
	On July 16, 2014, the Company completed a private offering of $1.1 billion aggregate principal amount of 5.625% senior unsecured notes due 2022 (the “2022 Senior Unsecured Notes”). The 2022 Senior Unsecured Notes are general unsecured obligations of the Company and are guaranteed by the Company and existing and subsequently acquired or organized wholly-owned domestic subsidiaries (the “Guarantors”). The 2022 Senior Unsecured Notes are pari passu in right of payment with all the existing and future senior debt of the Company and senior to all existing and future subordinated debt of the Company. Interest on the 2022 Senior Unsecured Notes accrues at the rate of 5.625% per annum and is payable semi-annually in arrears on January 15 and July 15, beginning on January 15, 2015, and ending on the maturity date of July 15, 2022.
	Prior to July 15, 2017, the Company may redeem up to 35% of the aggregate principal amount of the 2022 Senior Unsecured Notes at a redemption price of 105.625% of the principal amount thereof, plus accrued and unpaid interest and liquidated damages, if any, using proceeds of one or more equity offerings. On or after July 15, 2017, the Company may redeem the 2022 Senior Unsecured Notes in whole or in part. The redemption price for such a redemption (expressed as percentages of principal amount) is set forth below, plus accrued and unpaid interest and liquidated damages, if any, if redeemed during the twelve-month period beginning on July 15 of the years indicated below:
	Period		Redemption Price
	2017		104.219	%
	2018		102.813	%
	2019		101.406	%
	2020 and thereafter		100	%
	The 2022 Senior Unsecured Notes contain certain covenants which, among other things, limit, but may not restrict the Company’s ability to enter into or guarantee additional borrowings, sell preferred stock, pay dividends and repurchase stock. Based on the terms of the 2022 Notes, the Company has adequate ability to meet its obligations to pay dividends as required under the terms of its mandatory preferred stock. The Company was in compliance with the covenants contained in the indenture relating to the 2022 Senior Unsecured Notes at December 31, 2014.
	In connection with the issuance of the 2022 Senior Unsecured Notes, the Company entered into a registration rights agreement, dated July 16, 2014 (the “Registration Rights Agreement”). On January 16, 2015, under the terms of the Registrations Rights Agreement, the Company commenced an offer to exchange the outstanding 2022 Senior Unsecured Notes for an equal amount of such notes that are registered under the Securities Act of 1933, as amended. The exchange offer was completed on February 19, 2015, and all holders of the 2022 Senior Unsecured Notes participated in the exchange.
	c.     Senior Secured Notes
	On May 28, 2010, the Company issued $75.0 million principal amount of senior secured notes (the “Senior Secured Notes”) pursuant to a note purchase agreement.  The Senior Secured Notes had a maturity date of May 28, 2020.  The Senior Secured Notes, which were originally issued with a stated interest rate of 6.04%, were amended on November 7, 2012 to allow for the Company’s issuance of the 2020 Senior Unsecured Notes, resulting in an increase in the annual interest rate to 8.04%, and certain other adjustments to the existing covenants.  Principal payments on the Senior Secured Notes did not begin until August 2013.  On July 16, 2014, the Company redeemed the Senior Secured Notes utilizing proceeds received from its common and preferred stock offerings. As a result of the early extinguishment, the Company paid an early termination fee of approximately $12.4 million to the holders of the Senior Secured Notes, which is recognized as a component of debt extinguishment costs during the year ended December 31, 2014 in the accompanying statements of operations.
	d.     Other debt
	Certain partnerships included in the Company’s consolidated financial statements have loans with local lending institutions, included above in other debt, which are collateralized by certain assets of the surgery centers with a book value of approximately $47.8 million. The Company and the partners have guaranteed payment of the loans in proportion to the relative partnership interests.

Other_Longterm_Liabilities

Other Long-term Liabilities	12 Months Ended
	Dec. 31, 2014
Other Liabilities Disclosure [Abstract]
Other Long-term Liabilities	Other Long-term Liabilities
	The following table presents a summary of items comprising other long-term liabilities in the accompanying consolidated balance sheets as of December 31, 2014 and 2013 (in thousands):
		2014		2013
	Accrued professional liabilities	$	41,802	$	—
	Contingent purchase price payable	8,470		—
	Deferred rent	16,814		14,637
	Tax-effected unrecognized benefits	8,353		6,888
	Other	14,004		3,978
	Other long-term liabilities	$	89,443	$	25,503

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes
	The Company files a consolidated federal income tax return.  Income taxes are accounted for under the asset and liability method.  Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.
	The Company applies recognition thresholds and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return as it relates to accounting for uncertainty in income taxes.  In addition, it is the Company’s policy to recognize interest accrued and penalties, if any, related to unrecognized benefits as income tax expense in its statement of earnings.  The Company does not expect significant changes to its tax positions or liability for tax uncertainties during the next 12 months.
	The Company and its subsidiaries file income tax returns in the U.S. federal jurisdiction and various state jurisdictions.  With few exceptions, the Company is no longer subject to U.S. federal or state income tax examinations for years prior to 2011.
	Total income taxes expense (benefit) for the years ended December 31, 2014, 2013 and 2012 was included within the following sections of the consolidated financial statements as follows (in thousands):
		2014			2013			2012
	Income from continuing operations	$	48,103		$	48,654		$	40,893
	Discontinued operations	(643		)	9			3,045
	Shareholders’ equity	(3,177		)	(7,381		)	(1,581		)
	Total	$	44,283		$	41,282		$	42,357
	Income tax expense from continuing operations for the years ended December 31, 2014, 2013 and 2012 was comprised of the following (in thousands):
		2014			2013			2012
	Current:
	Federal	$	8,640		$	7,895		$	14,602
	State	4,396			3,598			4,806
	Deferred:
	Federal	27,505			31,509			18,018
	State	7,562			5,652			3,467
	Income tax expense	$	48,103		$	48,654		$	40,893
	Income tax expense from continuing operations for the years ended December 31, 2014, 2013 and 2012 differed from the amount computed by applying the U.S. federal income tax rate of 35% to earnings before income taxes as a result of the following (in thousands):
		2014			2013			2012
	Statutory federal income tax	$	102,967		$	106,101		$	89,806
	Less federal income tax assumed directly by noncontrolling interests	(66,783		)	(64,219		)	(56,378		)
	State income taxes, net of federal income tax benefit	6,616			5,539			7,020
	Increase in valuation allowances	4,662			924			419
	Interest related to unrecognized tax benefits	(161		)	(155		)	(109		)
	Other	802			464			135
	Income tax expense	$	48,103		$	48,654		$	40,893
	The Company recognizes interest and penalties related to unrecognized tax benefits in income tax expense.  Decreases in interest and penalty obligations of $0.1 million, $0.2 million and $0.1 million were recognized in the consolidated statement of earnings for the years ended December 31, 2014, 2013 and 2012, respectively, resulting in a total recognition of interest and penalty obligations of approximately $1.2 million and $0.9 million in the consolidated balance sheet at December 31, 2014 and 2013, respectively.
	The Company primarily has unrecognized tax benefits that represent an amortization deduction which is temporary in nature.  A reconciliation of the beginning and ending amount of the liability associated with unrecognized tax benefits for the years ended December 31, 2014, 2013 and 2012 is as follows (in thousands):
		2014			2013			2012
	Balance at beginning of year	$	6,330		$	9,235		$	7,252
	Additions for tax positions of current year	204			46			119
	Increases for tax positions taken during a prior period	1,069			—			1,985
	Lapse of statute of limitations	(267		)	(2,951		)	(121		)
	Balance at end of year	$	7,336		$	6,330		$	9,235
	The Company believes that the total amount of increases in unrecognized tax benefits within the next 12 months will not be significant.  The total amount of unrecognized tax benefits that would affect the Company’s effective tax rate if recognized is approximately $0.4 million.
	The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at December 31, 2014 and 2013 were as follows (in thousands):
		2014			2013
	Deferred tax assets:
	Allowance for uncollectible accounts	$	1,096		$	897
	Accrued assets and other	27,537			5,292
	Valuation allowances	(3,736		)	(2,021		)
	Total current deferred tax assets	24,897			4,168
	Share-based compensation	7,719			7,635
	Interest on unrecognized tax benefits	245			230
	Accrued liabilities and other	3,931			3,629
	Medical malpractice	16,240			—
	Operating and capital loss carryforwards	22,709			9,185
	Valuation allowances	(13,721		)	(7,665		)
	Total non-current deferred tax assets	37,123			13,014
	Total deferred tax assets	62,020			17,182
	Deferred tax liabilities:
	Prepaid expenses	2,435			1,071
	Property and equipment, principally due to differences in depreciation	15,235			4,137
	Goodwill, intangible assets and other, principally due to differences in amortization	655,368			184,897
	Total deferred tax liabilities	673,038			190,105
	Net deferred tax liabilities	$	611,018		$	172,923
	The net deferred tax liabilities at December 31, 2014 and 2013 were recorded as follows (in thousands):
		2014			2013
	Current deferred income tax assets	$	22,462		$	3,097
	Non-current deferred income tax liabilities	633,480			176,020
	Net deferred tax liabilities	$	611,018		$	172,923
	The Company has provided valuation allowances on its gross deferred tax assets to the extent that management does not believe that it is more likely than not that such asset will be realized.  Capital loss carryforwards began to expire in 2014, and state net operating losses will begin to expire in 2015.

Shareholders_Equity

Shareholders' Equity	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Shareholders' Equity	Shareholders’ Equity
	a.   Common Stock
	On July 2, 2014, the Company issued 9,775,000 shares of its common stock in a public offering, at $45.00 per share, prior to underwriting discounts, commissions and other related offering expenses of approximately $18.5 million. Proceeds from the issuance were used to satisfy certain debt obligations with the remaining amount utilized to fund a portion of the Sheridan acquisition. In addition, on July 16, 2014, the Company issued 5,713,909 shares of its common stock directly to the former owners of Sheridan as part of the total consideration for the Sheridan acquisition.
	In connection with the Sheridan transaction, the Company entered into a registration rights agreement (the “Equity Registration Rights Agreement”) with the former owners of Sheridan, which provides certain demand and piggy-back registration rights with respect to the shares of Company common stock issued pursuant to the Sheridan transaction. Under the Equity Registration Rights Agreement, the Company was required, at the demand of the former owners of Sheridan, to file a shelf registration statement to register the shares of common stock issued pursuant to the Sheridan transaction. On October 22, 2014, pursuant to a request under the Equity Registration Rights Agreement, the Company filed a registration statement on Form S-3 with the Securities and Exchange Commission to register the common stock to certain of the former owners of Sheridan. During November 2014, the shares registered on Form S-3 were sold. As a result of that transaction, the Company has no future obligation to register additional shares under the Equity Registration Rights Agreement.
	On April 24, 2012, the Board of Directors authorized a stock purchase program for up to $40.0 million of the Company’s shares of common stock.  The Company completed this repurchase program in August 2013.  On August 9, 2013, the Board of Directors authorized a stock purchase program for up to $40.0 million of the Company’s shares of common stock which expired on February 9, 2015.  As of December 31, 2014, there was approximately $27.1 million available under the stock repurchase program.
	During the year ended 2014, the Company did not purchase any shares under the stock repurchase program.  During the year ended 2013, the Company purchased 1,154,378 shares of the Company’s common stock for approximately $42.7 million, at an average price of $36.93 per share, in order to mitigate the dilutive effect of shares issued upon the exercise of stock options pursuant to the Company’s stock incentive plans.
	In addition, the Company repurchases shares by withholding a portion of employee restricted stock that vested to cover payroll withholding taxes in accordance with the restricted stock agreements.  During 2014 and 2013, the Company repurchased 100,720 shares and 102,252 shares, respectively, of common stock for approximately $4.6 million and $3.3 million, respectively.
	b. Mandatory Convertible Preferred Stock
	On July 2, 2014, the Company issued 1,725,000 shares of its mandatory convertible preferred stock in a public offering, at $100.00 per share, prior to underwriting discounts, commissions and other related offering expenses of approximately $5.9 million.
	The mandatory convertible preferred stock pays dividends at an annual rate of 5.25% of the initial liquidation preference of $100 per share. Dividends accrue and cumulate from the date of issuance and, to the extent lawful and declared by the Company's Board of Directors, will be paid on each January 1, April 1, July 1 and October 1 in cash or, at the Company's election (subject to certain limitations), by delivery of any combination of cash and shares of common stock. Each share of the mandatory convertible preferred stock has a liquidation preference of $100, plus an amount equal to accrued and unpaid dividends. Each share of the mandatory convertible preferred stock will automatically convert on July 1, 2017 (subject to postponement in certain cases), into between 1.8141 and 2.2222 shares of common stock (the “minimum conversion rate” and “maximum conversion rate,” respectively), each subject to adjustment. The number of shares of common stock issuable on conversion will be determined based on the average volume weighted average price per share of the Company's common stock over the 20 consecutive trading day period commencing on and including the 22nd scheduled trading day prior to July 1, 2017. At any time prior to July 1, 2017, holders may elect to convert all or a portion of their shares of mandatory convertible preferred stock into shares of common stock at the minimum conversion rate. If any holder elects to convert shares of mandatory convertible preferred stock during a specified period beginning on the effective date of a fundamental change, as defined in the Description of the Mandatory Convertible Preferred Stock (the “Preferred Stock Agreement”), the conversion rate will be adjusted under certain circumstances and such holder will also be entitled to a fundamental change dividend make-whole amount (as defined in the Preferred Stock Agreement).
	On August 29, 2014, the Company's Board of Directors declared its first dividend of $1.2979 per share in cash, or $2.2 million, for the Company’s 5.25% Mandatory Convertible Preferred Stock. Subsequent quarterly dividends, to the extent lawful and declared by the Company’s Board of Directors, will be $1.3125 per share, or $2.3 million, of Mandatory Convertible Preferred Stock. For the year ended December 31, 2014, the Company's Board of Directors declared dividend payments in August and November, respectively, totaling $4.5 million.
	c.   Stock Incentive Plans
	Transactions in which the Company receives employee and non-employee services in exchange for the Company’s equity instruments or liabilities that are based on the fair value of the Company’s equity securities or may be settled by the issuance of these securities are accounted using a fair value method. The Company applies the Black-Scholes method of valuation in determining share-based compensation expense for option awards.
	Benefits of tax deductions in excess of recognized compensation cost are reported as a financing cash flow, thus reducing the Company’s net operating cash flows and increasing its financing cash flows by $3.2 million, $7.2 million and $1.8 million for the years ended December 31, 2014, 2013 and 2012, respectively.
	The Company examines its concentrations of holdings, its historical patterns of award exercises and forfeitures as well as forward-looking factors, in an effort to determine if there were any discernible employee populations.  From this analysis, the Company has identified three employee populations, consisting of senior executives, officers and all other recipients.  The expected volatility rate applied was estimated based on historical volatility.  The expected term assumption applied is based on contractual terms, historical exercise and cancellation patterns and forward-looking factors where present for each population identified.  The risk-free interest rate used is based on the U.S. Treasury yield curve in effect at the time of the grant.  The pre-vesting forfeiture rate is based on historical rates and forward-looking factors for each population identified.  The Company will adjust the estimated forfeiture rate to its actual experience.  The Company intends to retain its earnings to finance growth and development of the business and does not expect to declare or pay any cash dividends in the foreseeable future except as required in accordance with the terms of the Company's mandatory convertible preferred stock.
	In May 2014, the Company adopted the AmSurg Corp. 2014 Equity and Incentive Plan.  The Company also has unvested restricted stock and fully vested options outstanding under the AmSurg Corp. 2006 Stock Incentive Plan, as amended, and the AmSurg Corp. 1997 Stock Incentive Plan, as amended, under which no additional awards may be granted.  Under these plans, the Company has granted restricted stock and non-qualified options to purchase shares of common stock to employees and outside directors from its authorized but unissued common stock.  At December 31, 2014, 1,200,000 shares were authorized for grant under the 2014 Equity and Incentive Plan and 1,132,862 shares were available for future equity grants.  Restricted stock granted to outside directors vests over a one year period.  Restricted stock granted to employees vests over four years in three equal installments beginning on the second anniversary of the date of grant. The fair value of restricted stock is determined based on the closing bid price of the Company’s common stock on the grant date.  Under Company policy, shares held by outside directors and senior management are subject to certain holding restrictions and anti-pledging activities.
	No options have been issued subsequent to 2008 and all outstanding options are fully vested.  Options were granted at market value on the date of the grant and vested over four years.  Outstanding options have a term of ten years from the date of grant.
	Other information pertaining to share-based activity for the years ended December 31, 2014, 2013 and 2012 was as follows (in thousands):
		2014			2013			2012
	Share-based compensation expense	$	10,104		$	8,321		$	6,692
	Fair value of shares vested	15,126			11,742			6,425
	Cash received from option exercises	2,630			33,349			18,214
	Tax benefit from option exercises	3,177			7,247			1,784
	As of December 31, 2014, the Company had total unrecognized compensation cost of approximately $8.4 million related to non-vested awards, which the Company expects to recognize through 2018 and over a weighted average period of 1.2 years.
	Average outstanding share-based awards to purchase approximately 20,000 shares of common stock that had an exercise price in excess of the average market price of the common stock during the year ended December 31, 2012 were not included in the calculation of diluted securities under the treasury method for purposes of determining diluted earnings per share due to their anti-dilutive impact. During the years ended December 31, 2014 and 2013, there were no options that were anti-dilutive.
	A summary of the status of and changes for non-vested restricted shares for the three years ended December 31, 2014, is as follows:
				Weighted
		Number		Average
		of Shares		Grant Price
	Non-vested shares at January 1, 2012	732,412		$	21.91
	Shares granted	281,429		26.78
	Shares vested	(183,019	)	25.98
	Shares forfeited	(2,136	)	26.26
	Non-vested shares at December 31, 2012	828,686		$	22.5
	Shares granted	291,863		31.66
	Shares vested	(360,337	)	21.55
	Shares forfeited	(16,343	)	23.11
	Non-vested shares at December 31, 2013	743,869		$	26.54
	Shares granted	272,780		43.12
	Shares vested	(336,160	)	25.69
	Shares forfeited	(12,380	)	38.94
	Non-vested shares at December 31, 2014	668,109		$	33.51
	A summary of stock option activity for the three years ended December 31, 2014 is summarized as follows:
							Weighted
				Weighted			Average
				Average			Remaining
		Number		Exercise			Contractual
		of Shares		Price			Term (in years)
	Outstanding at January 1, 2012	2,510,054		$	23.09		3.4
	Options exercised with total intrinsic value of $6.3 million	(841,599	)	21.64
	Options terminated	(5,625	)	21.85
	Outstanding at December 31, 2012	1,662,830		$	23.82		2.9
	Options exercised with total intrinsic value of $33.3 million	(1,392,366	)	23.95
	Outstanding at December 31, 2013	270,464		$	23.16		2.5
	Options exercised with total intrinsic value of $2.6 million	(111,743	)	23.53
	Outstanding, Vested and Exercisable at December 31, 2014 with an aggregate intrinsic value of $3.6 million	158,721		$	22.89		1.7
	The aggregate intrinsic value represents the total pre-tax intrinsic value received by the option holders on the exercise date or that would have been received by the option holders had all holders of in-the-money outstanding options at December 31, 2014 exercised their options at the Company’s closing stock price on December 31, 2014.
	d. Earnings per Share
	Basic net earnings attributable to AmSurg Corp. common stockholders, per common share, excludes dilution and is computed by dividing net earnings attributable to AmSurg Corp. common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net earnings attributable to AmSurg common stockholders, per common share is computed by dividing net earnings attributable to AmSurg Corp. common stockholders by the weighted-average number of common shares outstanding during the period plus any potential dilutive common share equivalents, including shares issuable (1) upon the vesting of restricted stock awards as determined under the treasury stock method and (2) upon conversion of the Company's 5.250% Mandatory Convertible Preferred Stock as determined under the if-converted method. For purposes of calculating diluted earnings per share, preferred stock dividends have been subtracted from both net earnings from continuing operations attributable to AmSurg Corp. and net earnings attributable to AmSurg Corp. common shareholders in periods in which utilizing the if-converted method would be anti-dilutive. For the year ended December 31, 2014, 1.8 million common share equivalents related to the Mandatory Convertible Preferred Stock were anti-dilutive and therefore are excluded from the dilutive weighted average number of shares outstanding.
	The following is a reconciliation of the numerator and denominators of basic and diluted earnings per share (in thousands, except per share amounts):
		Earnings			Shares		Per Share
		(Numerator)			(Denominator)		Amount
	For the year ended December 31, 2014:
	Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (basic)	$	50,777		39,311		$	1.29
Effect of dilutive securities options and non-vested shares	—			314
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (diluted)	$	50,777		39,625		$	1.28
For the year ended December 31, 2013:
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (basic)	$	71,009		31,338		$	2.27
Effect of dilutive securities options and non-vested shares	—			616
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (diluted)	$	71,009		31,954		$	2.22
For the year ended December 31, 2012:
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (basic)	$	60,037		30,773		$	1.95
Effect of dilutive securities options and non-vested shares	—			835
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (diluted)	$	60,037		31,608		$	1.9

Leases

Leases	12 Months Ended
	Dec. 31, 2014
Leases [Abstract]
Leases	Leases
	The Company has entered into various building and equipment capital and operating leases in operation and under development and for office space, expiring at various dates through 2036.  Future minimum lease payments, including payments during expected renewal option periods, at December 31, 2014 were as follows (in thousands):
	Year Ended December 31,	Capital Leases		Operating Leases
	2015	$	2,613	$	53,007
	2016	2,146		51,687
	2017	1,901		50,260
	2018	1,594		47,978
	2019	1,388		46,880
	Thereafter	11,361		356,337
	Total minimum rentals	21,003		$	606,149
	Less amounts representing interest at rates ranging from 2.7% to 11.8%	5,797
	Capital lease obligations	$	15,206
	At December 31, 2014, buildings and equipment with a cost of approximately $19.2 million and accumulated depreciation of approximately $4.7 million were held under capital leases.  The Company and the partners in the partnerships have guaranteed payment of certain of these leases.  Rental expense for operating leases for the years ended December 31, 2014, 2013 and 2012 was approximately $66.1 million, $52.6 million and $47.3 million, respectively.

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2014
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions
	Certain surgery centers lease space from entities affiliated with their physician partners at negotiated rates that management believes were equal to fair market value at the inception of the leases based on relevant market data.  Certain surgery centers reimburse their physician partners for salaries and benefits and billing fees related to time spent by employees of their practices on activities of the centers at current market rates.  In addition, certain centers compensate at market rates their physician partners for physician advisory services provided to the surgery centers, including medical director and performance improvement services.
	Related party payments for the years ended December 31, 2014, 2013 and 2012 were as follows (in thousands):
		2014		2013		2012
	Operating leases	$	27,559	$	29,240	$	29,079
	Salaries and benefits	66,763		72,892		65,908
	Billing fees	9,899		11,591		11,126
	Medical advisory services	2,811		2,993		2,671
	The Company also reimburses their physician partners for operating expenses paid by the physician partners to third party providers on the behalf of the surgery center. The Company believes that the foregoing transactions are reasonably expected to benefit the Company and that the amount of reimbursed expenses included in other operating expenses in the accompanying consolidated statements of earnings for each of the years ended December 31, 2014, 2013 and 2012 were not significant.
	It is the Company’s policy that all transactions by the Company with officers, directors, five percent shareholders and their affiliates be entered into only if such transactions are on terms no less favorable to the Company than could be obtained from unaffiliated third parties, are reasonably expected to benefit the Company and are approved by the Nominating and Corporate Governance Committee of the Company’s Board of Directors.

Employee_Benefit_Programs

Employee Benefit Programs	12 Months Ended
	Dec. 31, 2014
Compensation and Retirement Disclosure [Abstract]
Employee Benefit Plans	Employee Benefit Programs
	The Company maintains the AmSurg 401(k) Plan and Trust.  This plan is a defined contribution plan covering substantially all employees of the Company and provides for voluntary contributions by these employees, subject to certain limits.  Company contributions are based on specified percentages of employee compensation.  The Company funds contributions as accrued.  The Company’s contributions for the years ended December 31, 2014, 2013 and 2012 were approximately $1.6 million, $1.1 million and $1.0 million, respectively, and vest immediately or incrementally over five years, depending on the tenures of the respective employees for which the contributions were made.
	As part of the Sheridan acquisition, the Company maintains qualified contributory savings plans as allowed under Section 401(k) of the Internal Revenue Code. In addition, in connection with certain acquisitions, the Company continues to maintain defined contribution savings plans allowed under the Internal Revenue Code. The plans permit participant contributions and allow elective Company contributions or required Company contributions subject to the limits defined by each of the Plans. For the year ended December 31, 2014, the Company has recorded expense of approximately $5.6 million related to the Company's contributions to these plans. Employees generally vest incrementally over four years, depending on the tenures of the respective employees for which the contributions were made.
	The Company maintains the Supplemental Executive and Director Retirement Savings Plan.  This plan is a defined contribution plan covering all officers of the Company and provides for voluntary contributions of up to 50% of employee annual compensation.  Company contributions are at the discretion of the Compensation Committee of the Board of Directors and vest incrementally over five years.  The employee and employer contributions are placed in a Rabbi Trust and recorded in the accompanying consolidated balance sheets in prepaid and other current assets.  Employer contributions to this plan for the years ended December 31, 2014, 2013 and 2012 were approximately $0.8 million, $2.3 million and $1.7 million, respectively. As of December 31, 2014 and 2013, the cash surrender value of the supplemental executive and director retirement savings plan investments, which are included in prepaid and other current assets in the accompanying consolidated balance sheets, was $17.3 million and $13.3 million, respectively.

Commitments_And_Contingencies

Commitments And Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments And Contingencies	Commitments and Contingencies
	Litigation
	From time to time the Company is named as a party to legal claims and proceedings in the ordinary course of business. The Company's management is not aware of any claims or proceedings that are expected to have a material adverse impact on the Company's consolidated financial condition, results of operations or cash flows.
	Insurance Programs
	Given the nature of the services provided, the Company and its subsidiaries are subject to professional and general liability claims and related lawsuits in the ordinary course of business. The Company maintains professional insurance with third-party insurers generally on a claims-made basis, subject to self-insured retentions, exclusions and other restrictions. A substantial portion of the professional liability loss risks are being provided by a third-party insurer which is fully reinsured by the Company's wholly-owned captive. In addition, the wholly-owned captive provides stop loss coverage for the Company’s self-insured employee health program. The assets, liabilities and results of operations of the wholly-owned captive are consolidated in the accompanying consolidated financial statements. The liabilities for self-insurance in the accompanying consolidated balance sheets include estimates of the ultimate costs related to both reported claims on an individual and aggregate basis and unreported claims. The Company also obtains professional liability insurance on a claims-made basis from third party insurers for its surgery centers and certain of its owned practices and employed physicians.
	The Company’s reserves for professional liability claims within the self-insured retention are based upon periodic actuarial calculations. These actuarial estimates consider historical claims frequency and severity, loss development patterns and other actuarial assumptions and are not discounted to present value.
	The Company also maintains insurance for director and officer liability, workers’ compensation liability and property damage.  Certain policies are subject to deductibles.  In addition to the insurance coverage provided, the Company indemnifies its officers and directors for actions taken on behalf of the Company and its subsidiaries.
	Redeemable Noncontrolling Interests
	Certain of the Company’s wholly-owned subsidiaries, as general partners in the LPs, are responsible for all debts incurred but unpaid by the LPs. As manager of the operations of the LPs, the Company has the ability to limit potential liabilities by curtailing operations or taking other operating actions. In the event of a change in current law that would prohibit the physicians’ current form of ownership in the partnerships, the Company would be obligated to purchase the physicians’ interests in a substantial majority of the Company’s partnerships.  The purchase price to be paid in such event would be determined by a predefined formula, as specified in the partnership agreements.  The Company believes the likelihood of a change in current law that would trigger such purchases was remote as of December 31, 2014. As a result, the noncontrolling interests that are subject to this redemption feature are not included as part of the Company’s equity and are classified as noncontrolling interests – redeemable on the Company’s consolidated balance sheets.
	Corporate Headquarters Operating Lease
	On December 27, 2012, the Company entered into a lease agreement to lease an approximately 110,000 square foot building in Nashville, Tennessee that will serve as its corporate headquarters. The Company took possession of the building in the fourth quarter of 2014.

Segment_Reporting

Segment Reporting	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Segment Reporting	Segment Reporting
	Prior to the Sheridan acquisition, the Company operated its centers as individual components of one operating and reportable segment. Upon completion of the Sheridan acquisition, the Company operates in two major lines of business - the operation of ambulatory surgery centers and providing multi-specialty outsourced physician services, which have been identified as its operating and reportable segments. Through the ambulatory services segment, the Company acquires, develops and operates ambulatory surgery centers in partnership with physicians. Through the physician services segment, the Company provides outsourced physician services in multiple specialties to hospitals, ambulatory surgery centers and other healthcare facilities, primarily in the areas of anesthesiology, children’s services, emergency medicine and radiology.
	The Company’s financial information by operating segment is prepared on an internal management reporting basis that the chief operating decision maker uses to allocate resources and assess the performance of the operating segments. The Company’s operating segments have been defined based on the separate financial information that is regularly produced and reviewed by the Company’s chief operating decision maker which is its Chief Executive Officer.
	The following table presents financial information for each reportable segment (in thousands):
		Year ended December 31,
		2014			2013			2012
	Net Revenue:
	Ambulatory Services	$	1,109,935		$	1,057,196		$	899,245
	Physician Services	512,014			—			—
	Total	$	1,621,949		$	1,057,196		$	899,245
	Adjusted Segment EBITDA:
	Ambulatory Services	$	197,377		$	187,972		$	154,527
	Physician Services	107,105			—			—
	Total	$	304,482		$	187,972		$	154,527
	Adjusted Segment EBITDA:	$	304,482		$	187,972		$	154,527
	Earnings from continuing operations attributable to noncontrolling interests	190,809			183,484			155,661
	Interest expense, net	(83,285		)	(29,525		)	(16,950		)
	Depreciation and amortization	(60,344		)	(32,400		)	(29,255		)
	Share-based compensation	(10,104		)	(8,321		)	(6,692		)
	Transaction costs	(33,890		)	(300		)	(700		)
	Debt extinguishment costs	(16,887		)	—			—
	Gain on deconsolidation	3,411			2,237			—
	Earnings from continuing operations before income taxes	$	294,192		$	303,147		$	256,591
	Acquisition and Capital Expenditures:
	Ambulatory Services (1)	$	81,156		$	102,450		$	306,252
	Physician Services	28,909			—			—
	Total	$	110,065		$	102,450		$	306,252
		2014			2013
	Assets:
	Ambulatory Services	$	2,528,525		$	2,177,944
	Physician Services	2,994,999			—
	Total	$	5,523,524		$	2,177,944
	-1	Excludes the purchase price to acquire Sheridan.

Financial_Information_for_the_

Financial Information for the Company and Its Subsidiaries	12 Months Ended
	Dec. 31, 2014
Condensed Financial Information of Parent Company Only Disclosure [Abstract]
Financial Information for the Company and Its Subsidiaries	Financial Information for the Company and Its Subsidiaries
	The 2020 Senior Unsecured Notes and 2022 Senior Unsecured Notes are senior unsecured obligations of the Company and are guaranteed by its existing and subsequently acquired or organized 100% owned domestic subsidiaries.  The 2020 Senior Unsecured Notes and 2022 Senior Unsecured Notes are guaranteed on a full and unconditional and joint and several basis, with limited exceptions considered customary for such guarantees, including the release of the guarantee when a subsidiary's assets are sold. The following condensed consolidating financial statements present the Company (as parent issuer), the subsidiary guarantors, the subsidiary non-guarantors and consolidating adjustments. These condensed consolidating financial statements have been prepared and presented in accordance with Rule 3-10 of Regulation S-X “Financial Statements of Guarantors and Issuers of Guaranteed Securities Registered or Being Registered.”  The operating and investing activities of the separate legal entities are fully interdependent and integrated. Accordingly, the results of the separate legal entities are not representative of what the operating results would be on a stand-alone basis.
	Condensed Consolidating Balance Sheet - December 31, 2014 (In thousands)
			Parent Issuer				Guarantor Subsidiaries				Non-Guarantor Subsidiaries				Consolidating Adjustments				Total Consolidated
	Assets
	Current assets:
	Cash and cash equivalents		$	134,351			$	23,471			$	50,257			$	—			$	208,079
	Restricted cash and marketable securities		—				—				10,219				—				10,219
	Accounts receivable, net		—				123,772				109,281				—				233,053
	Supplies inventory		—				301				19,673				—				19,974
	Prepaid and other current assets		47,997				58,388				13,795				(4,818		)		115,362
	Total current assets		182,348				205,932				203,225				(4,818		)		586,687
	Property and equipment, net		10,391				9,972				160,085				—				180,448
	Investments in and receivables from unconsolidated affiliates		3,912,804				1,587,881				—				(5,425,210		)		75,475
	Goodwill		—				1,490,981				—				1,890,168				3,381,149
	Intangible assets, net		67,678				1,203,218				2,983				—				1,273,879
	Other assets		3,323				943				23,086				(1,466		)		25,886
	Total assets		$	4,176,544			$	4,498,927			$	389,379			$	(3,541,326	)		$	5,523,524
	Liabilities and Equity
	Current liabilities:
	Current portion of long-term debt		$	8,700			$	—			$	10,126			$	—			$	18,826
	Accounts payable		1,849				35				31,781				(4,080		)		29,585
	Accrued salaries and benefits		25,035				101,395				13,614				—				140,044
	Accrued interest		29,621				—				23				—				29,644
	Other accrued liabilities		8,051				44,305				16,368				(738		)		67,986
	Total current liabilities		73,256				145,735				71,912				(4,818		)		286,085
	Long-term debt		2,206,950				—				53,648				(28,412		)		2,232,186
	Deferred income taxes		209,400				425,546				—				(1,466		)		633,480
	Other long-term liabilities		7,391				63,616				18,436				—				89,443
	Intercompany payable		—				1,219,979				8,010				(1,227,989		)		—
	Noncontrolling interests – redeemable		—				—				63,544				120,555				184,099
	Equity:
	Total AmSurg Corp. equity		1,679,547				2,644,051				130,206				(2,774,257		)		1,679,547
	Noncontrolling interests – non-redeemable		—				—				43,623				375,061				418,684
	Total equity		1,679,547				2,644,051				173,829				(2,399,196		)		2,098,231
	Total liabilities and equity		$	4,176,544			$	4,498,927			$	389,379			$	(3,541,326	)		$	5,523,524
	Condensed Consolidating Balance Sheet - December 31, 2013 (In thousands)
			Parent Issuer				Guarantor Subsidiaries				Non-Guarantor Subsidiaries				Consolidating Adjustments				Total Consolidated
	Assets
	Current assets:
	Cash and cash equivalents		$	6,710			$	—			$	44,130			$	—			$	50,840
	Accounts receivable, net		—				—				105,072				—				105,072
	Supplies inventory		33				—				18,381				—				18,414
	Prepaid and other current assets		27,090				—				13,971				(4,362		)		36,699
	Total current assets		33,833				—				181,554				(4,362		)		211,025
	Property and equipment, net		6,024				—				157,666				—				163,690
	Investments in and receivables from unconsolidated affiliates		1,484,108				1,453,596				—				(2,922,178		)		15,526
	Goodwill		—				—				—				1,758,970				1,758,970
	Intangible assets, net		24,489				—				3,378				—				27,867
	Other assets		866				—				—				—				866
	Total assets		$	1,549,320			$	1,453,596			$	342,598			$	(1,167,570	)		$	2,177,944
	Liabilities and Equity
	Current liabilities:
	Current portion of long-term debt		$	10,714			$	—			$	10,130			$	—			$	20,844
	Accounts payable		1,972				—				29,487				(3,958		)		27,501
	Accrued salaries and benefits		21,115				—				11,179				—				32,294
	Accrued interest		1,847				—				38				—				1,885
	Other accrued liabilities		4,457				—				3,293				(404		)		7,346
	Total current liabilities		40,105				—				54,127				(4,362		)		89,870
	Long-term debt		561,429				—				53,246				(31,377		)		583,298
	Deferred income taxes		176,020				—				—				—				176,020
	Other long-term liabilities		7,569				—				17,934				—				25,503
	Noncontrolling interests – redeemable		—				—				63,704				113,993				177,697
	Equity:
Total AmSurg Corp. equity		764,197				1,453,596				114,671				(1,568,267		)		764,197
Noncontrolling interests – non-redeemable		—				—				38,916				322,443				361,359
Total equity		764,197				1,453,596				153,587				(1,245,824		)		1,125,556
Total liabilities and equity		$	1,549,320			$	1,453,596			$	342,598			$	(1,167,570	)		$	2,177,944
Condensed Consolidating Statement of Earnings - Year Ended December 31, 2014 (In thousands)
	Parent Issuer				Guarantor Subsidiaries				Non-Guarantor Subsidiaries				Consolidating Adjustments				Total Consolidated
Net revenues	$	24,773			$	508,572			$	1,112,940			$	(24,336	)		$	1,621,949
Operating expenses:
Salaries and benefits	65,697				350,615				284,050				(5,786		)		694,576
Supply cost	—				1,292				163,004				—				164,296
Other operating expenses	18,667				53,413				231,398				(18,550		)		284,928
Transaction costs	29,004				4,886				—				—				33,890
Depreciation and amortization	4,044				25,610				30,690				—				60,344
Total operating expenses	117,412				435,816				709,142				(24,336		)		1,238,034
Gain on deconsolidation	3,411				3,411				—				(3,411		)		3,411
Equity in earnings of unconsolidated affiliates	234,246				211,889				—				(439,097		)		7,038
Operating income	145,018				288,056				403,798				(442,508		)		394,364
Interest expense, net	47,997				33,026				2,262				—				83,285
Debt extinguishment costs	16,887				—				—				—				16,887
Earnings from continuing operations before income taxes	80,134				255,030				401,536				(442,508		)		294,192
Income tax expense	29,166				17,373				1,564				—				48,103
Net earnings from continuing operations	50,968				237,657				399,972				(442,508		)		246,089
Net earnings (loss) from discontinued operations	2,733				—				(4,029		)		—				(1,296		)
Net earnings	53,701				237,657				395,943				(442,508		)		244,793
Net earnings attributable to noncontrolling interests	—				21				191,071				—				191,092
Net earnings attributable to AmSurg Corp. shareholders	53,701				237,636				204,872				(442,508		)		53,701
Preferred stock dividends	(4,503		)		—				—				—				(4,503		)
Net earnings attributable to AmSurg Corp. common shareholders	$	49,198			$	237,636			$	204,872			$	(442,508	)		$	49,198
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax	$	46,465			$	237,636			$	209,184			$	(442,508	)		$	50,777
Earnings (loss) from discontinued operations, net of income tax	2,733				—				(4,312		)		—				(1,579		)
Net earnings attributable to AmSurg Corp. common shareholders	$	49,198			$	237,636			$	204,872			$	(442,508	)		$	49,198
Condensed Consolidating Statement of Earnings - Year Ended December 31, 2013 (In thousands)
	Parent Issuer				Guarantor Subsidiaries				Non-Guarantor Subsidiaries				Consolidating Adjustments				Total Consolidated
Net revenues	$	24,167			$	—			$	1,050,547			$	(17,518	)		$	1,057,196
Operating expenses:
Salaries and benefits	61,038				—				267,014				(467		)		327,585
Supply cost	—				—				153,126				—				153,126
Other operating expenses	22,360				—				211,192				(17,051		)		216,501
Transaction costs	300				—				—				—				300
Depreciation and amortization	3,186				—				29,214				—				32,400
Total operating expenses	86,884				—				660,546				(17,518		)		729,912
Gain on deconsolidation	2,237				2,237				—				(2,237		)		2,237
Equity in earnings of unconsolidated affiliates	204,962				204,962				—				(406,773		)		3,151
Operating income	144,482				207,199				390,001				(409,010		)		332,672
Interest expense, net	27,282				—				2,243				—				29,525
Earnings from continuing operations before income taxes	117,200				207,199				387,758				(409,010		)		303,147
Income tax expense	47,139				—				1,515				—				48,654
Net earnings from continuing operations	70,061				207,199				386,243				(409,010		)		254,493
Net earnings from discontinued operations	2,642				—				4,409				—				7,051
Net earnings	72,703				207,199				390,652				(409,010		)		261,544
Net earnings attributable to noncontrolling interests	—				—				188,841				—				188,841
Net earnings attributable to AmSurg Corp. common shareholders	$	72,703			$	207,199			$	201,811			$	(409,010	)		$	72,703
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax	$	70,061			$	207,199			$	202,759			$	(409,010	)		$	71,009
Earnings (loss) from discontinued operations, net of income tax	2,642				—				(948		)		—				1,694
Net earnings attributable to AmSurg Corp. common shareholders	$	72,703			$	207,199			$	201,811			$	(409,010	)		$	72,703
Condensed Consolidating Statement of Earnings - Year Ended December 31, 2012 (In thousands)
	Parent Issuer				Guarantor Subsidiaries				Non-Guarantor Subsidiaries				Consolidating Adjustments				Total Consolidated
Net revenues	$	19,907			$	—			$	894,239			$	(14,901	)		$	899,245
Operating expenses:
Salaries and benefits	54,895				—				230,083				(450		)		284,528
Supply cost	—				—				126,919				—				126,919
Other operating expenses	19,799				—				180,518				(14,451		)		185,866
Transaction costs	700				—				—				—				700
Depreciation and amortization	2,860				—				26,395				—				29,255
Total operating expenses	78,254				—				563,915				(14,901		)		627,268
Equity in earnings of unconsolidated affiliates	178,137				178,137				—				(354,710		)		1,564
Operating income	119,790				178,137				330,324				(354,710		)		273,541
Interest expense, net	14,803				—				2,147				—				16,950
Earnings from continuing operations before income taxes	104,987				178,137				328,177				(354,710		)		256,591
Income tax expense	39,339				—				1,554				—				40,893
Net earnings from continuing operations	65,648				178,137				326,623				(354,710		)		215,698
Net earnings (loss) from discontinued operations	(3,085		)		—				11,030				—				7,945
Net earnings	62,563				178,137				337,653				(354,710		)		223,643
Net earnings attributable to noncontrolling interests	—				—				161,080				—				161,080
Net earnings attributable to AmSurg Corp. common shareholders	$	62,563			$	178,137			$	176,573			$	(354,710	)		$	62,563
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax	$	65,648			$	178,137			$	170,962			$	(354,710	)		$	60,037
Earnings (loss) from discontinued operations, net of income tax	(3,085		)		—				5,611				—				2,526
Net earnings attributable to AmSurg Corp. common shareholders	$	62,563			$	178,137			$	176,573			$	(354,710	)		$	62,563
Condensed Consolidating Statement of Cash Flows - Year Ended December 31, 2014 (In thousands)
		Parent Issuer				Guarantor Subsidiaries				Non-Guarantor Subsidiaries				Consolidating Adjustments				Total Consolidated
Cash flows from operating activities:
Net cash flows provided by operating activities		$	96,681			$	298,415			$	430,880			$	(413,605	)		$	412,371
Cash flows from investing activities:
Acquisitions and related transactions		(2,124,124		)		(2,188,191		)		1,520				2,126,737				(2,184,058		)
Acquisition of property and equipment		(7,877		)		(9,933		)		(22,407		)		—				(40,217		)
Proceeds from sale of interests in surgery centers		—				7,069				—				—				7,069
Purchases of marketable securities		—				—				(6,474		)		—				(6,474		)
Maturities of marketable securities		—				—				3,486				—				3,486
Other		(3,068		)		(6,594		)		4,721				—				(4,941		)
Net cash flows used in investing activities		(2,135,069		)		(2,197,649		)		(19,154		)		2,126,737				(2,225,135		)
Cash flows from financing activities:
Proceeds from long-term borrowings		2,040,000				—				8,958				—				2,048,958
Repayment on long-term borrowings		(396,493		)		—				(11,982		)		—				(408,475		)
Distributions to owners, including noncontrolling interests		—				(202,247		)		(401,455		)		413,605				(190,097		)
Capital contributions		—				2,124,124				—				(2,124,124		)		—
Proceeds from preferred stock offering		172,500				—				—				—				172,500
Cash dividends for preferred shares		(4,503		)		—				—				—				(4,503		)
Proceeds from common stock offering		439,875				—				—				—				439,875
Payments of equity issuance costs		(24,494		)		—				—				—				(24,494		)
Financing cost incurred		(65,811		)		—				—				—				(65,811		)
Changes in intercompany balances with affiliates, net		2,965				—				(2,965		)		—				—
Other financing activities, net		1,990				828				1,845				(2,613		)		2,050
Net cash flows provided by (used in) financing activities		2,166,029				1,922,705				(405,599		)		(1,713,132		)		1,970,003
Net increase in cash and cash equivalents		127,641				23,471				6,127				—				157,239
Cash and cash equivalents, beginning of period		6,710				—				44,130				—				50,840
Cash and cash equivalents, end of period		$	134,351			$	23,471			$	50,257			$	—			$	208,079
Condensed Consolidating Statement of Cash Flows - Year Ended December 31, 2013 (In thousands)
		Parent Issuer				Guarantor Subsidiaries				Non-Guarantor Subsidiaries				Consolidating Adjustments				Total Consolidated
Cash flows from operating activities:
Net cash flows provided by operating activities		$	45,127			$	208,773			$	426,572			$	(347,648	)		$	332,824
Cash flows from investing activities:
Acquisitions and related transactions		—				(74,288		)		—				694				(73,594		)
Acquisition of property and equipment		(3,693		)		—				(25,163		)		—				(28,856		)
Proceeds from sale of interests in surgery centers		—				3,553				—				—				3,553
Other		—				159				—				—				159
Net cash flows used in investing activities		(3,693		)		(70,576		)		(25,163		)		694				(98,738		)
Cash flows from financing activities:
Proceeds from long-term borrowings		152,700				—				9,504				—				162,204
Repayment on long-term borrowings		(188,081		)		—				(14,002		)		—				(202,083		)
Distributions to owners, including noncontrolling interests		—				(138,875		)		(392,922		)		347,648				(184,149		)
Changes in intercompany balances with affiliates, net		88				—				(88		)		—				—
Other financing activities, net		(6,690		)		678				1,090				(694		)		(5,616		)
Net cash flows used in financing activities		(41,983		)		(138,197		)		(396,418		)		346,954				(229,644		)
Net increase (decrease) in cash and cash equivalents		(549		)		—				4,991				—				4,442
Cash and cash equivalents, beginning of period		7,259				—				39,139				—				46,398
Cash and cash equivalents, end of period		$	6,710			$	—			$	44,130			$	—			$	50,840
Condensed Consolidating Statement of Cash Flows - Year Ended December 31, 2012 (In thousands)
		Parent Issuer				Guarantor Subsidiaries				Non-Guarantor Subsidiaries				Consolidating Adjustments				Total Consolidated
Cash flows from operating activities:
Net cash flows provided by operating activities		$	(83,605	)		$	182,851			$	379,257			$	(182,851	)		$	295,652
Cash flows from investing activities:
Acquisitions and related transactions		(90,029		)		(280,189		)		—				92,830				(277,388		)
Acquisition of property and equipment		(3,681		)		—				(25,183		)		—				(28,864		)
Proceeds from sale of interests in surgery centers		—				7,309				—				—				7,309
Net cash flows used in investing activities		(93,710		)		(272,880		)		(25,183		)		92,830				(298,943		)
Cash flows from financing activities:
Proceeds from long-term borrowings		560,000				—				5,566				—				565,566
Repayment on long-term borrowings		(381,220		)		—				(12,944		)		—				(394,164		)
Distributions to owners, including noncontrolling interests		—				—				(345,792		)		182,851				(162,941		)
Capital contributions		—				90,029				—				(90,029		)		—
Changes in intercompany balances with affiliates, net		(2,666		)		—				2,666				—				—
Other financing activities, net		(70		)		—				3,381				(2,801		)		510
Net cash flows provided by (used in) financing activities		176,044				90,029				(347,123		)		90,021				8,971
Net increase (decrease) in cash and cash equivalents		(1,271		)		—				6,951				—				5,680
Cash and cash equivalents, beginning of period		8,530				—				32,188				—				40,718
Cash and cash equivalents, end of period		$	7,259			$	—			$	39,139			$	—			$	46,398

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events
	The Company assessed events occurring subsequent to December 31, 2014 for potential recognition and disclosure in the consolidated financial statements. In January and February 2015, the Company, through a wholly-owned subsidiary, acquired a majority interest in a surgery center for a purchase price of approximately $42.0 million and acquired two physician practices for an aggregate purchase price of approximately $35.0 million.
	On January 16, 2015, the Company entered into an agreement to lease approximately 222,000 square feet of office space in Plantation, Florida which it intends to be the future headquarters of the Company’s Physician Services Division. The Company expects to occupy approximately 167,000 square feet of office space by September 1, 2016 and an additional approximately 55,000 square feet of space commencing May 1, 2017. The initial term of this lease agreement is set to expire in February 2029. According to the terms of the lease, the Company will take possession in March of 2015 to begin tenant improvements. As the lease is expected to be operating in nature, the Company will begin to recognize rent expense on a straight line basis when possession is obtained. Annual rent expense is expected to be approximately $2.7 million per year.
	Other than the items described above, no events have occurred that would require adjustment to or disclosure in the consolidated financial statements.

Quarterly_Statement_of_Earning

Quarterly Statement of Earnings Data (Unaudited)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Quarterly Statement of Earnings Data (Unaudited)	Quarterly Statement of Earnings Data (Unaudited)
	The following table presents certain quarterly statement of earnings data for the years ended December 31, 2014 and 2013.  The quarterly statement of earnings data set forth below was derived from the Company’s unaudited financial statements and includes all adjustments, consisting of normal recurring adjustments, which the Company considers necessary for a fair presentation thereof.  Results of operations for any particular quarter are not necessarily indicative of results of operations for a full year or predictive of future periods.
		2014											2013
		Q1			Q2		Q3 (2)			Q4			Q1		Q2		Q3		Q4
		(In thousands, except per share data)
	Net revenues	$	259,561		$	278,227	$	502,350		$	581,811		$	253,364	$	262,497	$	262,240	$	279,095
	Earnings from continuing operations before income taxes	73,029			80,487		39,141			101,535			73,069		77,100		72,615		80,363
	Net earnings from continuing operations	60,047			67,689		39,119			79,234			61,068		64,607		61,470		67,348
	Net earnings (loss) from discontinued operations(1)	68			483		(1,697		)	(150		)	1,205		1,229		797		3,820
	Net earnings	60,115			68,172		37,422			79,084			62,273		65,836		62,267		71,168
	Net earnings (loss) attributable to AmSurg Corp. common shareholders:
	Continuing	17,392			18,771		(10,697		)	25,311			17,349		18,093		16,636		18,931
	Discontinued	(197		)	190		(1,376		)	(196		)	462		470		135		627
	Net earnings (loss)	$	17,195		$	18,961	$	(12,073	)	$	25,115		$	17,811	$	18,563	$	16,771	$	19,558
	Basic net earnings (loss) from	$	0.55		$	0.59	$	(0.23	)	$	0.53		$	0.56	$	0.58	$	0.53	$	0.6
	continuing operations per share
	Basic net earnings (loss) per share	$	0.54		$	0.6	$	(0.26	)	$	0.53		$	0.57	$	0.59	$	0.53	$	0.62
	Diluted net earnings (loss) from continuing operations per share	$	0.54		$	0.58	$	(0.23	)	$	0.53		$	0.54	$	0.57	$	0.52	$	0.59
	Diluted net earnings (loss) per share	$	0.54		$	0.59	$	(0.26	)	$	0.53		$	0.56	$	0.58	$	0.52	$	0.61
	(1)      Certain previously reported amounts have been reclassified for current year presentation for discontinued operations.
	(2)     The results of operations for Sheridan are effective July 16, 2014. Additionally, $16.9 million of debt extinguishment costs and $25.1 million of transaction
	costs were incurred during the quarter.

Schedule_II_Valuation_and_Qual

Schedule II – Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2014
Valuation and Qualifying Accounts [Abstract]
Schedule II – Valuation and Qualifying Accounts	AmSurg Corp.
	Schedule II – Valuation and Qualifying Accounts
	For the Years Ended December 31, 2014, 2013 and 2012
	(In thousands)
		Balance at		Charged to		Charge-off			Balance
		Beginning		Cost and		Against			at End of
		of Period		Expenses		Allowances			Period
	Allowance for uncollectible accounts included under the balance sheet caption “Accounts receivable”:
	Year ended December 31, 2014	$	27,862	$	139,274	$	(53,779	)	$	113,357
	Year ended December 31, 2013	$	22,379	$	21,983	$	(16,500	)	$	27,862
	Year ended December 31, 2012	$	18,844	$	20,340	$	(16,805	)	$	22,379

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation
	Ambulatory Services
	AmSurg Corp. (the “Company”), through its wholly-owned subsidiaries, owns interests, primarily 51%, in LPs and LLCs which own and operate ASCs primarily in the following specialties: gastroenterology; multi-specialty; ophthalmology; and orthopaedics.  The Company does not have an ownership interest in a LP or LLC greater than 51% which it does not consolidate.  The Company has ownership interests of less than 51% in ten LPs and LLCs, one of which it consolidates as the Company has substantive participation rights and nine of which it does not consolidate as the Company’s rights are limited to protective rights only.  The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries and the consolidated LPs and LLCs.  Consolidation of such LPs and LLCs is necessary as the Company’s wholly-owned subsidiaries have primarily 51% or more of the financial interest of the LPs and LLCs, are the general partner or majority member with all the duties, rights and responsibilities thereof, are responsible for the day-to-day management of the LPs and LLCs, and have control of the entities.  The responsibilities of the Company’s noncontrolling partners (LPs and noncontrolling members) are to supervise the delivery of medical services, with their rights being restricted to those that protect their financial interests, such as approval of the acquisition of significant assets or the incurrence of debt which they are generally required to guarantee on a pro rata basis based upon their respective ownership interests.  Intercompany profits, transactions and balances have been eliminated.  All LPs and LLCs and noncontrolling partners are referred to herein as “partnerships” and “partners”, respectively.
	Ownership interests in consolidated subsidiaries held by parties other than the Company are identified and generally presented in the consolidated financial statements within the equity section but separate from the Company’s equity.  However, for instances in which certain redemption features that are not solely within the control of the Company are present, classification of noncontrolling interests outside of permanent equity is required.  Consolidated net income attributable to the Company and to the noncontrolling interests are identified and presented on the consolidated statements of operations; changes in ownership interests are accounted for as equity transactions; and when a subsidiary is deconsolidated, any retained noncontrolling equity investment in the former subsidiary and the gain or loss on the deconsolidation of the subsidiary are measured at fair value.  Certain transactions with noncontrolling interests are also classified within financing activities in the statements of cash flows.
	As further described in note 19, upon the occurrence of various fundamental regulatory changes, the Company would be obligated, under the terms of certain partnership and operating agreements, to purchase the noncontrolling interests related to a substantial majority of the Company’s partnerships. While the Company believes that the likelihood of a change in current law that would trigger such purchases was remote as of December 31, 2014, the occurrence of such regulatory changes is outside the control of the Company. As a result, these noncontrolling interests that are subject to this redemption feature are not included as part of the Company’s equity and are classified as noncontrolling interests – redeemable on the Company’s consolidated balance sheets.
	Center profits and losses of consolidated entities are allocated to the Company’s partners in proportion to their ownership percentages and reflected in the aggregate as net earnings attributable to noncontrolling interests.  The partners of the Company’s center partnerships typically are organized as general partnerships, LPs or LLCs that are not subject to federal income tax.  Each partner shares in the pre-tax earnings of the center in which it is a partner.  Accordingly, the earnings attributable to noncontrolling interests in each of the Company’s consolidated partnerships are generally determined on a pre-tax basis, and total net earnings attributable to noncontrolling interests are presented after net earnings.  However, the Company considers the impact of the net earnings attributable to noncontrolling interests on earnings before income taxes in order to determine the amount of pre-tax earnings on which the Company must determine its tax expense.  In addition, distributions from the partnerships are made to both the Company’s wholly-owned subsidiaries and the partners on a pre-tax basis.
	Physician Services
	On July 16, 2014, the Company completed its acquisition of Sheridan. Sheridan is a national provider of multi-specialty physician and administrative services to hospitals, ambulatory surgery centers and other healthcare facilities. Sheridan focuses on delivering comprehensive physician services, primarily in the areas of anesthesiology, children's services, radiology and emergency medicine to healthcare facilities. Through its contracts with healthcare facilities, Sheridan is authorized to bill and collect charges for fee for service medical services rendered by its healthcare professionals and employees in exchange for the provision of services to the patients of these facilities. Contract revenue is earned directly from hospital customers through a variety of payment arrangements that are established when payments from third-party payors are inadequate to support the costs of providing the services required under the contract. Sheridan also provides physician services and manages office-based practices in the areas of gynecology, obstetrics and perinatology. The consolidated financial statements include the accounts of Sheridan and its wholly-owned subsidiaries along with the accounts of affiliated PCs with which Sheridan currently has management arrangements. Sheridan's agreements with these PCs provide that the term of the arrangements is permanent, subject only to termination by the Company, except in the case of gross negligence, fraud or bankruptcy of the Company. These arrangements are captive in nature as a majority of the outstanding voting equity instruments of the PCs are owned by nominee shareholders appointed at the sole discretion of the Company. The Company has a contractual right to transfer the ownership of the PCs at any time to any person it designates as the nominee shareholder. The Company has the right to receive income, both as ongoing fees and as proceeds from the sale of its interest in the PCs, in an amount that fluctuates based on the performance of the PCs and the change in the fair value of the Company’s interest in the PCs. The Company has exclusive responsibility for the provision of all non-medical services required for the day-to-day operation and management of the PCs and establishes the guidelines for the employment and compensation of the physicians and other employees of the PCs. In addition, the agreements provide that the Company has the right, but not the obligation, to purchase, or to designate a person(s) to purchase, the stock of the PCs for a nominal amount. Separately, in its sole discretion, the Company has the right to assign its interest in the management and purchase agreements. Based upon the provisions of these agreements, the Company has determined that the PCs are variable interest entities and that the Company is the primary beneficiary as defined in the accounting guidance for consolidation.
Cash and Cash Equivalents	Cash and Cash Equivalents
	Cash and cash equivalents are comprised principally of demand deposits at banks and other highly liquid short-term investments with maturities of less than three months when purchased. Cash and cash equivalents are reflected in the financial statements at cost, which approximates fair value.
Restricted Cash	Restricted Cash and Marketable Securities
	As of December 31, 2014 the Company had $30.3 million of restricted cash and marketable securities in the accompanying consolidated balance sheets, which is restricted for the purpose of satisfying the obligations of the Company's wholly-owned captive insurance company. The Company has reflected $20.1 million of its restricted cash and marketable securities as a component of other assets in the accompanying consolidated balance sheet. The remaining $10.2 million is reflected as a component of total current assets in the accompanying consolidated balance sheet as such amount is available to satisfy the claims payments estimated to occur in the next twelve months. As of December 31, 2014, the Company had $3.0 million included in restricted cash and marketable securities which are certificates of deposit with maturities less than 180 days, which approximates fair value.
Supplies Inventory	Supplies Inventory
	Supplies inventory consists of medical and drug supplies and is recorded at cost on a first-in, first-out basis.
Fair Value Measurements	Fair Value Measurements
	The fair value of a financial instrument is the amount at which the instrument could be exchanged in an orderly transaction between market participants to sell the asset or transfer the liability.  The inputs used by the Company to measure fair value are classified into the following hierarchy:
	Level 1: Quoted prices in active markets for identical assets or liabilities.
	Level 2: Inputs other than quoted prices included in Level 1 that are observable for the asset or liability through corroboration with market data at the measurement date.
	Level 3: Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date.
	In determining the fair value of assets and liabilities that are measured on a recurring basis at December 31, 2014 and 2013, with the exception of the contingent purchase price payable (further discussed in note 4), the Company utilized Level 1 and 2 inputs to perform such measurements methods, which were commensurate with the market approach. There were no transfers to or from Levels 1 and 2 during the year ended December 31, 2014. The Company's non-patient receivables and accounts payable are reflected in the financial statements at cost, which approximates fair value.
Use of Estimates	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.
Reclassifications	Reclassifications
	Certain amounts in the consolidated financial statements and these notes have been reclassified to conform to the current period presentation. Such reclassifications primarily result from the acquisition of Sheridan and the impact of additional discontinued operations as further discussed in note 6.
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	In April 2014, the Financial Accounting Standards Board issued ASU 2014-08 “Presentation of Financial Statements and Property, Plant and Equipment,” which raised the threshold for a disposal to qualify as a discontinued operation and requires certain new disclosures for individually material disposals that do not meet the new definition of a discontinued operation.  The ASU’s intent is to reduce the number of disposals reported as discontinued operations by focusing on strategic shifts that have or will have a major effect on the Company’s operations and financial results rather than routine disposals that are not a change in the Company’s strategy.  The guidance is effective for interim and annual periods beginning after December 15, 2014, with earlier adoption permitted.  From time to time, the Company will dispose of certain of its entities due to management’s assessment of the Company’s strategy in the market and due to limited growth opportunities at those entities.  Historically, these dispositions were classified as discontinued operations and recorded separately from continuing operations.  Upon adoption in the first quarter of 2015, this ASU will require the Company to record the results of operations and the associated gain or loss from similar dispositions as a component of continuing operations.  The Company does not believe this ASU will have a material impact on the Company’s consolidated financial position or cash flows.
	In May 2014, Financial Accounting Standards Board issued ASU 2014-09 “Revenue from Contracts with Customers,” which will eliminate the transaction and industry-specific revenue recognition guidance under current GAAP and replace it with a principle-based approach using the following steps: identify the contract(s) with a customer, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract and recognize revenue when (or as) the entity satisfies a performance obligation. The guidance in ASU 2014-09 is effective for public entities for annual reporting periods beginning after December 15, 2016, including interim periods therein. Early adoption is not permitted. The Company has yet to assess the impact, if any, this ASU will have on the Company's consolidated financial position, results of operations or cash flows.
	In February 2015, the FASB issued ASU No. 2015-02, "Consolidations (Topic 810) - Amendments to the Consolidation Analysis". The new guidance makes amendments to the current consolidation guidance, including introducing a separate consolidation analysis specific to limited partnerships and other similar entities. Under this analysis, limited partnerships and other similar entities will be considered a variable-interest entity unless the limited partners hold substantive kick-out rights or participating rights. The standard is effective for annual periods beginning after December 15, 2015. The Company has yet to assess the impact, if any, this ASU will have on the Company's consolidated financial position, results of operations or cash flows.
Revenue Recognition	Ambulatory Services
	Ambulatory services revenues consist of billing for the use of the centers’ facilities directly to the patient or third-party payor and, at certain of the Company’s centers (primarily centers that perform gastrointestinal endoscopy procedures), billing for anesthesia services provided by medical professionals employed or contracted by the Company’s centers.  Such revenues are recognized when the related surgical procedures are performed.  Revenues exclude any amounts billed for physicians’ surgical services, which are billed separately by the physicians to the patient or third-party payor.
	Revenues from ambulatory services are recognized on the date of service, net of estimated contractual adjustments from third-party medical service payors including Medicare and Medicaid.  During the years ended December 31, 2014, 2013 and 2012, the Company derived approximately 25%, 25% and 27%, respectively, of its ambulatory services revenues from governmental healthcare programs, primarily Medicare and managed Medicare programs.  Concentration of credit risk with respect to other payors is limited due to the large number of such payors.
	Physician Services
	Physician services revenue primarily consists of fee for service revenue and contract revenue and is derived principally from the provision of physician services to patients of the healthcare facilities the Company serves. Contract revenue represents income earned from the Company's hospital customers to subsidize contract costs when payments from third-party payors are inadequate to support such costs.
	The Company records revenue at the time services are provided, net of a contractual allowance and a provision for uncollectibles. Revenue less the contractual allowance represents the net revenue expected to be collected from third-party payors (including managed care, commercial and governmental payors such as Medicare and Medicaid) and patients insured by these payors.
	The Company also recognizes revenue for services provided during the period but are not yet billed. Expected collections are estimated based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patients’ healthcare plan, mandated payment rates under the Medicare and Medicaid programs, and historical cash collections.
	The Company's provision for uncollectibles includes its estimate of uncollectible balances due from uninsured patients, uncollectible co-pay and deductible balances due from insured patients and special charges, if any, for uncollectible balances due from managed care, commercial and governmental payors. The Company records net revenue from uninsured patients at its estimated realizable value, which includes a provision for uncollectible balances, based on historical cash collections (net of recoveries).
Accounts Receivable	Accounts Receivable
	The Company manages accounts receivable by regularly reviewing its accounts and contracts and by providing appropriate allowances for contractual adjustments and uncollectible amounts. Some of the factors considered by management in determining the amount of such allowances are the historical trends of cash collections, contractual and bad debt write-offs, accounts receivable agings, established fee schedules, contracts with payors, changes in payor mix and procedure statistics. Actual collections of accounts receivable in subsequent periods may require changes in the estimated contractual allowance and provision for uncollectibles. The Company tests its analysis by comparing cash collections to net patient revenues and monitoring self-pay utilization. In addition, when actual collection percentages differ from expected results, on a contract by contract basis, supplemental detailed reviews of the outstanding accounts receivable balances may be performed by the Company’s billing operations to determine whether there are facts and circumstances existing that may cause a different conclusion as to the estimate of the collectability of that contract’s accounts receivable from the estimate resulting from using the historical collection experience. The Company also supplements its allowance for doubtful accounts policy for its physician services quarterly using a hindsight calculation that utilizes write-off data for all payor classes during the previous 12-month period to estimate the allowance for doubtful accounts at a point in time. Changes in these estimates are charged or credited to the consolidated statements of operations in the period of change. Material changes in estimates may result from unforeseen write-offs of patient or third party accounts receivable, unsuccessful disputes with managed care payors, adverse macro-economic conditions which limit patients’ ability to meet their financial obligations for the care provided by physicians, or broad changes to government regulations that adversely impact reimbursement rates for services provided by the Company. Significant changes in payor mix, business office operations, general economic conditions and health care coverage provided by federal or state governments or private insurers may have a significant impact on the Company’s estimates and significantly affect its results of operations and cash flows.
Acquisitions	Acquisitions
	The Company accounts for its business combinations under the fundamental requirements of the acquisition method of accounting and under the premise that an acquirer be identified for each business combination.  The acquirer is the entity that obtains control of one or more businesses in the business combination and the acquisition date is the date the acquirer achieves control.  The assets acquired, liabilities assumed and any noncontrolling interests in the acquired business at the acquisition date are recognized at their fair values as of that date, and the direct costs incurred in connection with the business combination are recorded and expensed separately from the business combination.  Acquisitions in which the Company is able to exert significant influence but does not have control are accounted for using the equity method.
Investments in Unconsolidated Affiliates	Investments in Unconsolidated Affiliates
	Investments in unconsolidated affiliates in which the Company exerts significant influence but does not control or otherwise consolidate are accounted for using the equity method.  Equity method investments are initially recorded at cost, unless such investments are a result of the Company entering into a transaction whereby the Company loses control of a previously controlled entity but retains a noncontrolling interest.  Such transactions, which result in the deconsolidation of a previously consolidated entity, are measured at fair value. These investments are included as investments in unconsolidated affiliates in the accompanying consolidated balance sheets. The Company’s share of the profits and losses from these investments are reported in equity in earnings of unconsolidated affiliates in the accompanying consolidated statement of earnings.  The Company monitors its investments for other-than-temporary impairment by considering factors such as current economic and market conditions and the operating performance of the companies and records reductions in carrying values when necessary.
Property and Equipment	Property and Equipment
	Property and equipment are stated at cost.  Equipment held under capital leases is stated at the present value of minimum lease payments at the inception of the related leases.  Depreciation for buildings and improvements is recognized under the straight-line method over 20 to 40 years or, for leasehold improvements, over the remaining term of the lease plus renewal options for which failure to renew the lease imposes a penalty on the Company in such an amount that a renewal appears, at the inception of the lease, to be reasonably assured.  The primary penalty to which the Company is subject is the economic detriment associated with existing leasehold improvements which might be impaired if a decision is made not to continue the use of the leased property.  Depreciation for movable equipment is recognized over useful lives of three to ten years.
Goodwill and Intangible Assets	Goodwill and Intangible Assets
	The Company’s intangible assets include goodwill and other intangibles, which include the fair value of both the customer relationships with hospitals and trade names acquired in our physician services segment. The Company's indefinite lived intangibles include goodwill and trade names. Goodwill represents the excess of purchase price over the fair value of net assets acquired. The Company evaluates indefinite-lived intangible assets, including goodwill, for impairment at least on an annual basis and more frequently if certain indicators are encountered. Indefinite lived intangibles are to be tested at the reporting unit level, defined as an operating segment or one level below an operating segment (referred to as a component), with the fair value of the reporting unit being compared to its carrying amount. If the fair value of a reporting unit exceeds its carrying amount, the indefinite lived intangibles associated with the reporting unit is not considered to be impaired. The Company completed its annual impairment test as of October 1, 2014, and determined that its indefinite lived intangibles were not impaired. The Company's finite lived intangibles includes its customer relationship with hospitals. The Company tests its finite lived intangibles for impairment whenever events or circumstances indicate that the carrying amount may not be recoverable. The Company's policy is to recognize an impairment charge when the carrying amount is not recoverable and such amount exceeds fair value. During the year ended December 31, 2014, there were no events or circumstances that indicated a potential impairment in the Company's finite lived intangibles.
	In the fourth quarter of 2014, the Company prospectively changed its annual goodwill impairment testing date from the last day of its fiscal year to the first day of October. The voluntary change was to better align its goodwill impairment testing procedures with the completion of its annual financial and strategic planning process and to provide the Company with adequate time to evaluate goodwill for impairment. As a result, during 2014, the Company tested the goodwill of all of its reporting units for impairment as of October 1, 2014 and concluded that there was no impairment of the carrying value of goodwill.  The change in accounting principle related to changing the annual goodwill impairment testing date did not accelerate, delay, avoid, or cause an impairment charge. This change was not applied retrospectively, as it is impracticable to objectively determine the assumptions that would have been used as of each October 1 for periods prior to October 1, 2014 without the use of hindsight. Accordingly, the change will be applied prospectively.
Amortization of Intangible Assets	Intangible assets consist primarily of customer relationships with hospitals, deferred financing costs, capitalized software and certain amortizable and non-amortizable non-compete and customer agreements.  Customer relationships with hospitals are initially recorded at their estimated fair value and typically amortized on a straight-line basis over 20 years. Deferred financing costs and amortizable non-compete agreements and customer agreements are amortized over the term of the related debt as interest expense and the contractual term or estimated life (five to ten years) of the agreements as amortization expense. Capitalized software is amortized over estimated useful lives of three to eight years.
Insurance Programs	The Company maintains professional liability insurance policies with third-party insurers generally on a claims-made basis, subject to self-insured retention, exclusions and other restrictions. The Company’s self-insured retention under its professional liability insurance program is also maintained through a wholly-owned captive insurance subsidiary. The Company records an estimate of liabilities for self-insured amounts and claims incurred but not reported based on an actuarial valuation using historical loss patterns and are not discounted.
	Insurance Programs
	Given the nature of the services provided, the Company and its subsidiaries are subject to professional and general liability claims and related lawsuits in the ordinary course of business. The Company maintains professional insurance with third-party insurers generally on a claims-made basis, subject to self-insured retentions, exclusions and other restrictions. A substantial portion of the professional liability loss risks are being provided by a third-party insurer which is fully reinsured by the Company's wholly-owned captive. In addition, the wholly-owned captive provides stop loss coverage for the Company’s self-insured employee health program. The assets, liabilities and results of operations of the wholly-owned captive are consolidated in the accompanying consolidated financial statements. The liabilities for self-insurance in the accompanying consolidated balance sheets include estimates of the ultimate costs related to both reported claims on an individual and aggregate basis and unreported claims. The Company also obtains professional liability insurance on a claims-made basis from third party insurers for its surgery centers and certain of its owned practices and employed physicians.
Income Taxes	Income Taxes
	The Company files a consolidated federal income tax return.  Income taxes are accounted for under the asset and liability method.  Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.
	The Company applies recognition thresholds and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return as it relates to accounting for uncertainty in income taxes.  In addition, it is the Company’s policy to recognize interest accrued and penalties, if any, related to unrecognized benefits as income tax expense in its statement of earnings.  The Company does not expect significant changes to its tax positions or liability for tax uncertainties during the next 12 months.
	The Company and its subsidiaries file income tax returns in the U.S. federal jurisdiction and various state jurisdictions.  With few exceptions, the Company is no longer subject to U.S. federal or state income tax examinations for years prior to 2011.
Stock Incentive Plans	Stock Incentive Plans
	Transactions in which the Company receives employee and non-employee services in exchange for the Company’s equity instruments or liabilities that are based on the fair value of the Company’s equity securities or may be settled by the issuance of these securities are accounted using a fair value method. The Company applies the Black-Scholes method of valuation in determining share-based compensation expense for option awards.
	Benefits of tax deductions in excess of recognized compensation cost are reported as a financing cash flow, thus reducing the Company’s net operating cash flows and increasing its financing cash flows by $3.2 million, $7.2 million and $1.8 million for the years ended December 31, 2014, 2013 and 2012, respectively.
	The Company examines its concentrations of holdings, its historical patterns of award exercises and forfeitures as well as forward-looking factors, in an effort to determine if there were any discernible employee populations.  From this analysis, the Company has identified three employee populations, consisting of senior executives, officers and all other recipients.  The expected volatility rate applied was estimated based on historical volatility.  The expected term assumption applied is based on contractual terms, historical exercise and cancellation patterns and forward-looking factors where present for each population identified.  The risk-free interest rate used is based on the U.S. Treasury yield curve in effect at the time of the grant.  The pre-vesting forfeiture rate is based on historical rates and forward-looking factors for each population identified.  The Company will adjust the estimated forfeiture rate to its actual experience.  The Company intends to retain its earnings to finance growth and development of the business and does not expect to declare or pay any cash dividends in the foreseeable future except as required in accordance with the terms of the Company's mandatory convertible preferred stock.
Earnings per Share	Earnings per Share
	Basic net earnings attributable to AmSurg Corp. common stockholders, per common share, excludes dilution and is computed by dividing net earnings attributable to AmSurg Corp. common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net earnings attributable to AmSurg common stockholders, per common share is computed by dividing net earnings attributable to AmSurg Corp. common stockholders by the weighted-average number of common shares outstanding during the period plus any potential dilutive common share equivalents, including shares issuable (1) upon the vesting of restricted stock awards as determined under the treasury stock method and (2) upon conversion of the Company's 5.250% Mandatory Convertible Preferred Stock as determined under the if-converted method. For purposes of calculating diluted earnings per share, preferred stock dividends have been subtracted from both net earnings from continuing operations attributable to AmSurg Corp. and net earnings attributable to AmSurg Corp. common shareholders in periods in which utilizing the if-converted method would be anti-dilutive.
Related Party Transactions	It is the Company’s policy that all transactions by the Company with officers, directors, five percent shareholders and their affiliates be entered into only if such transactions are on terms no less favorable to the Company than could be obtained from unaffiliated third parties, are reasonably expected to benefit the Company and are approved by the Nominating and Corporate Governance Committee of the Company’s Board of Directors.
Segment Reporting	Segment Reporting
	Prior to the Sheridan acquisition, the Company operated its centers as individual components of one operating and reportable segment. Upon completion of the Sheridan acquisition, the Company operates in two major lines of business - the operation of ambulatory surgery centers and providing multi-specialty outsourced physician services, which have been identified as its operating and reportable segments. Through the ambulatory services segment, the Company acquires, develops and operates ambulatory surgery centers in partnership with physicians. Through the physician services segment, the Company provides outsourced physician services in multiple specialties to hospitals, ambulatory surgery centers and other healthcare facilities, primarily in the areas of anesthesiology, children’s services, emergency medicine and radiology.
	The Company’s financial information by operating segment is prepared on an internal management reporting basis that the chief operating decision maker uses to allocate resources and assess the performance of the operating segments. The Company’s operating segments have been defined based on the separate financial information that is regularly produced and reviewed by the Company’s chief operating decision maker which is its Chief Executive Officer.

Revenue_Recognition_Tables

Revenue Recognition (Tables)	12 Months Ended
	Dec. 31, 2014
Revenue Recognition [Abstract]
Schedule of Revenue and Fees by Segment and Major Payors	Net revenue for the physician services segment consists of the following major payors (in thousands):
		July 16, 2014 - December 31, 2014 (1)
	Medicare	$	61,378		12	%
	Medicaid	28,224			5.5
	Commercial and managed care	382,343			74.7
	Self-pay	102,727			20.1
	Net fee for service revenue	574,672			112.3
	Contract and other revenue	54,343			10.6
	Provision for uncollectibles	(117,001		)	(22.9	)
	Net revenue for physician services	$	512,014		100	%
	-1	Net revenue by payor is for the period July 16, 2014, the date of the acquisition of Sheridan, through December 31, 2014. As such, historical amounts are not included.

Acquisitions_Tables

Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2014
Business Combinations [Abstract]
Fair Value Of Total Consideration Transferred And Major Class Of Consideration	The acquisition date fair value of the total consideration transferred and acquisition date fair value of each major class of consideration for the acquisitions completed during 2014 and 2013, including post acquisition date adjustments recorded to purchase price allocations, are as follows (in thousands):
		2014						2013
					Individual			Individual
		Sheridan (1)			Acquisitions (1)			Acquisitions
	Accounts receivable	$	130,260		$	1,816		$	4,011
	Other current assets	105,757			1,075			2,014
	Property and equipment	20,185			3,294			6,894
	Goodwill	1,534,656			101,865			116,243
	Intangible assets	1,200,028			14,207			—
	Other long-term assets	50,304			—			—
	Accounts payable	(5,862		)	(2,519		)	(2,214		)
	Other accrued liabilities	(118,548		)	(626		)	(532		)
	Deferred income taxes	(432,792		)	—			—
	Other long-term liabilities	(69,456		)	(8,588		)	(254		)
	Long-term debt	(4,594		)	(717		)	(3,028		)
	Total fair value	2,409,938			109,807			123,134
	Less:  Fair value attributable to noncontrolling interests	24,365			39,371			49,792
	Acquisition date fair value of total consideration transferred	$	2,385,573		$	70,436		$	73,342
	-1	Represents the preliminary allocation of fair value of acquired assets and liabilities associated with these acquisitions at December 31, 2014.
Revenues And Net Earnings Associated With Acquisitions	Revenues and net earnings included in the years ended December 31, 2014 and 2013 associated with completed acquisitions are as follows (in thousands):
		2014						2013
					Individual			Individual
		Sheridan			Acquisitions			Acquisitions
	Net revenues	$	517,213		$	20,844		$	15,616
	Net earnings	26,776			5,155			4,596
	Less:  Net earnings attributable to noncontrolling interests	459			2,859			2,603
	Net earnings attributable to AmSurg Corp. common shareholders	$	26,317		$	2,296		$	1,993
Consolidated Pro Forma Results Of Acquisition	The unaudited consolidated pro forma results for the years ended December 31, 2014 and 2013, assuming all 2014 acquisitions had been consummated on January 1, 2013, all 2013 acquisitions had been consummated on January 1, 2012 are as follows (in thousands):
		2014			2013
	Revenues	$	2,217,682		$	2,171,999
	Net earnings	295,156			243,675
	Amounts attributable to AmSurg Corp. common shareholders:
	Net earnings	97,538			39,980
	Net earnings per common share:
	Basic	$	1.88		$	0.66
	Diluted	$	1.86		$	0.65

Dispositions_Tables

Dispositions (Tables)	12 Months Ended
	Dec. 31, 2014
Discontinued Operations and Disposal Groups [Abstract]
Results Of Operations Of Centers Discontinued	Results of operations and associated gain (loss) on disposal of the centers discontinued for the years ended December 31, 2014, 2013 and 2012 are as follows (in thousands):
		2014			2013		2012
	Revenues	$	9,545		$	25,373	$	34,911
	Earnings before income taxes	893			5,607		9,919
	Results of discontinued operations, net of tax:
	Earnings from operations of discontinued interests in surgery centers	710			4,449		7,920
	Gain (loss) on disposal of discontinued interests in surgery centers	(2,006		)	2,602		25
	Net earnings (loss) from discontinued operations	(1,296		)	7,051		7,945
	Less: Net earnings from discontinued operations attributable to noncontrolling interests	283			5,357		5,419
	Net earnings (loss) from discontinued operations attributable to AmSurg Corp. common shareholders	$	(1,579	)	$	1,694	$	2,526

Prepaid_and_Other_Current_Asse1

Prepaid and Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2014
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Prepaid and Other Current Assets	The following table presents a summary of items comprising prepaid and other current assets in the accompanying consolidated balance sheets as of December 31, 2014 and 2013 (in thousands):
		2014		2013
	Income taxes receivable	$	28,694	$	1,865
	Prepaid expenses	18,682		12,730
	Deferred compensation plan assets	17,320		13,313
	Deferred income taxes	22,462		3,097
	Other	28,204		5,694
	Total prepaid and other current assets	$	115,362	$	36,699

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and equipment at December 31, 2014 and 2013 were as follows (in thousands):
		2014			2013
	Building and improvements	$	170,420		$	161,805
	Movable equipment	215,444			207,176
	Construction in progress	11,940			2,321
		397,804			371,302
	Less accumulated depreciation	(217,356		)	(207,612		)
	Property and equipment, net	$	180,448		$	163,690

Goodwill_And_Intangible_Assets1

Goodwill And Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Changes In Carrying Amount Of Goodwill	The changes in the carrying amount of goodwill for the years ended December 31, 2014 and 2013 are as follows (in thousands):
		2014			2013
	Balance, beginning of year	$	1,758,970		$	1,652,002
	Goodwill acquired, including post acquisition adjustments	1,636,521			112,951
	Goodwill disposed, including impact of deconsolidation transactions	(14,342		)	(5,983		)
	Balance, end of year	$	3,381,149		$	1,758,970
Schedule of Finite-Lived Intangible Assets	Intangible assets at December 31, 2014 and 2013 consisted of the following (in thousands):
		2014								2013
		Gross								Gross
		Carrying			Accumulated					Carrying		Accumulated
		Amount			Amortization			Net		Amount		Amortization			Net
	Amortizable intangible assets:
	Customer relationships with hospitals	$	971,645		$	(22,145	)	$	949,500	$	—	$	—		$	—
	Deferred financing costs	59,574			(5,151		)	54,423		15,814		(4,953		)	10,861
	Capitalized software	50,387			(19,197		)	31,190		21,036		(14,831		)	6,205
	Agreements, contracts and other	3,523			(2,752		)	771		3,448		(2,472		)	976
	Total amortizable intangible assets	1,085,129			(49,245		)	1,035,884		40,298		(22,256		)	18,042
	Non-amortizable intangible assets:
	Trade name	228,000			—			228,000		—		—			—
	Restrictive covenant arrangements	9,995			—			9,995		9,825		—			9,825
	Total non-amortizable intangible assets	237,995			—			237,995		9,825		—			9,825
	Total intangible assets	$	1,323,124		$	(49,245	)	$	1,273,879	$	50,123	$	(22,256	)	$	27,867

Other_Accrued_Liabilities_Tabl

Other Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2014
Accrued Liabilities, Current [Abstract]
Schedule of Other Accrued Liabilities	The following table presents a summary of items comprising other accrued liabilities in the accompanying consolidated balance sheets as of December 31, 2014 and 2013 (in thousands):
		2014		2013
	Refunds payable	$	17,752	$	—
	Accrued professional liabilities	11,983		1,171
	Contingent purchase price payable	12,213		—
	Other	26,038		6,175
	Total other accrued liabilities	$	67,986	$	7,346

Accrued_Professional_Liabiliti1

Accrued Professional Liabilities (Tables)	12 Months Ended
	Dec. 31, 2014
Payables and Accruals [Abstract]
Schedule of Accrued Professional Liabilities	At December 31, 2014, the Company had total accrued professional liabilities of $53.8 million, which are included in other accrued liabilities and other long-term liabilities in the accompanying consolidated balance sheets and consisted of the following (in thousands):
		2014
	Estimated losses under self-insured programs	$	25,337
	Incurred but not reported losses	28,448
	Total accrued professional liabilities	53,785
	Less estimated losses payable within one year	11,983
	Total	$	41,802
Schedule of Self Insurance Reserve Roll Forward	The changes to the Company's estimated losses under self-insured programs as of December 31, 2014 were as follows (in thousands):
	Balance at December 31, 2013	$	1,171
	Assumed liabilities through acquisitions	53,512
	Provision related to current period reserves	5,423
	Payments for current period reserves	(1,595		)
	Benefit related to changes in prior period reserves	(661		)
	Payments for prior period reserves	(6,055		)
	Other, net	1,990
	Balance at December 31, 2014	$	53,785

LongTerm_Debt_Tables

Long-Term Debt (Tables)	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Components Of Long-Term Debt	Long-term debt at December 31, 2014 and 2013 consisted of the following (in thousands):
		2014			2013
	Revolving credit agreement	$	—		$	252,500
	Term loan	865,650			—
	5.625% Senior Unsecured Notes due 2020	250,000			250,000
	5.625% Senior Unsecured Notes due 2022	1,100,000			—
	8.04% Senior Secured Notes due 2020	—			69,643
	Other debt at an average rate of 3.4%, due through 2025	20,156			21,149
	Capitalized lease arrangements at an average rate of 5.4%, due through 2031	15,206			10,850
		2,251,012			604,142
	Less current portion	18,826			20,844
	Long-term debt	$	2,232,186		$	583,298
Redemption Price Percentage	The redemption price for such a redemption (expressed as percentages of principal amount) is set forth below, plus accrued and unpaid interest and liquidated damages, if any, if redeemed during the twelve-month period beginning on November 30 of the years indicated below:
	Period		Redemption Price
	2015		104.219	%
	2016		102.813	%
	2017		101.406	%
	2018 and thereafter		100	%
	The redemption price for such a redemption (expressed as percentages of principal amount) is set forth below, plus accrued and unpaid interest and liquidated damages, if any, if redeemed during the twelve-month period beginning on July 15 of the years indicated below:
	Period		Redemption Price
	2017		104.219	%
	2018		102.813	%
	2019		101.406	%
	2020 and thereafter		100	%

Other_Longterm_Liabilities_Tab

Other Long-term Liabilities (Tables)	12 Months Ended
	Dec. 31, 2014
Other Liabilities Disclosure [Abstract]
Other Long-term Liabilities	The following table presents a summary of items comprising other long-term liabilities in the accompanying consolidated balance sheets as of December 31, 2014 and 2013 (in thousands):
		2014		2013
	Accrued professional liabilities	$	41,802	$	—
	Contingent purchase price payable	8,470		—
	Deferred rent	16,814		14,637
	Tax-effected unrecognized benefits	8,353		6,888
	Other	14,004		3,978
	Other long-term liabilities	$	89,443	$	25,503

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Schedule Of Total Income Tax Expense	Total income taxes expense (benefit) for the years ended December 31, 2014, 2013 and 2012 was included within the following sections of the consolidated financial statements as follows (in thousands):
		2014			2013			2012
	Income from continuing operations	$	48,103		$	48,654		$	40,893
	Discontinued operations	(643		)	9			3,045
	Shareholders’ equity	(3,177		)	(7,381		)	(1,581		)
	Total	$	44,283		$	41,282		$	42,357
Schedule of Components of Income Tax Expense (Benefit)	Income tax expense from continuing operations for the years ended December 31, 2014, 2013 and 2012 was comprised of the following (in thousands):
		2014			2013			2012
	Current:
	Federal	$	8,640		$	7,895		$	14,602
	State	4,396			3,598			4,806
	Deferred:
	Federal	27,505			31,509			18,018
	State	7,562			5,652			3,467
	Income tax expense	$	48,103		$	48,654		$	40,893
Schedule of Effective Income Tax Rate Reconciliation	Income tax expense from continuing operations for the years ended December 31, 2014, 2013 and 2012 differed from the amount computed by applying the U.S. federal income tax rate of 35% to earnings before income taxes as a result of the following (in thousands):
		2014			2013			2012
	Statutory federal income tax	$	102,967		$	106,101		$	89,806
	Less federal income tax assumed directly by noncontrolling interests	(66,783		)	(64,219		)	(56,378		)
	State income taxes, net of federal income tax benefit	6,616			5,539			7,020
	Increase in valuation allowances	4,662			924			419
	Interest related to unrecognized tax benefits	(161		)	(155		)	(109		)
	Other	802			464			135
	Income tax expense	$	48,103		$	48,654		$	40,893
Summary of Income Tax Contingencies	A reconciliation of the beginning and ending amount of the liability associated with unrecognized tax benefits for the years ended December 31, 2014, 2013 and 2012 is as follows (in thousands):
		2014			2013			2012
	Balance at beginning of year	$	6,330		$	9,235		$	7,252
	Additions for tax positions of current year	204			46			119
	Increases for tax positions taken during a prior period	1,069			—			1,985
	Lapse of statute of limitations	(267		)	(2,951		)	(121		)
	Balance at end of year	$	7,336		$	6,330		$	9,235
Schedule of Deferred Tax Assets and Liabilities	The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at December 31, 2014 and 2013 were as follows (in thousands):
		2014			2013
	Deferred tax assets:
	Allowance for uncollectible accounts	$	1,096		$	897
	Accrued assets and other	27,537			5,292
	Valuation allowances	(3,736		)	(2,021		)
	Total current deferred tax assets	24,897			4,168
	Share-based compensation	7,719			7,635
	Interest on unrecognized tax benefits	245			230
	Accrued liabilities and other	3,931			3,629
	Medical malpractice	16,240			—
	Operating and capital loss carryforwards	22,709			9,185
	Valuation allowances	(13,721		)	(7,665		)
	Total non-current deferred tax assets	37,123			13,014
	Total deferred tax assets	62,020			17,182
	Deferred tax liabilities:
	Prepaid expenses	2,435			1,071
	Property and equipment, principally due to differences in depreciation	15,235			4,137
	Goodwill, intangible assets and other, principally due to differences in amortization	655,368			184,897
	Total deferred tax liabilities	673,038			190,105
	Net deferred tax liabilities	$	611,018		$	172,923
Schedule Of Deferred Tax Assets And Liabilities	The net deferred tax liabilities at December 31, 2014 and 2013 were recorded as follows (in thousands):
		2014			2013
	Current deferred income tax assets	$	22,462		$	3,097
	Non-current deferred income tax liabilities	633,480			176,020
	Net deferred tax liabilities	$	611,018		$	172,923

Shareholders_Equity_Tables

Shareholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Share-Based Activity	Other information pertaining to share-based activity for the years ended December 31, 2014, 2013 and 2012 was as follows (in thousands):
		2014			2013			2012
	Share-based compensation expense	$	10,104		$	8,321		$	6,692
	Fair value of shares vested	15,126			11,742			6,425
	Cash received from option exercises	2,630			33,349			18,214
	Tax benefit from option exercises	3,177			7,247			1,784
Schedule Of Changes In Non-Vested Restricted Shares	A summary of the status of and changes for non-vested restricted shares for the three years ended December 31, 2014, is as follows:
				Weighted
		Number		Average
		of Shares		Grant Price
	Non-vested shares at January 1, 2012	732,412		$	21.91
	Shares granted	281,429		26.78
	Shares vested	(183,019	)	25.98
	Shares forfeited	(2,136	)	26.26
	Non-vested shares at December 31, 2012	828,686		$	22.5
	Shares granted	291,863		31.66
	Shares vested	(360,337	)	21.55
	Shares forfeited	(16,343	)	23.11
	Non-vested shares at December 31, 2013	743,869		$	26.54
	Shares granted	272,780		43.12
	Shares vested	(336,160	)	25.69
	Shares forfeited	(12,380	)	38.94
	Non-vested shares at December 31, 2014	668,109		$	33.51
Schedule Of Stock Option Activity	A summary of stock option activity for the three years ended December 31, 2014 is summarized as follows:
							Weighted
				Weighted			Average
				Average			Remaining
		Number		Exercise			Contractual
		of Shares		Price			Term (in years)
	Outstanding at January 1, 2012	2,510,054		$	23.09		3.4
	Options exercised with total intrinsic value of $6.3 million	(841,599	)	21.64
	Options terminated	(5,625	)	21.85
	Outstanding at December 31, 2012	1,662,830		$	23.82		2.9
	Options exercised with total intrinsic value of $33.3 million	(1,392,366	)	23.95
	Outstanding at December 31, 2013	270,464		$	23.16		2.5
	Options exercised with total intrinsic value of $2.6 million	(111,743	)	23.53
	Outstanding, Vested and Exercisable at December 31, 2014 with an aggregate intrinsic value of $3.6 million	158,721		$	22.89		1.7
Schedule Of Reconciliation Of Numerator And Denominators Of Basic And Diluted Earnings Per Share	The following is a reconciliation of the numerator and denominators of basic and diluted earnings per share (in thousands, except per share amounts):
		Earnings			Shares		Per Share
		(Numerator)			(Denominator)		Amount
	For the year ended December 31, 2014:
	Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (basic)	$	50,777		39,311		$	1.29
	Effect of dilutive securities options and non-vested shares	—			314
	Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (diluted)	$	50,777		39,625		$	1.28
	For the year ended December 31, 2013:
	Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (basic)	$	71,009		31,338		$	2.27
	Effect of dilutive securities options and non-vested shares	—			616
	Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (diluted)	$	71,009		31,954		$	2.22
	For the year ended December 31, 2012:
	Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (basic)	$	60,037		30,773		$	1.95
	Effect of dilutive securities options and non-vested shares	—			835
	Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (diluted)	$	60,037		31,608		$	1.9

Leases_Tables

Leases (Tables)	12 Months Ended
	Dec. 31, 2014
Leases [Abstract]
Future Minimum Lease Payment Schedule	Future minimum lease payments, including payments during expected renewal option periods, at December 31, 2014 were as follows (in thousands):
	Year Ended December 31,	Capital Leases		Operating Leases
	2015	$	2,613	$	53,007
	2016	2,146		51,687
	2017	1,901		50,260
	2018	1,594		47,978
	2019	1,388		46,880
	Thereafter	11,361		356,337
	Total minimum rentals	21,003		$	606,149
	Less amounts representing interest at rates ranging from 2.7% to 11.8%	5,797
	Capital lease obligations	$	15,206

Related_Party_Transactions_Tab

Related Party Transactions (Tables)	12 Months Ended
	Dec. 31, 2014
Related Party Transactions [Abstract]
Schedule of Related Party Payments	Related party payments for the years ended December 31, 2014, 2013 and 2012 were as follows (in thousands):
		2014		2013		2012
	Operating leases	$	27,559	$	29,240	$	29,079
	Salaries and benefits	66,763		72,892		65,908
	Billing fees	9,899		11,591		11,126
	Medical advisory services	2,811		2,993		2,671

Segment_Reporting_Tables

Segment Reporting (Tables)	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	The following table presents financial information for each reportable segment (in thousands):
		Year ended December 31,
		2014			2013			2012
	Net Revenue:
	Ambulatory Services	$	1,109,935		$	1,057,196		$	899,245
	Physician Services	512,014			—			—
	Total	$	1,621,949		$	1,057,196		$	899,245
	Adjusted Segment EBITDA:
	Ambulatory Services	$	197,377		$	187,972		$	154,527
	Physician Services	107,105			—			—
	Total	$	304,482		$	187,972		$	154,527
	Adjusted Segment EBITDA:	$	304,482		$	187,972		$	154,527
	Earnings from continuing operations attributable to noncontrolling interests	190,809			183,484			155,661
	Interest expense, net	(83,285		)	(29,525		)	(16,950		)
	Depreciation and amortization	(60,344		)	(32,400		)	(29,255		)
	Share-based compensation	(10,104		)	(8,321		)	(6,692		)
	Transaction costs	(33,890		)	(300		)	(700		)
	Debt extinguishment costs	(16,887		)	—			—
	Gain on deconsolidation	3,411			2,237			—
	Earnings from continuing operations before income taxes	$	294,192		$	303,147		$	256,591
	Acquisition and Capital Expenditures:
	Ambulatory Services (1)	$	81,156		$	102,450		$	306,252
	Physician Services	28,909			—			—
	Total	$	110,065		$	102,450		$	306,252
		2014			2013
	Assets:
	Ambulatory Services	$	2,528,525		$	2,177,944
	Physician Services	2,994,999			—
	Total	$	5,523,524		$	2,177,944
	-1	Excludes the purchase price to acquire Sheridan.

Financial_Information_for_the_1

Financial Information for the Company and Its Subsidiaries (Tables)	12 Months Ended
	Dec. 31, 2014
Condensed Financial Information of Parent Company Only Disclosure [Abstract]
Condensed Consolidating Balance Sheet
	Condensed Consolidating Balance Sheet - December 31, 2014 (In thousands)
			Parent Issuer				Guarantor Subsidiaries				Non-Guarantor Subsidiaries				Consolidating Adjustments				Total Consolidated
	Assets
	Current assets:
	Cash and cash equivalents		$	134,351			$	23,471			$	50,257			$	—			$	208,079
	Restricted cash and marketable securities		—				—				10,219				—				10,219
	Accounts receivable, net		—				123,772				109,281				—				233,053
	Supplies inventory		—				301				19,673				—				19,974
	Prepaid and other current assets		47,997				58,388				13,795				(4,818		)		115,362
	Total current assets		182,348				205,932				203,225				(4,818		)		586,687
	Property and equipment, net		10,391				9,972				160,085				—				180,448
	Investments in and receivables from unconsolidated affiliates		3,912,804				1,587,881				—				(5,425,210		)		75,475
	Goodwill		—				1,490,981				—				1,890,168				3,381,149
	Intangible assets, net		67,678				1,203,218				2,983				—				1,273,879
	Other assets		3,323				943				23,086				(1,466		)		25,886
	Total assets		$	4,176,544			$	4,498,927			$	389,379			$	(3,541,326	)		$	5,523,524
	Liabilities and Equity
	Current liabilities:
	Current portion of long-term debt		$	8,700			$	—			$	10,126			$	—			$	18,826
	Accounts payable		1,849				35				31,781				(4,080		)		29,585
	Accrued salaries and benefits		25,035				101,395				13,614				—				140,044
	Accrued interest		29,621				—				23				—				29,644
	Other accrued liabilities		8,051				44,305				16,368				(738		)		67,986
	Total current liabilities		73,256				145,735				71,912				(4,818		)		286,085
	Long-term debt		2,206,950				—				53,648				(28,412		)		2,232,186
	Deferred income taxes		209,400				425,546				—				(1,466		)		633,480
	Other long-term liabilities		7,391				63,616				18,436				—				89,443
	Intercompany payable		—				1,219,979				8,010				(1,227,989		)		—
	Noncontrolling interests – redeemable		—				—				63,544				120,555				184,099
	Equity:
	Total AmSurg Corp. equity		1,679,547				2,644,051				130,206				(2,774,257		)		1,679,547
	Noncontrolling interests – non-redeemable		—				—				43,623				375,061				418,684
	Total equity		1,679,547				2,644,051				173,829				(2,399,196		)		2,098,231
	Total liabilities and equity		$	4,176,544			$	4,498,927			$	389,379			$	(3,541,326	)		$	5,523,524
	Condensed Consolidating Balance Sheet - December 31, 2013 (In thousands)
			Parent Issuer				Guarantor Subsidiaries				Non-Guarantor Subsidiaries				Consolidating Adjustments				Total Consolidated
	Assets
	Current assets:
	Cash and cash equivalents		$	6,710			$	—			$	44,130			$	—			$	50,840
	Accounts receivable, net		—				—				105,072				—				105,072
	Supplies inventory		33				—				18,381				—				18,414
	Prepaid and other current assets		27,090				—				13,971				(4,362		)		36,699
	Total current assets		33,833				—				181,554				(4,362		)		211,025
	Property and equipment, net		6,024				—				157,666				—				163,690
	Investments in and receivables from unconsolidated affiliates		1,484,108				1,453,596				—				(2,922,178		)		15,526
	Goodwill		—				—				—				1,758,970				1,758,970
	Intangible assets, net		24,489				—				3,378				—				27,867
	Other assets		866				—				—				—				866
	Total assets		$	1,549,320			$	1,453,596			$	342,598			$	(1,167,570	)		$	2,177,944
	Liabilities and Equity
	Current liabilities:
	Current portion of long-term debt		$	10,714			$	—			$	10,130			$	—			$	20,844
	Accounts payable		1,972				—				29,487				(3,958		)		27,501
	Accrued salaries and benefits		21,115				—				11,179				—				32,294
	Accrued interest		1,847				—				38				—				1,885
	Other accrued liabilities		4,457				—				3,293				(404		)		7,346
	Total current liabilities		40,105				—				54,127				(4,362		)		89,870
	Long-term debt		561,429				—				53,246				(31,377		)		583,298
	Deferred income taxes		176,020				—				—				—				176,020
	Other long-term liabilities		7,569				—				17,934				—				25,503
	Noncontrolling interests – redeemable		—				—				63,704				113,993				177,697
	Equity:
	Total AmSurg Corp. equity		764,197				1,453,596				114,671				(1,568,267		)		764,197
Noncontrolling interests – non-redeemable		—				—				38,916				322,443				361,359
Total equity		764,197				1,453,596				153,587				(1,245,824		)		1,125,556
Total liabilities and equity		$	1,549,320			$	1,453,596			$	342,598			$	(1,167,570	)		$	2,177,944
Condensed Consolidating Statement of Earnings
	Condensed Consolidating Statement of Earnings - Year Ended December 31, 2014 (In thousands)
		Parent Issuer				Guarantor Subsidiaries				Non-Guarantor Subsidiaries				Consolidating Adjustments				Total Consolidated
	Net revenues	$	24,773			$	508,572			$	1,112,940			$	(24,336	)		$	1,621,949
	Operating expenses:
	Salaries and benefits	65,697				350,615				284,050				(5,786		)		694,576
	Supply cost	—				1,292				163,004				—				164,296
	Other operating expenses	18,667				53,413				231,398				(18,550		)		284,928
	Transaction costs	29,004				4,886				—				—				33,890
	Depreciation and amortization	4,044				25,610				30,690				—				60,344
	Total operating expenses	117,412				435,816				709,142				(24,336		)		1,238,034
	Gain on deconsolidation	3,411				3,411				—				(3,411		)		3,411
	Equity in earnings of unconsolidated affiliates	234,246				211,889				—				(439,097		)		7,038
	Operating income	145,018				288,056				403,798				(442,508		)		394,364
	Interest expense, net	47,997				33,026				2,262				—				83,285
	Debt extinguishment costs	16,887				—				—				—				16,887
	Earnings from continuing operations before income taxes	80,134				255,030				401,536				(442,508		)		294,192
	Income tax expense	29,166				17,373				1,564				—				48,103
	Net earnings from continuing operations	50,968				237,657				399,972				(442,508		)		246,089
	Net earnings (loss) from discontinued operations	2,733				—				(4,029		)		—				(1,296		)
	Net earnings	53,701				237,657				395,943				(442,508		)		244,793
	Net earnings attributable to noncontrolling interests	—				21				191,071				—				191,092
	Net earnings attributable to AmSurg Corp. shareholders	53,701				237,636				204,872				(442,508		)		53,701
	Preferred stock dividends	(4,503		)		—				—				—				(4,503		)
	Net earnings attributable to AmSurg Corp. common shareholders	$	49,198			$	237,636			$	204,872			$	(442,508	)		$	49,198
	Amounts attributable to AmSurg Corp. common shareholders:
	Earnings from continuing operations, net of income tax	$	46,465			$	237,636			$	209,184			$	(442,508	)		$	50,777
	Earnings (loss) from discontinued operations, net of income tax	2,733				—				(4,312		)		—				(1,579		)
	Net earnings attributable to AmSurg Corp. common shareholders	$	49,198			$	237,636			$	204,872			$	(442,508	)		$	49,198
	Condensed Consolidating Statement of Earnings - Year Ended December 31, 2013 (In thousands)
		Parent Issuer				Guarantor Subsidiaries				Non-Guarantor Subsidiaries				Consolidating Adjustments				Total Consolidated
	Net revenues	$	24,167			$	—			$	1,050,547			$	(17,518	)		$	1,057,196
	Operating expenses:
	Salaries and benefits	61,038				—				267,014				(467		)		327,585
	Supply cost	—				—				153,126				—				153,126
	Other operating expenses	22,360				—				211,192				(17,051		)		216,501
	Transaction costs	300				—				—				—				300
	Depreciation and amortization	3,186				—				29,214				—				32,400
	Total operating expenses	86,884				—				660,546				(17,518		)		729,912
	Gain on deconsolidation	2,237				2,237				—				(2,237		)		2,237
	Equity in earnings of unconsolidated affiliates	204,962				204,962				—				(406,773		)		3,151
	Operating income	144,482				207,199				390,001				(409,010		)		332,672
	Interest expense, net	27,282				—				2,243				—				29,525
	Earnings from continuing operations before income taxes	117,200				207,199				387,758				(409,010		)		303,147
	Income tax expense	47,139				—				1,515				—				48,654
	Net earnings from continuing operations	70,061				207,199				386,243				(409,010		)		254,493
	Net earnings from discontinued operations	2,642				—				4,409				—				7,051
	Net earnings	72,703				207,199				390,652				(409,010		)		261,544
	Net earnings attributable to noncontrolling interests	—				—				188,841				—				188,841
	Net earnings attributable to AmSurg Corp. common shareholders	$	72,703			$	207,199			$	201,811			$	(409,010	)		$	72,703
	Amounts attributable to AmSurg Corp. common shareholders:
	Earnings from continuing operations, net of income tax	$	70,061			$	207,199			$	202,759			$	(409,010	)		$	71,009
	Earnings (loss) from discontinued operations, net of income tax	2,642				—				(948		)		—				1,694
	Net earnings attributable to AmSurg Corp. common shareholders	$	72,703			$	207,199			$	201,811			$	(409,010	)		$	72,703
	Condensed Consolidating Statement of Earnings - Year Ended December 31, 2012 (In thousands)
		Parent Issuer				Guarantor Subsidiaries				Non-Guarantor Subsidiaries				Consolidating Adjustments				Total Consolidated
	Net revenues	$	19,907			$	—			$	894,239			$	(14,901	)		$	899,245
	Operating expenses:
	Salaries and benefits	54,895				—				230,083				(450		)		284,528
	Supply cost	—				—				126,919				—				126,919
	Other operating expenses	19,799				—				180,518				(14,451		)		185,866
	Transaction costs	700				—				—				—				700
	Depreciation and amortization	2,860				—				26,395				—				29,255
	Total operating expenses	78,254				—				563,915				(14,901		)		627,268
Equity in earnings of unconsolidated affiliates	178,137				178,137				—				(354,710		)		1,564
Operating income	119,790				178,137				330,324				(354,710		)		273,541
Interest expense, net	14,803				—				2,147				—				16,950
Earnings from continuing operations before income taxes	104,987				178,137				328,177				(354,710		)		256,591
Income tax expense	39,339				—				1,554				—				40,893
Net earnings from continuing operations	65,648				178,137				326,623				(354,710		)		215,698
Net earnings (loss) from discontinued operations	(3,085		)		—				11,030				—				7,945
Net earnings	62,563				178,137				337,653				(354,710		)		223,643
Net earnings attributable to noncontrolling interests	—				—				161,080				—				161,080
Net earnings attributable to AmSurg Corp. common shareholders	$	62,563			$	178,137			$	176,573			$	(354,710	)		$	62,563
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax	$	65,648			$	178,137			$	170,962			$	(354,710	)		$	60,037
Earnings (loss) from discontinued operations, net of income tax	(3,085		)		—				5,611				—				2,526
Net earnings attributable to AmSurg Corp. common shareholders	$	62,563			$	178,137			$	176,573			$	(354,710	)		$	62,563
Condensed Consolidating Statement of Cash Flows
	Condensed Consolidating Statement of Cash Flows - Year Ended December 31, 2014 (In thousands)
			Parent Issuer				Guarantor Subsidiaries				Non-Guarantor Subsidiaries				Consolidating Adjustments				Total Consolidated
	Cash flows from operating activities:
	Net cash flows provided by operating activities		$	96,681			$	298,415			$	430,880			$	(413,605	)		$	412,371
	Cash flows from investing activities:
	Acquisitions and related transactions		(2,124,124		)		(2,188,191		)		1,520				2,126,737				(2,184,058		)
	Acquisition of property and equipment		(7,877		)		(9,933		)		(22,407		)		—				(40,217		)
	Proceeds from sale of interests in surgery centers		—				7,069				—				—				7,069
	Purchases of marketable securities		—				—				(6,474		)		—				(6,474		)
	Maturities of marketable securities		—				—				3,486				—				3,486
	Other		(3,068		)		(6,594		)		4,721				—				(4,941		)
	Net cash flows used in investing activities		(2,135,069		)		(2,197,649		)		(19,154		)		2,126,737				(2,225,135		)
	Cash flows from financing activities:
	Proceeds from long-term borrowings		2,040,000				—				8,958				—				2,048,958
	Repayment on long-term borrowings		(396,493		)		—				(11,982		)		—				(408,475		)
	Distributions to owners, including noncontrolling interests		—				(202,247		)		(401,455		)		413,605				(190,097		)
	Capital contributions		—				2,124,124				—				(2,124,124		)		—
	Proceeds from preferred stock offering		172,500				—				—				—				172,500
	Cash dividends for preferred shares		(4,503		)		—				—				—				(4,503		)
	Proceeds from common stock offering		439,875				—				—				—				439,875
	Payments of equity issuance costs		(24,494		)		—				—				—				(24,494		)
	Financing cost incurred		(65,811		)		—				—				—				(65,811		)
	Changes in intercompany balances with affiliates, net		2,965				—				(2,965		)		—				—
	Other financing activities, net		1,990				828				1,845				(2,613		)		2,050
	Net cash flows provided by (used in) financing activities		2,166,029				1,922,705				(405,599		)		(1,713,132		)		1,970,003
	Net increase in cash and cash equivalents		127,641				23,471				6,127				—				157,239
	Cash and cash equivalents, beginning of period		6,710				—				44,130				—				50,840
	Cash and cash equivalents, end of period		$	134,351			$	23,471			$	50,257			$	—			$	208,079
	Condensed Consolidating Statement of Cash Flows - Year Ended December 31, 2013 (In thousands)
			Parent Issuer				Guarantor Subsidiaries				Non-Guarantor Subsidiaries				Consolidating Adjustments				Total Consolidated
	Cash flows from operating activities:
	Net cash flows provided by operating activities		$	45,127			$	208,773			$	426,572			$	(347,648	)		$	332,824
	Cash flows from investing activities:
	Acquisitions and related transactions		—				(74,288		)		—				694				(73,594		)
	Acquisition of property and equipment		(3,693		)		—				(25,163		)		—				(28,856		)
	Proceeds from sale of interests in surgery centers		—				3,553				—				—				3,553
	Other		—				159				—				—				159
	Net cash flows used in investing activities		(3,693		)		(70,576		)		(25,163		)		694				(98,738		)
	Cash flows from financing activities:
	Proceeds from long-term borrowings		152,700				—				9,504				—				162,204
	Repayment on long-term borrowings		(188,081		)		—				(14,002		)		—				(202,083		)
	Distributions to owners, including noncontrolling interests		—				(138,875		)		(392,922		)		347,648				(184,149		)
	Changes in intercompany balances with affiliates, net		88				—				(88		)		—				—
	Other financing activities, net		(6,690		)		678				1,090				(694		)		(5,616		)
	Net cash flows used in financing activities		(41,983		)		(138,197		)		(396,418		)		346,954				(229,644		)
	Net increase (decrease) in cash and cash equivalents		(549		)		—				4,991				—				4,442
	Cash and cash equivalents, beginning of period		7,259				—				39,139				—				46,398
	Cash and cash equivalents, end of period		$	6,710			$	—			$	44,130			$	—			$	50,840
	Condensed Consolidating Statement of Cash Flows - Year Ended December 31, 2012 (In thousands)
			Parent Issuer				Guarantor Subsidiaries				Non-Guarantor Subsidiaries				Consolidating Adjustments				Total Consolidated
	Cash flows from operating activities:
	Net cash flows provided by operating activities		$	(83,605	)		$	182,851			$	379,257			$	(182,851	)		$	295,652
	Cash flows from investing activities:
	Acquisitions and related transactions		(90,029		)		(280,189		)		—				92,830				(277,388		)
	Acquisition of property and equipment		(3,681		)		—				(25,183		)		—				(28,864		)
	Proceeds from sale of interests in surgery centers		—				7,309				—				—				7,309
	Net cash flows used in investing activities		(93,710		)		(272,880		)		(25,183		)		92,830				(298,943		)
	Cash flows from financing activities:
	Proceeds from long-term borrowings		560,000				—				5,566				—				565,566
	Repayment on long-term borrowings		(381,220		)		—				(12,944		)		—				(394,164		)
	Distributions to owners, including noncontrolling interests		—				—				(345,792		)		182,851				(162,941		)
	Capital contributions		—				90,029				—				(90,029		)		—
	Changes in intercompany balances with affiliates, net		(2,666		)		—				2,666				—				—
Other financing activities, net		(70		)		—				3,381				(2,801		)		510
Net cash flows provided by (used in) financing activities		176,044				90,029				(347,123		)		90,021				8,971
Net increase (decrease) in cash and cash equivalents		(1,271		)		—				6,951				—				5,680
Cash and cash equivalents, beginning of period		8,530				—				32,188				—				40,718
Cash and cash equivalents, end of period		$	7,259			$	—			$	39,139			$	—			$	46,398

Quarterly_Statement_of_Earning1

Quarterly Statement of Earnings Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Financial Information	The following table presents certain quarterly statement of earnings data for the years ended December 31, 2014 and 2013.  The quarterly statement of earnings data set forth below was derived from the Company’s unaudited financial statements and includes all adjustments, consisting of normal recurring adjustments, which the Company considers necessary for a fair presentation thereof.  Results of operations for any particular quarter are not necessarily indicative of results of operations for a full year or predictive of future periods.
		2014											2013
		Q1			Q2		Q3 (2)			Q4			Q1		Q2		Q3		Q4
		(In thousands, except per share data)
	Net revenues	$	259,561		$	278,227	$	502,350		$	581,811		$	253,364	$	262,497	$	262,240	$	279,095
	Earnings from continuing operations before income taxes	73,029			80,487		39,141			101,535			73,069		77,100		72,615		80,363
	Net earnings from continuing operations	60,047			67,689		39,119			79,234			61,068		64,607		61,470		67,348
	Net earnings (loss) from discontinued operations(1)	68			483		(1,697		)	(150		)	1,205		1,229		797		3,820
	Net earnings	60,115			68,172		37,422			79,084			62,273		65,836		62,267		71,168
	Net earnings (loss) attributable to AmSurg Corp. common shareholders:
	Continuing	17,392			18,771		(10,697		)	25,311			17,349		18,093		16,636		18,931
	Discontinued	(197		)	190		(1,376		)	(196		)	462		470		135		627
	Net earnings (loss)	$	17,195		$	18,961	$	(12,073	)	$	25,115		$	17,811	$	18,563	$	16,771	$	19,558
	Basic net earnings (loss) from	$	0.55		$	0.59	$	(0.23	)	$	0.53		$	0.56	$	0.58	$	0.53	$	0.6
	continuing operations per share
	Basic net earnings (loss) per share	$	0.54		$	0.6	$	(0.26	)	$	0.53		$	0.57	$	0.59	$	0.53	$	0.62
	Diluted net earnings (loss) from continuing operations per share	$	0.54		$	0.58	$	(0.23	)	$	0.53		$	0.54	$	0.57	$	0.52	$	0.59
	Diluted net earnings (loss) per share	$	0.54		$	0.59	$	(0.26	)	$	0.53		$	0.56	$	0.58	$	0.52	$	0.61
	(1)      Certain previously reported amounts have been reclassified for current year presentation for discontinued operations.
	(2)     The results of operations for Sheridan are effective July 16, 2014. Additionally, $16.9 million of debt extinguishment costs and $25.1 million of transaction
	costs were incurred during the quarter.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
	center
Ownership Interests [Line Items]
Number of centers with ownership interest of less than 51%	10
Restricted Cash and Marketable Securities
Restricted cash and marketable securities, total	$30,300,000
Restricted cash and marketable securities, noncurrent	20,100,000
Restricted cash and marketable securities, current	10,219,000	0
Restricted marketable securities	$3,000,000
Consolidated [Member]
Ownership Interests [Line Items]
Number of centers with ownership interest of less than 51%	1
Nonconsolidated [Member]
Ownership Interests [Line Items]
Number of centers with ownership interest of less than 51%	9

Revenue_Recognition_Details

Revenue Recognition (Details) (USD $)

3 Months Ended

12 Months Ended

6 Months Ended

In Thousands, unless otherwise specified

Dec. 31, 2014

Sep. 30, 2014

Jun. 30, 2014

Mar. 31, 2014

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2014

Revenue, Major Customer [Line Items]

Provision for uncollectibles

($139,274)

($21,947)

($20,005)

Net revenue

581,811

502,350

278,227

259,561

279,095

262,240

262,497

253,364

1,621,949

1,057,196

899,245

Physician Services [Member]

Revenue, Major Customer [Line Items]

Net fee for service revenue

574,672

[1]

Contract and other revenue

54,343

[1]

Provision for uncollectibles

-117,001

0

0

-117,001

[1]

Net revenue

512,014

0

0

512,014

[1]

Ambulatory Services [Member]

Revenue, Major Customer [Line Items]

Percentage of revenues from governmental healthcare programs

25.00%

25.00%

27.00%

Net revenue

1,109,935

1,057,196

899,245

Medicare [Member] | Physician Services [Member]

Revenue, Major Customer [Line Items]

Net fee for service revenue

61,378

[1]

Medicaid [Member] | Physician Services [Member]

Revenue, Major Customer [Line Items]

Net fee for service revenue

28,224

[1]

Commercial and Managed Care [Member] | Physician Services [Member]

Revenue, Major Customer [Line Items]

Net fee for service revenue

382,343

[1]

Self-Pay [Member] | Physician Services [Member]

Revenue, Major Customer [Line Items]

Net fee for service revenue

$102,727

[1]

Sales Revenue, Net [Member] | Physician Services [Member]

Revenue, Major Customer [Line Items]

Percent of net revenue, over

100.00%

[1]

Health Care Organization, Patient Service Revenue [Member] | Sales Revenue, Net [Member] | Physician Services [Member]

Revenue, Major Customer [Line Items]

Percent of net revenue, over

112.30%

[1]

Health Care Organization, Patient Service Revenue [Member] | Sales Revenue, Net [Member] | Medicare [Member] | Physician Services [Member]

Revenue, Major Customer [Line Items]

Percent of net revenue, over

12.00%

[1]

Health Care Organization, Patient Service Revenue [Member] | Sales Revenue, Net [Member] | Medicaid [Member] | Physician Services [Member]

Revenue, Major Customer [Line Items]

Percent of net revenue, over

5.50%

[1]

Health Care Organization, Patient Service Revenue [Member] | Sales Revenue, Net [Member] | Commercial and Managed Care [Member] | Physician Services [Member]

Revenue, Major Customer [Line Items]

Percent of net revenue, over

74.70%

[1]

Health Care Organization, Patient Service Revenue [Member] | Sales Revenue, Net [Member] | Self-Pay [Member] | Physician Services [Member]

Revenue, Major Customer [Line Items]

Percent of net revenue, over

20.10%

[1]

Contract and Other Revenue [Member] | Sales Revenue, Net [Member] | Physician Services [Member]

Revenue, Major Customer [Line Items]

Percent of net revenue, over

10.60%

[1]

Provision for Uncollectibles [Member] | Sales Revenue, Net [Member] | Physician Services [Member]

Revenue, Major Customer [Line Items]

Percent of net revenue, over

-22.90%

[1]

[1]

Net revenue by payor is for the period July 16, 2014, the date of the acquisition of Sheridan, through December 31, 2014. As such, historical amounts are not included.

Accounts_Receivable_Details

Accounts Receivable (Details) (USD $)	6 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Accounts, Notes, Loans and Financing Receivable [Line Items]
Bad debt expense			$139,274	$21,947	$20,005
Allowances for accounts receivable	113,357		113,357	27,862
Product Concentration Risk [Member] | Allowance for Doubtful Accounts [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Allowance for doubtful accounts related to fee for service patient visits			73.00%
Ambulatory Services [Member] | Other Operating Expenses [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Bad debt expense			21,900	21,700	19,600
Physician Services [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Bad debt expense	$117,001	[1]	$117,001	$0	$0
[1]	Net revenue by payor is for the period July 16, 2014, the date of the acquisition of Sheridan, through December 31, 2014. As such, historical amounts are not included.

Acquisitions_Narrative_Details

Acquisitions (Narrative) (Details) (USD $)	3 Months Ended	12 Months Ended			0 Months Ended		12 Months Ended	3 Months Ended	6 Months Ended
	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jul. 16, 2014	Jul. 02, 2014	Dec. 31, 2011	Dec. 31, 2014	Dec. 31, 2014	Jul. 15, 2014
							center	physician_practice	physician_practice
Business Acquisition [Line Items]
Proceeds from common stock offering		$439,875,000	$0	$0
Proceeds from preferred stock offering		172,500,000	0	0
Payments of equity issuance costs		-24,494,000	0	0
Transaction costs	25,100,000	33,890,000	300,000	700,000
Debt extinguishment costs	-16,900,000	-16,887,000	0	0
Acquisitions and related expenses, net		2,184,058,000	73,594,000	277,388,000
Contingent purchase price payable		8,470,000	0					8,470,000	8,470,000
Sheridan Healthcare [Member]
Business Acquisition [Line Items]
Cash paid to acquire business					2,100,000,000
Value of common stock issued for acquisition					272,000,000
Fees and expenses associated with acquisition		139,100,000						139,100,000	139,100,000
Deferred financing costs		53,000,000						53,000,000	53,000,000
Transaction costs		31,900,000
Common Stock [Member]
Business Acquisition [Line Items]
Issuance of common stock (in shares)						9,775,000
Proceeds from common stock offering					421,300,000
Common Stock [Member] | Sheridan Healthcare [Member]
Business Acquisition [Line Items]
Shares of common stock issued for acquisition					5,713,909
Mandatory Convertible Preferred Stock [Member]
Business Acquisition [Line Items]
Issuance of common stock (in shares)						1,725,000
Proceeds from preferred stock offering					166,600,000
Senior Secured Credit Facility - Term Loan [Member]
Business Acquisition [Line Items]
Maximum borrowing capacity					870,000,000
Revolving Credit Facility [Member]
Business Acquisition [Line Items]
Maximum borrowing capacity					300,000,000					475,000,000
Debt extinguishment costs		4,500,000
Senior Notes [Member] | 2022 Senior Unsecured Notes [Member]
Business Acquisition [Line Items]
Face amount					1,100,000,000
Interest rate					5.63%
Bridge Loan [Member] | Interest Expense [Member] | Sheridan Healthcare [Member]
Business Acquisition [Line Items]
Fees paid to obtain a commitment for financing		12,800,000
Ambulatory Services [Member]
Business Acquisition [Line Items]
Acquisitions and related expenses, net		50,900,000	73,600,000
Ambulatory Services [Member] | Controlling Interest [Member]
Business Acquisition [Line Items]
Number of business acquisitions		8	5
Ambulatory Services [Member] | Sheridan Healthcare [Member] | Controlling Interest [Member]
Business Acquisition [Line Items]
Number of business acquisitions		3
Ambulatory Services [Member] | Series of Individually Immaterial Business Acquisitions [Member] | Controlling Interest [Member]
Business Acquisition [Line Items]
Number of business acquisitions		5
Ambulatory Services [Member] | National Surgical Care, Inc. [Member]
Business Acquisition [Line Items]
Number of business acquisitions							17
Final settlement of contingent earn out fee			2,700,000
Physician Services [Member] | Series of Individually Immaterial Business Acquisitions [Member]
Business Acquisition [Line Items]
Cash paid to acquire business									19,000,000
Number of business acquisitions								2	2
Contingent purchase price payable		20,700,000						20,700,000	20,700,000
Estimate contingent consideration payment, low		18,000,000						18,000,000	18,000,000
Estimate contingent consideration payment, high		$23,000,000						$23,000,000	$23,000,000
Contingent consideration payment period, low									1 year
Contingent consideration payment period, high									3 years

Acquisitions_Fair_Value_Of_Tot

Acquisitions (Fair Value Of Total Consideration Transferred And Major Class Of Consideration) (Details) (USD $)	Dec. 31, 2014		Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Business Acquisition [Line Items]
Goodwill	$3,381,149		$1,758,970	$1,652,002
Series of Individually Immaterial Business Acquisitions [Member]
Business Acquisition [Line Items]
Accounts receivable	1,816		4,011
Other current assets	1,075		2,014
Property and equipment	3,294		6,894
Goodwill	101,865		116,243
Intangible assets	14,207		0
Other long-term assets	0		0
Accounts payable	-2,519		-2,214
Other accrued liabilities	-626		-532
Deferred income taxes	0		0
Other long-term liabilities	-8,588		-254
Long-term debt	-717		-3,028
Total fair value	109,807		123,134
Less: Fair value attributable to noncontrolling interests	39,371		49,792
Acquisition date fair value of total consideration transferred	70,436		73,342
Sheridan Healthcare [Member]
Business Acquisition [Line Items]
Accounts receivable	130,260	[1]
Other current assets	105,757	[1]
Property and equipment	20,185	[1]
Goodwill	1,534,656	[1]
Intangible assets	1,200,028	[1]
Other long-term assets	50,304	[1]
Accounts payable	-5,862	[1]
Other accrued liabilities	-118,548	[1]
Deferred income taxes	-432,792	[1]
Other long-term liabilities	-69,456	[1]
Long-term debt	-4,594	[1]
Total fair value	2,409,938	[1]
Less: Fair value attributable to noncontrolling interests	24,365	[1]
Acquisition date fair value of total consideration transferred	$2,385,573	[1]
[1]	allocation of fair value of acquired assets and liabilities associated with these acquisitions at December 31, 2014.

Acquisitions_Revs_and_Earnings

Acquisitions (Revs and Earnings) (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Business Acquisition [Line Items]
Revenues	$581,811	$502,350	$278,227	$259,561	$279,095	$262,240	$262,497	$253,364	$1,621,949	$1,057,196	$899,245
Net earnings	79,084	37,422	68,172	60,115	71,168	62,267	65,836	62,273	244,793	261,544	223,643
Less: Net earnings attributable to noncontrolling interests									191,092	188,841	161,080
Net earnings attributable to AmSurg Corp. shareholders									53,701	72,703	62,563
Series of Individually Immaterial Business Acquisitions [Member]
Business Acquisition [Line Items]
Revenues									20,844	15,616
Net earnings									5,155	4,596
Less: Net earnings attributable to noncontrolling interests									2,859	2,603
Net earnings attributable to AmSurg Corp. shareholders									2,296	1,993
Sheridan Healthcare [Member]
Business Acquisition [Line Items]
Revenues									517,213
Net earnings									26,776
Less: Net earnings attributable to noncontrolling interests									459
Net earnings attributable to AmSurg Corp. shareholders									$26,317

Acquisitions_Consolidated_Pro_

Acquisitions (Consolidated Pro Forma Results Of Acquisition) (Details) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Business Combinations [Abstract]
Revenues	$2,217,682	$2,171,999
Net earnings	295,156	243,675
Net earnings attributable to AmSurg Corp. common shareholders	$97,538	$39,980
Net earnings per common share, Basic (usd per share)	$1.88	$0.66
Net earnings per common share, Diluted (usd per share)	$1.86	$0.65

Investments_in_Unconsolidated_1

Investments in Unconsolidated Affiliates (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jul. 16, 2014
Schedule of Equity Method Investments [Line Items]
Investments in unconsolidated affiliates	$75,475,000	$15,526,000
Equity in earnings of unconsolidated affiliates	7,038,000	3,151,000	1,564,000
Acquisitions and related expenses	-2,184,058,000	-73,594,000	-277,388,000
Gain on deconsolidation	3,411,000	2,237,000	0
Joint Venture [Member]
Schedule of Equity Method Investments [Line Items]
Investments in unconsolidated affiliates	75,500,000	15,500,000
Ambulatory Services [Member]
Schedule of Equity Method Investments [Line Items]
Acquisitions and related expenses	-50,900,000	-73,600,000
Ambulatory Services [Member] | Joint Venture [Member]
Schedule of Equity Method Investments [Line Items]
Investments in unconsolidated affiliates	7,000,000	5,200,000
Equity in earnings of unconsolidated affiliates	700,000	200,000
Proceeds from divestiture of interest in consolidated subsidiaries	1,700,000
Payments to acquire noncontrolling interest in jointly owned entity	-500,000
Acquisitions and related expenses		-300,000
Ambulatory Services [Member] | Controlling Interest [Member] | Joint Venture [Member]
Schedule of Equity Method Investments [Line Items]
Number consolidated centers contributed to joint venture	4	1
Ambulatory Services [Member] | Noncontrolling Interest In Centers [Member] | Joint Venture [Member]
Schedule of Equity Method Investments [Line Items]
Number of joint venture entities acquired	3
Ambulatory Services [Member] | Minimum [Member]
Schedule of Equity Method Investments [Line Items]
Estimated probability of fair value variables range	5.00%
Ambulatory Services [Member] | Maximum [Member]
Schedule of Equity Method Investments [Line Items]
Estimated probability of fair value variables range	35.00%
Arrangement with HCA Holdings, Inc. [Member] | Physician Services [Member] | Joint Venture [Member]
Schedule of Equity Method Investments [Line Items]
Equity in earnings of unconsolidated affiliates	3,400,000
Fair value of investment				49,400,000
Ownership percentage				51.00%
Management and billing fees	4,700,000
Arrangement with HCA Holdings, Inc. [Member] | Physician Services [Member] | Other Current Assets [Member] | Joint Venture [Member]
Schedule of Equity Method Investments [Line Items]
Receivable from entity	$3,500,000

Dispositions_Results_Of_Operat

Dispositions (Results Of Operations Of Centers Discontinued) (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Discontinued Operations and Disposal Groups [Abstract]
Revenues									$9,545	$25,373	$34,911
Earnings before income taxes									893	5,607	9,919
Results of discontinued operations, net of tax:
Earnings from operations of discontinued interests in surgery centers									710	4,449	7,920
Gain (loss) on disposal of discontinued interests in surgery centers									-2,006	2,602	25
Net earnings (loss) from discontinued operations	-150	-1,697	483	68	3,820	797	1,229	1,205	-1,296	7,051	7,945
Less: Net earnings from discontinued operations attributable to noncontrolling interests									283	5,357	5,419
Net earnings (loss) from discontinued operations attributable to AmSurg Corp. common shareholders	-196	-1,376	190	-197	627	135	470	462	-1,579	1,694	2,526
Cash proceeds from disposal									$7,069	$3,553	$7,309

Prepaid_and_Other_Current_Asse2

Prepaid and Other Current Assets (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Income taxes receivable	$28,694	$1,865
Prepaid expenses	18,682	12,730
Deferred compensation plan assets	17,320	13,313
Deferred income taxes	22,462	3,097
Other	28,204	5,694
Total prepaid and other current assets	$115,362	$36,699

Property_and_Equipment_Narrati

Property and Equipment (Narrative) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]
Unfunded construction and equipment purchases	$7.70
Depreciation expense	$33.20	$29.80	$26.70
Building and Improvements [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful life	20 years
Building and Improvements [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful life	40 years
Movable Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful life	3 years
Movable Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful life	10 years

Property_and_Equipment_PPE_Sch

Property and Equipment (PPE Schedule) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Property, Plant and Equipment [Abstract]
Building and improvements	$170,420	$161,805
Movable equipment	215,444	207,176
Construction in progress	11,940	2,321
Property and equipment, gross	397,804	371,302
Less accumulated depreciation	-217,356	-207,612
Property and equipment, net	$180,448	$163,690

Goodwill_And_Intangible_Assets2

Goodwill And Intangible Assets (Narrative) (Details) (USD $)	12 Months Ended				3 Months Ended		6 Months Ended
	Dec. 31, 2014		Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2014		Dec. 31, 2014
					physician_practice		physician_practice
Segment Reporting Information [Line Items]
Goodwill	$3,381,149,000		$1,758,970,000	$1,652,002,000	3,381,149,000		3,381,149,000
Increase in goodwill	1,636,521,000		112,951,000
Amortization period	18 years 110 days
Debt extinguishment costs	4,536,000		0	0
Amortization of Intangible Assets	32,500,000		2,200,000	1,400,000
Estimated amortization of intangible assets, 2015	64,700,000				64,700,000		64,700,000
Estimated amortization of intangible assets, 2016	63,800,000				63,800,000		63,800,000
Estimated amortization of intangible assets, 2017	62,500,000				62,500,000		62,500,000
Estimated amortization of intangible assets, 2018	61,600,000				61,600,000		61,600,000
Estimated amortization of intangible assets, 2019	59,100,000				59,100,000		59,100,000
Estimated amortization of intangible assets, 2020 and thereafter	724,200,000				724,200,000		724,200,000
Ambulatory Services [Member]
Segment Reporting Information [Line Items]
Goodwill	1,900,000,000				1,900,000,000		1,900,000,000
Increase in goodwill	131,200,000
Goodwill deductible for tax purposes	51,700,000		70,200,000		51,700,000		51,700,000
Physician Services [Member]
Segment Reporting Information [Line Items]
Goodwill	1,500,000,000				1,500,000,000		1,500,000,000
Goodwill deductible for tax purposes	12,800,000				12,800,000		12,800,000
Sheridan Healthcare [Member]
Segment Reporting Information [Line Items]
Goodwill	1,534,656,000	[1]			1,534,656,000	[1]	1,534,656,000	[1]
Deferred financing costs	53,000,000				53,000,000		53,000,000
Debt extinguishment costs	4,500,000
Intangible assets	1,200,028,000	[1]			1,200,028,000	[1]	1,200,028,000	[1]
Amount estimated to be amortized over weighted average period	1,000,000,000				1,000,000,000		1,000,000,000
Weighted average period of amortization	20 years
Series of Individually Immaterial Business Acquisitions [Member]
Segment Reporting Information [Line Items]
Goodwill	101,865,000		116,243,000		101,865,000		101,865,000
Intangible assets	14,207,000		0		14,207,000		14,207,000
Series of Individually Immaterial Business Acquisitions [Member] | Physician Services [Member]
Segment Reporting Information [Line Items]
Number of business acquisitions					2		2
Interest Expense [Member] | Bridge Loan [Member] | Sheridan Healthcare [Member]
Segment Reporting Information [Line Items]
Fees paid to obtain a commitment for financing	$12,800,000
Customer Relationships [Member]
Segment Reporting Information [Line Items]
Amortization period	20 years
Deferred Financing Costs, Amortizable Non-Compete Agreements, and Customer Agreements [Member] | Minimum [Member]
Segment Reporting Information [Line Items]
Amortization period	5 years
Deferred Financing Costs, Amortizable Non-Compete Agreements, and Customer Agreements [Member] | Maximum [Member]
Segment Reporting Information [Line Items]
Amortization period	10 years
Capitalized software [Member] | Minimum [Member]
Segment Reporting Information [Line Items]
Amortization period	3 years
Capitalized software [Member] | Maximum [Member]
Segment Reporting Information [Line Items]
Amortization period	8 years
[1]	allocation of fair value of acquired assets and liabilities associated with these acquisitions at December 31, 2014.

Goodwill_And_Intangible_Assets3

Goodwill And Intangible Assets (Changes In Carrying Amount Of Goodwill) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Goodwill [Roll Forward]
Balance, beginning of year	$1,758,970	$1,652,002
Goodwill acquired, including post acquisition adjustments	1,636,521	112,951
Goodwill disposed, including impact of deconsolidation transactions	-14,342	-5,983
Balance, end of year	$3,381,149	$1,758,970

Goodwill_And_Intangible_Assets4

Goodwill And Intangible Assets (Summary Of Intangible Assets) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Indefinite-lived Intangible Assets [Line Items]
Non-amortizable intangible assets	$237,995	$9,825
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,085,129	40,298
Accumulated Amortization	-49,245	-22,256
Net	1,035,884	18,042
Total intangible assets, gross carrying amount	1,323,124	50,123
Accumulated Amortization	-49,245	-22,256
Total intangible assets, net	1,273,879	27,867
Customer relationships with hospitals [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	971,645	0
Accumulated Amortization	-22,145	0
Net	949,500	0
Accumulated Amortization	-22,145	0
Deferred financing cost [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	59,574	15,814
Accumulated Amortization	-5,151	-4,953
Net	54,423	10,861
Accumulated Amortization	-5,151	-4,953
Capitalized software [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	50,387	21,036
Accumulated Amortization	-19,197	-14,831
Net	31,190	6,205
Accumulated Amortization	-19,197	-14,831
Agreements, contracts, and other intangible assets
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	3,523	3,448
Accumulated Amortization	-2,752	-2,472
Net	771	976
Accumulated Amortization	-2,752	-2,472
Trade name [Member]
Indefinite-lived Intangible Assets [Line Items]
Non-amortizable intangible assets	228,000	0
Restrictive covenant arrangements [Member]
Indefinite-lived Intangible Assets [Line Items]
Non-amortizable intangible assets	$9,995	$9,825

Other_Accrued_Liabilities_Deta

Other Accrued Liabilities (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accrued Liabilities, Current [Abstract]
Refunds payable	$17,752	$0
Accrued professional liabilities	11,983	1,171
Contingent purchase price payable	12,213	0
Other	26,038	6,175
Total other accrued liabilities	$67,986	$7,346

Accrued_Professional_Liabiliti2

Accrued Professional Liabilities - Components of Reserves (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Payables and Accruals [Abstract]
Estimated losses under self-insured programs	$25,337
Incurred but not reported losses	28,448
Total accrued professional liabilities	53,785	1,171
Less estimated losses payable within one year	11,983	1,171
Total	$41,802	$0

Accrued_Professional_Liabiliti3

Accrued Professional Liabilities - Rollforward of Reserves (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014
Self Insurance Reserve [Roll Forward]
Beginning balance	$1,171
Assumed liabilities through acquisitions	53,512
Provision related to current period reserves	5,423
Payments for current period reserves	-1,595
Benefit related to changes in prior period reserves	-661
Payments for prior period reserves	-6,055
Other, net	1,990
Ending balance	$53,785

LongTerm_Debt_Narrative_Detail

Long-Term Debt (Narrative) (Details) (USD $)	3 Months Ended	12 Months Ended			0 Months Ended	6 Months Ended
	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jul. 16, 2014	Jul. 15, 2014	Nov. 20, 2012	Nov. 07, 2012	Nov. 06, 2012	28-May-10
Payments required on Company's long-term debt and capital leases
2015		$18,800,000
2016		15,900,000
2017		13,700,000
2018		11,400,000
2019		10,200,000
Thereafter		2,181,000,000
Term Loan and Credit Facility
Debt extinguishment costs	-16,900,000	-16,887,000	0	0
Loans Payable [Member]
Other Debt
Book value of certain assets of surgery centers pledged as collateral		47,800,000
Fixed Interest Rate [Member]
Payments required on Company's long-term debt and capital leases
Long-term debt, carrying value		1,383,400,000
Long-term debt, fair value		1,418,600,000
Variable Interest Rate [Member]
Payments required on Company's long-term debt and capital leases
Long-term debt, fair value		867,600,000
5.625% Senior Unsecured Notes due 2020 [Member] | Senior Notes [Member]
Payments required on Company's long-term debt and capital leases
Long-term debt, carrying value		250,000,000	250,000,000
Senior Unsecured Debt
Face amount							250,000,000
Interest rate							5.63%
Redeemable principal percentage		35.00%
Senior Secured Debt
Face amount							250,000,000
Interest rate							5.63%
5.625% Senior Unsecured Notes due 2022 [Member] | Senior Notes [Member]
Payments required on Company's long-term debt and capital leases
Long-term debt, carrying value		1,100,000,000	0
Senior Unsecured Debt
Face amount					1,100,000,000
Interest rate					5.63%
Redeemable principal percentage		35.00%
Senior Secured Debt
Face amount					1,100,000,000
Interest rate					5.63%
8.04% Senior Secured Notes due 2020 [Member] | Senior Notes [Member]
Payments required on Company's long-term debt and capital leases
Long-term debt, carrying value		0	69,643,000
Senior Unsecured Debt
Face amount										75,000,000
Interest rate								8.04%	6.04%
Senior Secured Debt
Face amount										75,000,000
Interest rate								8.04%	6.04%
Early termination fee		12,400,000
Period Prior to November 30, 2015 [Member] | 5.625% Senior Unsecured Notes due 2020 [Member] | Senior Notes [Member]
Senior Unsecured Debt
Redemption price as percent of the principal amount		105.63%
Period Prior to July 15, 2017 [Member] | 5.625% Senior Unsecured Notes due 2022 [Member] | Senior Notes [Member]
Senior Unsecured Debt
Redemption price as percent of the principal amount		105.63%
Senior Secured Credit Facility - Term Loan [Member]
Term Loan and Credit Facility
Borrowing capacity of new revolving credit agreement					870,000,000
Quarterly principal payment as a percent of face amount					0.25%
Annual principal payment					8,700,000
Revolving Credit Facility [Member]
Term Loan and Credit Facility
Borrowing capacity of new revolving credit agreement					300,000,000	475,000,000
Unused commitment fee as a percent					0.38%
Quarterly installments as a percent of initial principal amount of term loan					0.25%
Debt extinguishment costs		4,500,000
Senior Secured Credit Facility [Member]
Term Loan and Credit Facility
Maximum increase in borrowing capacity					$300,000,000
Base Rate [Member] | Senior Secured Credit Facility - Term Loan [Member] | Maximum [Member]
Term Loan and Credit Facility
Basis spread					2.00%
Base Rate [Member] | Senior Secured Credit Facility - Term Loan [Member] | Minimum [Member]
Term Loan and Credit Facility
Basis spread					1.75%
Base Rate [Member] | Revolving Credit Facility [Member] | Maximum [Member]
Term Loan and Credit Facility
Basis spread					2.00%	1.00%
Base Rate [Member] | Revolving Credit Facility [Member] | Minimum [Member]
Term Loan and Credit Facility
Basis spread					1.75%	0.25%
LIBOR [Member] | Senior Secured Credit Facility - Term Loan [Member]
Term Loan and Credit Facility
Floor rate					0.75%
Current variable rate		3.75%
LIBOR [Member] | Senior Secured Credit Facility - Term Loan [Member] | Maximum [Member]
Term Loan and Credit Facility
Basis spread					3.00%
LIBOR [Member] | Senior Secured Credit Facility - Term Loan [Member] | Minimum [Member]
Term Loan and Credit Facility
Basis spread					2.75%
LIBOR [Member] | Revolving Credit Facility [Member] | Maximum [Member]
Term Loan and Credit Facility
Basis spread					3.00%	2.00%
LIBOR [Member] | Revolving Credit Facility [Member] | Minimum [Member]
Term Loan and Credit Facility
Basis spread					2.75%	1.25%

LongTerm_Debt_Components_Of_Lo

Long-Term Debt (Components Of Long-Term Debt) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Debt Instrument [Line Items]
Other debt at an average rate of 3.4%, due through 2025	$20,156	$21,149
Capitalized lease arrangements at an average rate of 5.4%, due through 2031	15,206	10,850
Long-term debt and capitalized lease arrangements	2,251,012	604,142
Less current portion	18,826	20,844
Long-term debt	2,232,186	583,298
Other debt, average rate	3.40%
Capitalized lease arrangements, average rate	5.40%
Line of Credit [Member]
Debt Instrument [Line Items]
Long-term debt	0	252,500
Term Loan [Member]
Debt Instrument [Line Items]
Long-term debt	865,650	0
5.625% Senior Unsecured Notes due 2020 [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Long-term debt	250,000	250,000
5.625% Senior Unsecured Notes due 2022 [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Long-term debt	1,100,000	0
8.04% Senior Secured Notes due 2020 [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Long-term debt	$0	$69,643

LongTerm_Debt_Redemption_Price

Long-Term Debt (Redemption Price) (Details) (Senior Notes [Member])	12 Months Ended
	Dec. 31, 2014
2015 [Member] | 5.625% Senior Unsecured Notes due 2020 [Member]
Redemption price as percent of the principal amount	104.22%
2016 [Member] | 5.625% Senior Unsecured Notes due 2020 [Member]
Redemption price as percent of the principal amount	102.81%
2017 [Member] | 5.625% Senior Unsecured Notes due 2020 [Member]
Redemption price as percent of the principal amount	101.41%
2017 [Member] | 5.625% Senior Unsecured Notes due 2022 [Member]
Redemption price as percent of the principal amount	104.22%
2018 and thereafter [Member] | 5.625% Senior Unsecured Notes due 2020 [Member]
Redemption price as percent of the principal amount	100.00%
2018 [Member] | 5.625% Senior Unsecured Notes due 2022 [Member]
Redemption price as percent of the principal amount	102.81%
2019 [Member] | 5.625% Senior Unsecured Notes due 2022 [Member]
Redemption price as percent of the principal amount	101.41%
2020 and thereafter [Member] | 5.625% Senior Unsecured Notes due 2022 [Member]
Redemption price as percent of the principal amount	100.00%

Other_Longterm_Liabilities_Det

Other Long-term Liabilities (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Other Liabilities Disclosure [Abstract]
Accrued professional liabilities	$41,802	$0
Contingent purchase price payable	8,470	0
Deferred rent	16,814	14,637
Tax-effected unrecognized benefits	8,353	6,888
Other	14,004	3,978
Other long-term liabilities	$89,443	$25,503

Income_Taxes_Narrative_Details

Income Taxes (Narrative) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
U.S. federal income tax rate	35.00%	35.00%	35.00%
Decreases in interest and penalty obligations	$0.10	$0.20	$0.10
Interest obligations	1.2	0.9
Tax-effected unrecognized benefits	$0.40

Income_Taxes_Total_Income_Tax_

Income Taxes (Total Income Tax Expense) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
Income from continuing operations	$48,103	$48,654	$40,893
Discontinued operations	-643	9	3,045
Shareholders’ equity	-3,177	-7,381	-1,581
Total	$44,283	$41,282	$42,357

Income_Taxes_Income_Tax_Expens

Income Taxes (Income Tax Expense from Cont. Ops) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Current:
Federal	$8,640	$7,895	$14,602
State	4,396	3,598	4,806
Deferred:
Federal	27,505	31,509	18,018
State	7,562	5,652	3,467
Income tax expense	$48,103	$48,654	$40,893

Income_Taxes_Income_Tax_Expens1

Income Taxes (Income Tax Expense Reconciliation to Federal Rate) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Effective Income Tax Rate Reconciliation, Amount [Abstract]
Statutory federal income tax	$102,967	$106,101	$89,806
Less federal income tax assumed directly by noncontrolling interests	-66,783	-64,219	-56,378
State income taxes, net of federal income tax benefit	6,616	5,539	7,020
Increase in valuation allowances	4,662	924	419
Interest related to unrecognized tax benefits	-161	-155	-109
Other	802	464	135
Income tax expense	$48,103	$48,654	$40,893

Income_Taxes_Unrecognized_Tax_

Income Taxes (Unrecognized Tax Liability Rec) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance at beginning of year	$6,330	$9,235	$7,252
Additions for tax positions of current year	204	46	119
Increases for tax positions taken during a prior period	1,069	0	1,985
Lapse of statute of limitations	-267	-2,951	-121
Balance at end of year	$7,336	$6,330	$9,235

Income_Taxes_Deferred_Assets_a

Income Taxes (Deferred Assets and Liabilities) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Deferred tax assets:
Allowance for uncollectible accounts	$1,096	$897
Accrued assets and other	27,537	5,292
Valuation allowances	-3,736	-2,021
Total current deferred tax assets	24,897	4,168
Share-based compensation	7,719	7,635
Interest on unrecognized tax benefits	245	230
Accrued liabilities and other	3,931	3,629
Medical malpractice	16,240	0
Operating and capital loss carryforwards	22,709	9,185
Valuation allowances	-13,721	-7,665
Total non-current deferred tax assets	37,123	13,014
Total deferred tax assets	62,020	17,182
Deferred tax liabilities:
Prepaid expenses	2,435	1,071
Property and equipment, principally due to differences in depreciation	15,235	4,137
Goodwill, intangible assets and other, principally due to differences in amortization	655,368	184,897
Total deferred tax liabilities	673,038	190,105
Net deferred tax liabilities	$611,018	$172,923

Income_Taxes_Deferred_Tax_Liab

Income Taxes (Deferred Tax Liability Schedule) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Deferred Tax Assets, Net, Classification [Abstract]
Current deferred income tax assets	$22,462	$3,097
Non-current deferred income tax liabilities	633,480	176,020
Net deferred tax liabilities	$611,018	$172,923

Shareholders_Equity_Narrative_

Shareholder's Equity (Narrative) (Details) (USD $)	12 Months Ended			0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jul. 02, 2014	Aug. 29, 2014	Jul. 16, 2014	Aug. 09, 2013	Apr. 24, 2012
Common Stock:
Stock repurchased program authorized by the board of directors							$40,000,000	$40,000,000
Amount remaining under stock repurchase plan	27,100,000
Mandatory Convertible Preferred Stock
Preferred stock dividends	4,503,000	0	0
Stock Incentive Plans:
Restricted marketable securities	3,000,000
Excess tax benefit from share-based compensation	3,177,000	7,247,000	1,784,000
Number of shares authorized for grant under share incentive plan	1,200,000
Shares available for future grants/issuance under stock incentive plan	1,132,862
Unrecognized compensation cost on non vested awards	8,400,000
Weighted average period	1 year 2 months 12 days
Stock Repurchased Under Repurchase Program [Member]
Common Stock:
Repurchase of common stock, shares		1,154,378
Repurchase of common stock		42,700,000
Average price per share		$36.93
Stock Repurchased To Cover Employee Tax Withholdings [Member]
Common Stock:
Repurchase of common stock, shares	100,720	102,252
Repurchase of common stock	4,600,000	3,300,000
Stock Options [Member]
Stock Incentive Plans:
Award vesting period	4 years
Options term	10 years
Outside Directors [Member] | Restricted Stock [Member]
Stock Incentive Plans:
Award vesting period	1 year
Employees [Member] | Restricted Stock [Member]
Stock Incentive Plans:
Award vesting period	4 years
Number of installments in restricted stock granted.	3
Stock Options [Member]
Stock Incentive Plans:
Number of anti-dilutive options	0	0	20,000
Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of stock (in shares)				9,775,000
Issuance of stock, price per share				$45
Stock offering expenses				18,500,000
Mandatory Convertible Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of stock (in shares)				1,725,000
Issuance of stock, price per share				$100
Stock offering expenses				5,900,000
Mandatory Convertible Preferred Stock
Dividend rate	5.25%
Initial liquidation preference (usd per share)	$100
Consecutive trading day	20 days
Dividends declared (usd per share)					$1.30
Preferred stock dividends					2,200,000
Future preferred stock dividends (usd per share)	$1.31
Future preferred stock dividends					$2,300,000
Sheridan Healthcare [Member] | Common Stock [Member]
Common Stock:
Shares of common stock issued for acquisition						5,713,909
Minimum [Member] | Mandatory Convertible Preferred Stock [Member]
Mandatory Convertible Preferred Stock
Conversion rate (shares)	1.8141
Maximum [Member] | Mandatory Convertible Preferred Stock [Member]
Mandatory Convertible Preferred Stock
Conversion rate (shares)	2.2222

Shareholders_Equity_ShareBased

Shareholders' Equity (Share-Based Activity) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Equity [Abstract]
Share-based compensation expense	$10,104	$8,321	$6,692
Fair value of shares vested	15,126	11,742	6,425
Cash received from option exercises	2,630	33,349	18,214
Tax benefit from option exercises	$3,177	$7,247	$1,784

Shareholders_Equity_Schedule_O

Shareholders Equity (Schedule Of Changes In Non-Vested Restricted Shares) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Non-vested shares at beginning of period, Number of Shares	743,869	828,686	732,412
Shares granted, Number of Shares	272,780	291,863	281,429
Shares vested, Number of Shares	-336,160	-360,337	-183,019
Shares forfeited, Number of Shares	-12,380	-16,343	-2,136
Non-vested shares at end of period, Number of Shares	668,109	743,869	828,686
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Non-vested shares at beginning of period, Weighted Average Grant Price (usd per share)	$26.54	$22.50	$21.91
Shares granted, Weighted Average Grant Price (usd per share)	$43.12	$31.66	$26.78
Shares vested, Weighted Average Grant Price (usd per share)	$25.69	$21.55	$25.98
Shares forfeited, Weighted Average Grant Price (usd per share)	$38.94	$23.11	$26.26
Non-vested shares at end of period, Weighted Average Grant Price (usd per share)	$33.51	$26.54	$22.50

Recovered_Sheet1

Shareholder's Equity (Schedule of Stock Option Activity (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding at beginning of period, Number of Shares	270,464	1,662,830	2,510,054
Options exercised, Number of Shares	-111,743	-1,392,366	-841,599
Options terminated, Number of Shares			-5,625
Outstanding at end of period, Number of Shares	158,721	270,464	1,662,830	2,510,054
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Outstanding at beginning of period, Weighted Average Exercise Price (usd per share)	$23.16	$23.82	$23.09
Options exercised, Weighted Average Exercise Price (usd per share)	$23.53	$23.95	$21.64
Options terminated, Weighted Average Exercise Price (usd per share)			$21.85
Outstanding at end of period, Weighted Average Exercise Price (usd per share)	$22.89	$23.16	$23.82	$23.09
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Outstanding at beginning of period, Weighted Average Remaining Contractual Life (in years)	1 year 256 days	2 years 6 months 0 days	2 years 329 days	3 years 146 days
Outstanding at end of period, Weighted Average Remaining Contractual Life (in years)	1 year 256 days	2 years 6 months 0 days	2 years 329 days	3 years 146 days

Shareholders_Equity_Schedule_o1

Shareholder's Equity (Schedule of Stock Option Activity - Additional) (Details) (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Equity [Abstract]
Total intrinsic value with options exercised	$2.60	$33.30	$6.30
Aggregate intrinsic value of options outstanding	3.6
Total intrinsic value of options vested or expected to vest	4.9
Vested or expected to vest at end of period, Number of Shares	158,721
Vested or expected to vest at end of period, weighted average exercise price (usd per share)
Vested or expected to vest at end of period, Weighted Average Remaining Contractual Life (in years)
Total Intrinsic value of options exercisable	$4.90
Exercisable at end of period, Number of Shares	158,721
Exercisable at end of period, Weighted Average Exercise Price (usd per share)
Exercisable at end of period, Weighted Average Remaining Contractual Life (in years)	1 year 292 days

Recovered_Sheet2

Shareholder's Equity (Schedule Of Reconciliation Of Numerator And Denominators Of Basic And Diluted Earnings Per Share) (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (Numerator)	$25,311	($10,697)	$18,771	$17,392	$18,931	$16,636	$18,093	$17,349	$50,777	$71,009	$60,037
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (basic), shares (Denominator)									39,311,000	31,338,000	30,773,000
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (basic) (usd per share)	$0.53	($0.23)	$0.59	$0.55	$0.60	$0.53	$0.58	$0.56	$1.29	$2.27	$1.95
Effect of dilutive securities options and non-vested shares, shares									314,000	616,000	835,000
Net earnings from continuing operations attributable to AmSurg Corp. (diluted), shares (Denominator)									39,625,000	31,954,000	31,608,000
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (diluted) (usd per share)	$0.53	($0.23)	$0.58	$0.54	$0.59	$0.52	$0.57	$0.54	$1.28	$2.22	$1.90
Mandatory Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of anti-dilutive shares									1,800,000

Leases_Narrative_Details

Leases (Narrative) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Leases [Abstract]
Lease Expiration Date	31-Jan-36
Capital lease assets	$19.20
Capital lease assets, accumulated depreciation	4.7
Operating leases, rental expense	$66.10	$52.60	$47.30

Leases_Future_Min_Schedule_Det

Leases (Future Min Schedule) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Capital Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
2015	$2,613
2016	2,146
2017	1,901
2018	1,594
2019	1,388
Thereafter	11,361
Total minimum rentals	21,003
Less amounts representing interest at rates ranging from 2.7% to 11.8%	5,797
Capital lease obligations	15,206	10,850
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
2015	53,007
2016	51,687
2017	50,260
2018	47,978
2019	46,880
Thereafter	356,337
Total minimum rentals	$606,149

Leases_Future_Min_Schedule_Add

Leases (Future Min Schedule - Additional) (Details)	12 Months Ended
	Dec. 31, 2014
Minimum [Member]
Capital Lease Interest Rate Range [Line Items]
Capital lease interest rates	2.70%
Maximum [Member]
Capital Lease Interest Rate Range [Line Items]
Capital lease interest rates	11.80%

Related_Party_Transactions_Rel

Related Party Transactions (Related Party Payments) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Related Party Transactions [Abstract]
Operating leases	$27,559	$29,240	$29,079
Salaries and benefits	66,763	72,892	65,908
Billing fees	9,899	11,591	11,126
Medical advisory services	$2,811	$2,993	$2,671

Employee_Benefit_Programs_Deta

Employee Benefit Programs (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Defined Contribution Plan Disclosure [Line Items]
Cash surrender value	$17,320,000	$13,313,000
AmSurg 401(k) Plan and Trust [Member]
Defined Contribution Plan Disclosure [Line Items]
Employer contributions	1,600,000	1,100,000	1,000,000
Requisite service period	5 years
401(k) as Part of Sheridan Acquisition [Member]
Defined Contribution Plan Disclosure [Line Items]
Requisite service period	4 years
Plan expense	5,600,000
Supplemental Executive And Director Retirement Savings Plan [Member]
Defined Contribution Plan Disclosure [Line Items]
Employer contributions	800,000	2,300,000	1,700,000
Maximum voluntary contribution as a percent of annual compensation	50.00%
Supplemental Executive And Director Retirement Savings Plan [Member] | Prepaid Expenses and Other Current Assets [Member]
Defined Contribution Plan Disclosure [Line Items]
Cash surrender value	$17,320,000	$13,313,000

Commitments_and_Contingencies_

Commitments and Contingencies (Details)	0 Months Ended
	Dec. 27, 2012
	sqft
Commitments and Contingencies Disclosure [Abstract]
Lease square footage	110,000

Segment_Reporting_Details

Segment Reporting (Details) (USD $)	3 Months Ended								6 Months Ended			12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014		Jul. 15, 2014	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
									segment		segment
Segment Reporting [Abstract]
Number of reportable segments									2		1
Segment Reporting Information [Line Items]
Net revenues	$581,811	$502,350	$278,227	$259,561	$279,095	$262,240	$262,497	$253,364				$1,621,949		$1,057,196		$899,245
Adjusted EBITDA												304,482		187,972		154,527
Earnings from continuing operations attributable to noncontrolling interests												190,809		183,484		155,661
Interest expense, net												-83,285		-29,525		-16,950
Depreciation and amortization												-60,344		-32,400		-29,255
Share-based compensation												-10,104		-8,321		-6,692
Transaction costs		-25,100										-33,890		-300		-700
Debt extinguishment costs		-16,900										-16,887		0		0
Gain on deconsolidation												3,411		2,237		0
Earnings from continuing operations before income taxes	101,535	39,141	80,487	73,029	80,363	72,615	77,100	73,069				294,192		303,147		256,591
Acquisition and Capital Expenditures												110,065		102,450		306,252
Assets	5,523,524				2,177,944				5,523,524			5,523,524		2,177,944
Ambulatory Services [Member]
Segment Reporting Information [Line Items]
Net revenues												1,109,935		1,057,196		899,245
Adjusted EBITDA												197,377		187,972		154,527
Acquisition and Capital Expenditures												81,156	[1]	102,450	[1]	306,252	[1]
Assets	2,528,525				2,177,944				2,528,525			2,528,525		2,177,944
Physician Services [Member]
Segment Reporting Information [Line Items]
Net revenues									512,014	[2]		512,014		0		0
Adjusted EBITDA												107,105		0		0
Acquisition and Capital Expenditures												28,909		0		0
Assets	$2,994,999				$0				$2,994,999			$2,994,999		$0
[1]	Excludes the purchase price to acquire Sheridan.
[2]	Net revenue by payor is for the period July 16, 2014, the date of the acquisition of Sheridan, through December 31, 2014. As such, historical amounts are not included.

Financial_Information_for_the_2

Financial Information for the Company and Its Subsidiaries (Balance Sheets) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
In Thousands, unless otherwise specified
Assets
Cash and cash equivalents	$208,079	$50,840	$46,398	$40,718
Restricted cash and marketable securities	10,219	0
Accounts receivable, net	233,053	105,072
Supplies inventory	19,974	18,414
Prepaid and other current assets	115,362	36,699
Total current assets	586,687	211,025
Property and equipment, net	180,448	163,690
Investments in and receivables from unconsolidated affiliates	75,475	15,526
Goodwill	3,381,149	1,758,970	1,652,002
Intangible assets, net	1,273,879	27,867
Other assets	25,886	866
Total assets	5,523,524	2,177,944
Liabilities and Equity
Current portion of long-term debt	18,826	20,844
Accounts payable	29,585	27,501
Accrued salaries and benefits	140,044	32,294
Accrued interest	29,644	1,885
Other accrued liabilities	67,986	7,346
Total current liabilities	286,085	89,870
Long-term debt	2,232,186	583,298
Deferred income taxes	633,480	176,020
Other long-term liabilities	89,443	25,503
Intercompany payable	0
Noncontrolling interests – redeemable	184,099	177,697
Equity:
Total AmSurg Corp. equity	1,679,547	764,197
Noncontrolling interests – non-redeemable	418,684	361,359
Total equity	2,098,231	1,125,556
Total liabilities and equity	5,523,524	2,177,944
Consolidating Adjustments [Member]
Assets
Cash and cash equivalents	0	0	0	0
Restricted cash and marketable securities	0
Accounts receivable, net	0	0
Supplies inventory	0	0
Prepaid and other current assets	-4,818	-4,362
Total current assets	-4,818	-4,362
Property and equipment, net	0	0
Investments in and receivables from unconsolidated affiliates	-5,425,210	-2,922,178
Goodwill	1,890,168	1,758,970
Intangible assets, net	0	0
Other assets	-1,466	0
Total assets	-3,541,326	-1,167,570
Liabilities and Equity
Current portion of long-term debt	0	0
Accounts payable	-4,080	-3,958
Accrued salaries and benefits	0	0
Accrued interest	0	0
Other accrued liabilities	-738	-404
Total current liabilities	-4,818	-4,362
Long-term debt	-28,412	-31,377
Deferred income taxes	-1,466	0
Other long-term liabilities	0	0
Intercompany payable	-1,227,989
Noncontrolling interests – redeemable	120,555	113,993
Equity:
Total AmSurg Corp. equity	-2,774,257	-1,568,267
Noncontrolling interests – non-redeemable	375,061	322,443
Total equity	-2,399,196	-1,245,824
Total liabilities and equity	-3,541,326	-1,167,570
Parent Company [Member]
Assets
Cash and cash equivalents	134,351	6,710	7,259	8,530
Restricted cash and marketable securities	0
Accounts receivable, net	0	0
Supplies inventory	0	33
Prepaid and other current assets	47,997	27,090
Total current assets	182,348	33,833
Property and equipment, net	10,391	6,024
Investments in and receivables from unconsolidated affiliates	3,912,804	1,484,108
Goodwill	0	0
Intangible assets, net	67,678	24,489
Other assets	3,323	866
Total assets	4,176,544	1,549,320
Liabilities and Equity
Current portion of long-term debt	8,700	10,714
Accounts payable	1,849	1,972
Accrued salaries and benefits	25,035	21,115
Accrued interest	29,621	1,847
Other accrued liabilities	8,051	4,457
Total current liabilities	73,256	40,105
Long-term debt	2,206,950	561,429
Deferred income taxes	209,400	176,020
Other long-term liabilities	7,391	7,569
Intercompany payable	0
Noncontrolling interests – redeemable	0	0
Equity:
Total AmSurg Corp. equity	1,679,547	764,197
Noncontrolling interests – non-redeemable	0	0
Total equity	1,679,547	764,197
Total liabilities and equity	4,176,544	1,549,320
Guarantor Subsidiaries [Member]
Assets
Cash and cash equivalents	23,471	0	0	0
Restricted cash and marketable securities	0
Accounts receivable, net	123,772	0
Supplies inventory	301	0
Prepaid and other current assets	58,388	0
Total current assets	205,932	0
Property and equipment, net	9,972	0
Investments in and receivables from unconsolidated affiliates	1,587,881	1,453,596
Goodwill	1,490,981	0
Intangible assets, net	1,203,218	0
Other assets	943	0
Total assets	4,498,927	1,453,596
Liabilities and Equity
Current portion of long-term debt	0	0
Accounts payable	35	0
Accrued salaries and benefits	101,395	0
Accrued interest	0	0
Other accrued liabilities	44,305	0
Total current liabilities	145,735	0
Long-term debt	0	0
Deferred income taxes	425,546	0
Other long-term liabilities	63,616	0
Intercompany payable	1,219,979
Noncontrolling interests – redeemable	0	0
Equity:
Total AmSurg Corp. equity	2,644,051	1,453,596
Noncontrolling interests – non-redeemable	0	0
Total equity	2,644,051	1,453,596
Total liabilities and equity	4,498,927	1,453,596
Non-Guarantor Subsidiaries [Member]
Assets
Cash and cash equivalents	50,257	44,130	39,139	32,188
Restricted cash and marketable securities	10,219
Accounts receivable, net	109,281	105,072
Supplies inventory	19,673	18,381
Prepaid and other current assets	13,795	13,971
Total current assets	203,225	181,554
Property and equipment, net	160,085	157,666
Investments in and receivables from unconsolidated affiliates	0	0
Goodwill	0	0
Intangible assets, net	2,983	3,378
Other assets	23,086	0
Total assets	389,379	342,598
Liabilities and Equity
Current portion of long-term debt	10,126	10,130
Accounts payable	31,781	29,487
Accrued salaries and benefits	13,614	11,179
Accrued interest	23	38
Other accrued liabilities	16,368	3,293
Total current liabilities	71,912	54,127
Long-term debt	53,648	53,246
Deferred income taxes	0	0
Other long-term liabilities	18,436	17,934
Intercompany payable	8,010
Noncontrolling interests – redeemable	63,544	63,704
Equity:
Total AmSurg Corp. equity	130,206	114,671
Noncontrolling interests – non-redeemable	43,623	38,916
Total equity	173,829	153,587
Total liabilities and equity	$389,379	$342,598

Financial_Information_for_the_3

Financial Information for the Company and Its Subsidiaries (Income Statements) (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Condensed Financial Statements, Captions [Line Items]
Net revenues	$581,811	$502,350	$278,227	$259,561	$279,095	$262,240	$262,497	$253,364	$1,621,949	$1,057,196	$899,245
Operating expenses:
Salaries and benefits									694,576	327,585	284,528
Supply cost									164,296	153,126	126,919
Other operating expenses									284,928	216,501	185,866
Transaction costs		25,100							33,890	300	700
Depreciation and amortization									60,344	32,400	29,255
Total operating expenses									1,238,034	729,912	627,268
Gain on deconsolidation									3,411	2,237	0
Equity in earnings of unconsolidated affiliates									7,038	3,151	1,564
Operating income									394,364	332,672	273,541
Interest expense, net									83,285	29,525	16,950
Debt extinguishment costs		16,900							16,887	0	0
Earnings from continuing operations before income taxes	101,535	39,141	80,487	73,029	80,363	72,615	77,100	73,069	294,192	303,147	256,591
Income tax expense									48,103	48,654	40,893
Net earnings from continuing operations	79,234	39,119	67,689	60,047	67,348	61,470	64,607	61,068	246,089	254,493	215,698
Net earnings (loss) from discontinued operations	-150	-1,697	483	68	3,820	797	1,229	1,205	-1,296	7,051	7,945
Net earnings	79,084	37,422	68,172	60,115	71,168	62,267	65,836	62,273	244,793	261,544	223,643
Less net earnings attributable to noncontrolling interests									191,092	188,841	161,080
Net earnings attributable to AmSurg Corp. shareholders									53,701	72,703	62,563
Preferred stock dividends									-4,503	0	0
Net earnings attributable to AmSurg Corp. common shareholders	25,115	-12,073	18,961	17,195	19,558	16,771	18,563	17,811	49,198	72,703	62,563
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax	25,311	-10,697	18,771	17,392	18,931	16,636	18,093	17,349	50,777	71,009	60,037
Earnings (loss) from discontinued operations, net of income tax	-196	-1,376	190	-197	627	135	470	462	-1,579	1,694	2,526
Net earnings attributable to AmSurg Corp. common shareholders	25,115	-12,073	18,961	17,195	19,558	16,771	18,563	17,811	49,198	72,703	62,563
Consolidating Adjustments [Member]
Condensed Financial Statements, Captions [Line Items]
Net revenues									-24,336	-17,518	-14,901
Operating expenses:
Salaries and benefits									-5,786	-467	-450
Supply cost									0	0	0
Other operating expenses									-18,550	-17,051	-14,451
Transaction costs									0	0	0
Depreciation and amortization									0	0	0
Total operating expenses									-24,336	-17,518	-14,901
Gain on deconsolidation									-3,411	-2,237
Equity in earnings of unconsolidated affiliates									-439,097	-406,773	-354,710
Operating income									-442,508	-409,010	-354,710
Interest expense, net									0	0	0
Debt extinguishment costs									0
Earnings from continuing operations before income taxes									-442,508	-409,010	-354,710
Income tax expense									0	0	0
Net earnings from continuing operations									-442,508	-409,010	-354,710
Net earnings (loss) from discontinued operations									0	0	0
Net earnings									-442,508	-409,010	-354,710
Less net earnings attributable to noncontrolling interests									0	0	0
Net earnings attributable to AmSurg Corp. shareholders									-442,508
Preferred stock dividends									0
Net earnings attributable to AmSurg Corp. common shareholders									-442,508	-409,010	-354,710
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax									-442,508	-409,010	-354,710
Earnings (loss) from discontinued operations, net of income tax									0	0	0
Net earnings attributable to AmSurg Corp. common shareholders									-442,508	-409,010	-354,710
Parent Company [Member]
Condensed Financial Statements, Captions [Line Items]
Net revenues									24,773	24,167	19,907
Operating expenses:
Salaries and benefits									65,697	61,038	54,895
Supply cost									0	0	0
Other operating expenses									18,667	22,360	19,799
Transaction costs									29,004	300	700
Depreciation and amortization									4,044	3,186	2,860
Total operating expenses									117,412	86,884	78,254
Gain on deconsolidation									3,411	2,237
Equity in earnings of unconsolidated affiliates									234,246	204,962	178,137
Operating income									145,018	144,482	119,790
Interest expense, net									47,997	27,282	14,803
Debt extinguishment costs									16,887
Earnings from continuing operations before income taxes									80,134	117,200	104,987
Income tax expense									29,166	47,139	39,339
Net earnings from continuing operations									50,968	70,061	65,648
Net earnings (loss) from discontinued operations									2,733	2,642	-3,085
Net earnings									53,701	72,703	62,563
Less net earnings attributable to noncontrolling interests									0	0	0
Net earnings attributable to AmSurg Corp. shareholders									53,701
Preferred stock dividends									-4,503
Net earnings attributable to AmSurg Corp. common shareholders									49,198	72,703	62,563
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax									46,465	70,061	65,648
Earnings (loss) from discontinued operations, net of income tax									2,733	2,642	-3,085
Net earnings attributable to AmSurg Corp. common shareholders									49,198	72,703	62,563
Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Net revenues									508,572	0	0
Operating expenses:
Salaries and benefits									350,615	0	0
Supply cost									1,292	0	0
Other operating expenses									53,413	0	0
Transaction costs									4,886	0	0
Depreciation and amortization									25,610	0	0
Total operating expenses									435,816	0	0
Gain on deconsolidation									3,411	2,237
Equity in earnings of unconsolidated affiliates									211,889	204,962	178,137
Operating income									288,056	207,199	178,137
Interest expense, net									33,026	0	0
Debt extinguishment costs									0
Earnings from continuing operations before income taxes									255,030	207,199	178,137
Income tax expense									17,373	0	0
Net earnings from continuing operations									237,657	207,199	178,137
Net earnings (loss) from discontinued operations									0	0	0
Net earnings									237,657	207,199	178,137
Less net earnings attributable to noncontrolling interests									21	0	0
Net earnings attributable to AmSurg Corp. shareholders									237,636
Preferred stock dividends									0
Net earnings attributable to AmSurg Corp. common shareholders									237,636	207,199	178,137
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax									237,636	207,199	178,137
Earnings (loss) from discontinued operations, net of income tax									0	0	0
Net earnings attributable to AmSurg Corp. common shareholders									237,636	207,199	178,137
Non-Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Net revenues									1,112,940	1,050,547	894,239
Operating expenses:
Salaries and benefits									284,050	267,014	230,083
Supply cost									163,004	153,126	126,919
Other operating expenses									231,398	211,192	180,518
Transaction costs									0	0	0
Depreciation and amortization									30,690	29,214	26,395
Total operating expenses									709,142	660,546	563,915
Gain on deconsolidation									0	0
Equity in earnings of unconsolidated affiliates									0	0	0
Operating income									403,798	390,001	330,324
Interest expense, net									2,262	2,243	2,147
Debt extinguishment costs									0
Earnings from continuing operations before income taxes									401,536	387,758	328,177
Income tax expense									1,564	1,515	1,554
Net earnings from continuing operations									399,972	386,243	326,623
Net earnings (loss) from discontinued operations									-4,029	4,409	11,030
Net earnings									395,943	390,652	337,653
Less net earnings attributable to noncontrolling interests									191,071	188,841	161,080
Net earnings attributable to AmSurg Corp. shareholders									204,872
Preferred stock dividends									0
Net earnings attributable to AmSurg Corp. common shareholders									204,872	201,811	176,573
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax									209,184	202,759	170,962
Earnings (loss) from discontinued operations, net of income tax									-4,312	-948	5,611
Net earnings attributable to AmSurg Corp. common shareholders									$204,872	$201,811	$176,573

Financial_Information_for_the_4

Financial Information for the Company and Its Subsidiaries (Cash Flow Statements) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities:
Net cash flows provided by operating activities	$412,371	$332,824	$295,652
Cash flows from investing activities:
Acquisitions and related transactions	-2,184,058	-73,594	-277,388
Acquisition of property and equipment	-40,217	-28,856	-28,864
Proceeds from sale of interests in surgery centers	7,069	3,553	7,309
Purchases of marketable securities	-6,474	0	0
Maturities of marketable securities	3,486	0	0
Other	-4,941	159	0
Net cash flows used in investing activities	-2,225,135	-98,738	-298,943
Cash flows from financing activities:
Proceeds from long-term borrowings	2,048,958	162,204	565,566
Repayment on long-term borrowings	-408,475	-202,083	-394,164
Distributions to owners, including noncontrolling interests	-190,097	-184,149	-162,941
Capital contributions	0		0
Proceeds from preferred stock offering	172,500	0	0
Cash dividends for preferred shares	-4,503	0	0
Proceeds from common stock offering	439,875	0	0
Payments of equity issuance costs	-24,494	0	0
Financing costs incurred	-65,811	-1,322	-7,982
Changes in intercompany balances with affiliates, net	0	0	0
Other financing activities, net	2,050	-5,616	510
Net cash flows provided by (used in) financing activities	1,970,003	-229,644	8,971
Net increase in cash and cash equivalents	157,239	4,442	5,680
Cash and cash equivalents, beginning of year	50,840	46,398	40,718
Cash and cash equivalents, end of year	208,079	50,840	46,398
Consolidating Adjustments [Member]
Cash flows from operating activities:
Net cash flows provided by operating activities	-413,605	-347,648	-182,851
Cash flows from investing activities:
Acquisitions and related transactions	2,126,737	694	92,830
Acquisition of property and equipment	0	0	0
Proceeds from sale of interests in surgery centers	0	0	0
Purchases of marketable securities	0
Maturities of marketable securities	0
Other	0	0
Net cash flows used in investing activities	2,126,737	694	92,830
Cash flows from financing activities:
Proceeds from long-term borrowings	0	0	0
Repayment on long-term borrowings	0	0	0
Distributions to owners, including noncontrolling interests	413,605	347,648	182,851
Capital contributions	-2,124,124		-90,029
Proceeds from preferred stock offering	0
Cash dividends for preferred shares	0
Proceeds from common stock offering	0
Payments of equity issuance costs	0
Financing costs incurred	0
Changes in intercompany balances with affiliates, net	0	0	0
Other financing activities, net	-2,613	-694	-2,801
Net cash flows provided by (used in) financing activities	-1,713,132	346,954	90,021
Net increase in cash and cash equivalents	0	0	0
Cash and cash equivalents, beginning of year	0	0	0
Cash and cash equivalents, end of year	0	0	0
Parent Company [Member]
Cash flows from operating activities:
Net cash flows provided by operating activities	96,681	45,127	-83,605
Cash flows from investing activities:
Acquisitions and related transactions	-2,124,124	0	-90,029
Acquisition of property and equipment	-7,877	-3,693	-3,681
Proceeds from sale of interests in surgery centers	0	0	0
Purchases of marketable securities	0
Maturities of marketable securities	0
Other	-3,068	0
Net cash flows used in investing activities	-2,135,069	-3,693	-93,710
Cash flows from financing activities:
Proceeds from long-term borrowings	2,040,000	152,700	560,000
Repayment on long-term borrowings	-396,493	-188,081	-381,220
Distributions to owners, including noncontrolling interests	0	0	0
Capital contributions	0		0
Proceeds from preferred stock offering	172,500
Cash dividends for preferred shares	-4,503
Proceeds from common stock offering	439,875
Payments of equity issuance costs	-24,494
Financing costs incurred	-65,811
Changes in intercompany balances with affiliates, net	2,965	88	-2,666
Other financing activities, net	1,990	-6,690	-70
Net cash flows provided by (used in) financing activities	2,166,029	-41,983	176,044
Net increase in cash and cash equivalents	127,641	-549	-1,271
Cash and cash equivalents, beginning of year	6,710	7,259	8,530
Cash and cash equivalents, end of year	134,351	6,710	7,259
Guarantor Subsidiaries [Member]
Cash flows from operating activities:
Net cash flows provided by operating activities	298,415	208,773	182,851
Cash flows from investing activities:
Acquisitions and related transactions	-2,188,191	-74,288	-280,189
Acquisition of property and equipment	-9,933	0	0
Proceeds from sale of interests in surgery centers	7,069	3,553	7,309
Purchases of marketable securities	0
Maturities of marketable securities	0
Other	-6,594	159
Net cash flows used in investing activities	-2,197,649	-70,576	-272,880
Cash flows from financing activities:
Proceeds from long-term borrowings	0	0	0
Repayment on long-term borrowings	0	0	0
Distributions to owners, including noncontrolling interests	-202,247	-138,875	0
Capital contributions	2,124,124		90,029
Proceeds from preferred stock offering	0
Cash dividends for preferred shares	0
Proceeds from common stock offering	0
Payments of equity issuance costs	0
Financing costs incurred	0
Changes in intercompany balances with affiliates, net	0	0	0
Other financing activities, net	828	678	0
Net cash flows provided by (used in) financing activities	1,922,705	-138,197	90,029
Net increase in cash and cash equivalents	23,471	0	0
Cash and cash equivalents, beginning of year	0	0	0
Cash and cash equivalents, end of year	23,471	0	0
Non-Guarantor Subsidiaries [Member]
Cash flows from operating activities:
Net cash flows provided by operating activities	430,880	426,572	379,257
Cash flows from investing activities:
Acquisitions and related transactions	1,520	0	0
Acquisition of property and equipment	-22,407	-25,163	-25,183
Proceeds from sale of interests in surgery centers	0	0	0
Purchases of marketable securities	-6,474
Maturities of marketable securities	3,486
Other	4,721	0
Net cash flows used in investing activities	-19,154	-25,163	-25,183
Cash flows from financing activities:
Proceeds from long-term borrowings	8,958	9,504	5,566
Repayment on long-term borrowings	-11,982	-14,002	-12,944
Distributions to owners, including noncontrolling interests	-401,455	-392,922	-345,792
Capital contributions	0		0
Proceeds from preferred stock offering	0
Cash dividends for preferred shares	0
Proceeds from common stock offering	0
Payments of equity issuance costs	0
Financing costs incurred	0
Changes in intercompany balances with affiliates, net	-2,965	-88	2,666
Other financing activities, net	1,845	1,090	3,381
Net cash flows provided by (used in) financing activities	-405,599	-396,418	-347,123
Net increase in cash and cash equivalents	6,127	4,991	6,951
Cash and cash equivalents, beginning of year	44,130	39,139	32,188
Cash and cash equivalents, end of year	$50,257	$44,130	$39,139

Subsequent_Events_Details

Subsequent Events (Details) (USD $)	0 Months Ended	2 Months Ended	0 Months Ended
In Millions, unless otherwise specified	Jan. 16, 2015	Feb. 27, 2015	1-May-17	Sep. 01, 2016
	sqft	center	sqft	sqft
Subsequent Event [Member]
Subsequent Event [Line Items]
Operating lease, square feet	222,000
Expected rental expense, per year	$2.70
Surgery Center [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Consideration transferred		42
Number of business acquisitions		1
Physician Practices [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Consideration transferred		$35
Number of business acquisitions		2
Scenario, Forecast [Member]
Subsequent Event [Line Items]
Operating lease, square feet			55,000	167,000

Quarterly_Statement_of_Earning2

Quarterly Statement of Earnings Data (Unaudited) (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Quarterly Financial Information Disclosure [Abstract]
Net revenues	$581,811	$502,350	$278,227	$259,561	$279,095	$262,240	$262,497	$253,364	$1,621,949	$1,057,196	$899,245
Earnings from continuing operations before income taxes	101,535	39,141	80,487	73,029	80,363	72,615	77,100	73,069	294,192	303,147	256,591
Net earnings from continuing operations	79,234	39,119	67,689	60,047	67,348	61,470	64,607	61,068	246,089	254,493	215,698
Net earnings (loss) from discontinued operations	-150	-1,697	483	68	3,820	797	1,229	1,205	-1,296	7,051	7,945
Net earnings	79,084	37,422	68,172	60,115	71,168	62,267	65,836	62,273	244,793	261,544	223,643
Net earnings (loss) attributable to AmSurg Corp. common shareholders:
Continuing	25,311	-10,697	18,771	17,392	18,931	16,636	18,093	17,349	50,777	71,009	60,037
Discontinued	-196	-1,376	190	-197	627	135	470	462	-1,579	1,694	2,526
Net earnings attributable to AmSurg Corp. common shareholders	25,115	-12,073	18,961	17,195	19,558	16,771	18,563	17,811	49,198	72,703	62,563
Basic net earnings (loss) from continuing operations per share	$0.53	($0.23)	$0.59	$0.55	$0.60	$0.53	$0.58	$0.56	$1.29	$2.27	$1.95
Basic net earnings (loss) per share	$0.53	($0.26)	$0.60	$0.54	$0.62	$0.53	$0.59	$0.57	$1.25	$2.32	$2.03
Diluted net earnings (loss) from continuing operations per share	$0.53	($0.23)	$0.58	$0.54	$0.59	$0.52	$0.57	$0.54	$1.28	$2.22	$1.90
Diluted net earnings (loss) per share	$0.53	($0.26)	$0.59	$0.54	$0.61	$0.52	$0.58	$0.56	$1.24	$2.28	$1.98
Debt extinguishment costs		-16,900							-16,887	0	0
Transaction costs		$25,100							$33,890	$300	$700

Schedule_II_Valuation_and_Qual1

Schedule II – Valuation and Qualifying Accounts (Details) (Allowance for Doubtful Accounts [Member], USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Allowance for Doubtful Accounts [Member]
Movement in Valuation Allowances and Reserves [Roll Forward]
Valuation Allowances and Reserves, Balance, Beginning Balance	$27,862	$22,379	$18,844
Charged to Cost and Expenses	139,274	21,983	20,340
Charge-off Against Allowances	-53,779	-16,500	-16,805
Valuation Allowances and Reserves, Balance, Ending Balance	$113,357	$27,862	$22,379